var title_f27_24_28032="Papoose restraint for ear or nose foreign body removal";
var content_f27_24_28032=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F86352&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F86352&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 522px\">",
"   <div class=\"ttl\">",
"    Papoose restraint for ear or nose foreign body removal",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 502px; height: 144px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Prior to removal of the foreign body from the external auditory canal or nose, the child is restrained in the supine position using either a papoose board (pictured) or a sheet wrap. The head is then held by an assistant. For removal of ear foreign bodies, the affected ear is turned up as shown.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Glenn C Isaacson, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_24_28032=[""].join("\n");
var outline_f27_24_28032=null;
var title_f27_24_28033="Anisakiasis worm";
var content_f27_24_28033=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F52301&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F52301&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 590px\">",
"   <div class=\"ttl\">",
"    Anisakiasis worm",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 570px; height: 308px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (A) L3 larva of an anisakid worm.",
"    <br>",
"     (B) L3 larva of",
"     <em>",
"      Pseudoterranova",
"     </em>",
"     spp. Ten units = one centimeter.",
"     <div class=\"footnotes\">",
"     </div>",
"     <div class=\"reference\">",
"      Reproduced from: Centers for Disease Control and Prevention. Parasites and Health: Anisakiasis. Available at:",
"      <a href=\"file://dpd.cdc.gov/dpdx/html/Anisakiasis.htm\" target=\"_blank\">",
"       file://dpd.cdc.gov/dpdx/html/Anisakiasis.htm",
"      </a>",
"      .",
"     </div>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_24_28033=[""].join("\n");
var outline_f27_24_28033=null;
var title_f27_24_28034="Chondromyxoid fibroma tibia";
var content_f27_24_28034=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F71565&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F71565&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Chondromyxoid fibroma of the proximal tibia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 420px; height: 540px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAIcAaQDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD58ooooAKKKKAClXk44pKVetAEh6dKMkGm5/l0pTwehwe+KAJYJCGPpVyEkAKcmqMY+Yc1bhY4yDQBp2JKzbv4cYNdXosIaJ2BA/dnFcZHI6YZTj1rq9LZ2BJO1CuBQBv28oZWRxxs7CtJWWOBTGCUI5FY9pPi1ClfnwVY1ZhmHlImSVK9qAJt7KCQQBnBqaKX5RgnhuKimVXV0yNzDOKkt3RVXcfmHIHrQBPHIqu3zsQeeO9a1pJkxeWuByCTWRHKwulwm0MOmK1LQ72IaMg56igDds5F3gs2GAwMVpW4XZlpCdvQetZFuecbcYrQgcPGOduPzoAvodysCuQfepA2SOwIx06VWgbaM5JGCAacJfNRQRgjj60AWJzuIJPI7CoSpD8ZOOaEYb/mYjB9KcOVY849e5oAcJiVBwpA74pyzMwwB74NQvkYBBIx0xTY3Uj5tw5oAuBjIp3IGKnI4q7M8YgVRkE4J/KstZxnB3DnGc96kaY8hXy3TJ6UAXYupJPAqbflowwHJwMj0qlCylAGOW5PH6VZSQb1Zjkdck9M0ATrklSGyB8p5607a23L4AXA+ppjmPDKmcZHbrTif3yL19QO9AEsZ3fMG+dR0AoLsAygcsCcUnO4oDjnJFKc54YEnge3PNADlHy5yMr7UyPEjHGWAHQU7IClhyMHk9KA23KgjceOPpQA9S244XPpk4p24gtuc7jznuaZ5gC5K88UA7U6bmxnPpQA/OxUDZODjmo95dtrYAyXOD+lOXhYg+STksfxpsnlgux+VMYWgCvdSYjLljvBwtZN7cBGkVkBRVAyPWtB8McAEk8Lk9KypNrzzNNlh02/1oApanNuhs0UD72QK5/WSpuAFbDyZQYra1Ly47sndkRJlR74rmZ5wSk5y2yNmJPagDF1mQWZxI4I2lcCuI8kuZ5TgRKCcfyrf1NjIo3n95IxOD2rmvEEnkAQRnBOM4NAHPXkh2Me7HA9qzJT0q5etllqi9ADaKKKACiiigBrdaKG60UAPooooAKKKKAClxxmkpKAHYyeOtSs5MSrzgHOCajB564H0oJOPegBwJ7daswMBgZ+tVQakQ80AaKN8nPrXQ6PcFgFkJ6cVzETtn2rZtJwmxlPJ420AdRaXIa2LgHKv830q75gWJFUYUN1+tY2kSEmVDgq1a8Tp5bxEZ4oA0LaLEsbs3BFK6lrwcDjvTbbAjTd0q0y7QSeOc0AWLYDdHIeSvHFasbgbSGAOc4rLt2CMVDLweaekwWWQEZxnk0AdDFNhsgckc1at2OGBxkc1y0muQ27ZwGOMDFVJ9fuHP7r5FPpQB27TJEpLuB6ZNVrjV7aIgeZu4rhpLqaUkvISTUiHIUE846UAdafEewOY84zkVXbxFK4OBlc1gMRsHtTVkGT7c4oA3m8QXCsSAc1ai8RStFjYMZ5FcyWDFmBPrTo3aI5B60Adbb66pdWePkccVpQ6jazt97GRxnrmuNU7grDAGc80M25gyk5B4PSgDvhLk5VvwHcVbjmCsgI2jsTXA22rS20gBO8dMV0dhqaXSgP+7fORnoKAOl3kDLYJAI/+vSbwsowM46EVSWVjne2VI4b1qWF0Vc5Oc/nQBeRg0hIJBXrirEboshK4KK2cN39aoqwXJY547d6dkqm3B3c9qALT7uT/CRnBHv0p0bCSVui4HJHfNQST4jyyjBFEUgG0GPCnuPWgBzSb3wqjYcDJpzELkbm2n7pA96ikdUcJyDjjHamNKTIBn0GQOtAF1yPKGckg84qNmCtwcg8gGkaRvLTaSFZuKa+0M27PFAEU64li4AJYnPoKwWkV52JOSWIG3vWrcOQ8rYztXaPfNYgKJKWPy7Rk+1AGXqvzu4AwBwT/jXPXuySymSNmWPIHuQDW1qrFrS4dGBVjhfU1g3iC3yJCMfzoAwLpFuNRIB/dxjAz3rh9ffdqUwyODXZKzmZ5tw27jjHpXn+pyD7TMxySzHn3oAzLht0nHaq7mpH55qI9aAEooooAKKKKAGt1oobrRQA+iiigAooooAKO9FIOSaAAU4UhJHTjNAoAcOlSDpUVOVsHmgC3E3IFalo65UntWPGyEgE45zmtCGSL5cvigDpLacRlCmPm61rxPtbhgcjmuUh1C2jJ3biO2OtTya8Af3MXToTQB19tclHCnpirTXQdWLsAAvAJrgW129c5QqvGOlQ/a7iV/nkJJ65NAHbXGsQxSDymLE8NiqUuq3F0duSoPTHpWBAcEE45rQiBIG1uevFAGhbk9Hzkd/WrigHHJAqlaCQjkjg9a0FX8ietAE6MMA89MVahIYAHr7UWdm9yQsZyB1zXUaVo0cYDPywx9BQBkJY3Ei5jjJHeobmxmhbeyMOMZxXdJbBiwA46Cr0VgJIgkyoQ2PwFAHmY3YGAc9M1IoJwSM+tdjqHhjD5t88gkelYlxod1A2VRioPUUAZ8L7nKkEAUszHIxyfSnpayqGzkNz1p/9nzOQ2OBjk0AQw/MgJGRnv61btpNxwc8GiLTj3fHsKl+yOirgZ56+lAGhaahLbjh8oDwK2bHUoblFDHy3965qNdq9OM8inK20qANoJzk0AdwjlQcEbevTOamMhPMr8da46z1Se0+XdvB4APpWza6tBcEpI3ltu5z6UAavnu8hZuVHygVIZWVlHpn8KroA0avGQ2VOcHioQ7Iq7/vnv60AXgd7ryVHUGk3hQ+4jrgHuaz7i/KMETJ24CgetPEu/ao++vOSelAGiJyVAfChQAMe1JHJtViTzn8c1S8/ZEowNwOcHvSGckI3A65HvQAtzKY0JzyOCK56+n2wuRnng57VdvZ2eVG3YLscjvWJq9ySjjIG4/nQBlaldSi1VIeE/XNZmo3geCHzhzjrVuaVMKV7chawLuUoVeVgFORjrxQBV1WUQ2U7KSqhSQfevNrmXfI2c+9dP4l1DcmxGypzwa5R/fHIB4NAEL9KjbrT2NMPWgBKKKKACiijr0oAa3WihutFAD6KKKACiiigApSV2gYbd3OetJSE80AK2Plw2eOfb2oFJS0ALSUvakoAUdamXBP4VCOtSCgCVevvVhfeqyZ3DHWp0OcUATodoHNTpxz696gTGRj9atxxvIdqoSfQCgC3B1UZrWtULAgGoLDTLmbZtjI+tdNp/h2ZgCzqpNAFG0jOxST26VrWcD3ciQIu52Pat7S/CsbMpnk3c9B6V3WhaHZadDviiBmbu3NAGToWhNbwlQhJ5Jz61uQ2BUbXwoODxWjNKQwJUDA9MVSmmz35/u9aAFiVUzxkk5z7VNG+U+QbcccioArsnoVH6VLCDgbgQfSgCXzcsFPyt0PvWhCYypd0VQex9KzljBcMAMg8Z6VYHzFo0ycDIJoAdNYWkgLmFCSeCBWRqWkgAmIAH9K0oJ5FAH3Qeue1W4JY5Iyh5IPBPrQBxDWRidV25OetKkeI23jJzgD2rqtUsFK+YmOOePSsKezkjT5Rj1oAz57EOxMWCcdKypQUdd3Y81vwEpKAASe5qK7s1u1LqAsmScdjQBhpJ82HA9ajd/nB6c9BUkkZEmxgVfvxUTbTuLn6mgB8GozQNiKVgAc9a1rbxPldt5Bvx3HBxXNyYRMg4yMc1G5KsQpHA5yaAO2XUdPugGilCSZ6N2qVlYY2EMM8kNXnTMcHcRnPapotRuLdg6SMABgDPFAHb/aZCyll9V59KaLtzHwAAxJJ+lckniS7UqsipIvU+tLN4qRQMwEjHODQB0FwxJVlOSQSBmsTUBvRGPJQnjNZtz4viVEVbNuBgkNXP6h4tlaJ47eEJz1Y9KANq6eONR8wDY65rlNc1O1gEiiTfL0CjmsK/wBQurx98sxIHTHFZbHJOTz3oAhvJnmkLseTmqh6VYnPJ9qqn8aAGtTDTmppoAKKKKAKmo3BghAX7zcZ9KbpUhe2KnqpxTNZ/wBQn+9Ro3+of/e/pQBebrRQ3WigB9FFFABRRRQAUnelNNx70ALRRRigBaKUCnhQT0oAanXn8KkVWLdM1NHHu2gAdfxNXEhOeRzQBWgt3Y8DBq5bWe71z9Ku2lqXKbjgE1tadYA5yBQBnWOnKGGVLdx6V0llZBNuI8H171YtrQ4jwAATg4rftbIOSF+90Ix0oArWNvKGIXoTxXQ2NqxwrcEVJYaeVVQACw9BXS6bpW+IFxjnOcdKADSrM7I3C9s+tbJJji6YIPHNS20aRxAJjGOPrVO4k3Zc9jjHagBjS+dvD5DKM4zUGWIQKOM9e4qfyyykAgOpwSO9PRFG0NuwBgYoASEFWAfcS3ep1b5hgYA9T1pFADkc46AmnhRjPO40APh5faAT356UDO5wARjrQrBQDgilKlpCA5IZcmgBkittkG7BzjGKaqOEZiACeev61LKHDEBsjdnn2pMb1DKRuPUDtQBctLgGMRSgjsTVS+gEbsyAmPqDTo5CZEUgDHerUpEqA7hnrtPegDDktNyu0eNw7CqskLR7dw5FdD5Ko2GIyTgkVDLBG0gQj8u31oAwZLKG6GyXIYA4cVh6npEtoMhC0bdGHT8a7N7FizeW4YkflUKCRI2VxlPRumaAPNJFIJVySvIFQSKCmVPJ7eld9f6RBdB2CeXIRgY6Zrk9S0e4tQG2EgfxCgDDkB24U8giqryOobPQ5AzV1yoHHXHT6VRny2WbG3FAFXeyn3JqtcbAGDHtUskhxnnAqhdy5xxyDnNAFW6O3bgkZGMVm3GdrA4I9quXDhnYN1AyDWe7t5u0jg9fagCk7HnHA7VWfluaszldxUY61UJw2B1NAFeQfP0qFv51NK2SM9R6VC2O5oAjbrTTTmptABRRRQBnayw8qNe5OaXRj+5kH+1/SoNYbMyL6LmpNFP+tH0NAGi3WihutFAD6KKKACiiigBD1FFKaSgApaSnAEjPagAHJ6VNGOR1pijpzVmBfmOT0oAtW0JLbRWzY24cFcYYn0rPsQ7k4ODjPWuh0XbJKm7le9AG5YaYJIV3qo9CK6Cw0JWAyAnQ5Pes+2kESKM8ZIArdtb9PKBIbcOtAGlYeHYSYy8mDjNb8Gj2gKneCynnHes20lWUQknaSB3q9DL/AKS6Kc44znigDUgW2t5QFUEnp6VcNwWgJGFVflO2smO4BKgY3A9hxUstxH9nkw43BslRQBaM29FCHkDketMKkgg8qx6AdKiE2CjBemDxVmCQuGZsY3cDFADo4WKsN20KN3IySakIwis7nJpzSfKcfxdqiEjMFyQRjvQA4sMBgeCfyFTHaTvGc8VCrBSOhBGOlKZGwAOWz1oAerfIA2OPUdKZNkOrB+COgPSnhCclueCRn1pilCmGBweuKAHksEG5dxB3E9abGCXLggA8gVKuRAwXGe2DUTBQFbGMfeB6CgABKpywxnBIpQ5CqT90DrimRqG+/wAg9MVNgqhDEjjgHnFAEitvbdkMgHbsaQhBgH3OQeTVc5D7VwCe1LK2WUgnAGBQBLE+QQpK9smpwUCJGyEjnqO9VUlO4FOCe9WTLuDMpyy9c96AGGASKpwRnkAd6oS2BJwPmBGcHn8K0knVifmDAHA9cVYdkZfMHUjgUAcVqvhe2ul3woIpMZ46ZrjNX8N39kXzGHU8Ky+lexSW+8KQMNgcA9aga2RlPmLuQHBB5oA8AuLd4gyvkHuCMVm3aDy8DOK991HwzYXWf3XJG7OOh9K5TVfA1qJMYZc/3TwaAPHHQmQBuQFrPmXJkI5PXivVLz4f/MzxXO1enzCuY1LwNqduW8vEgJ6r6UAcFIuOSKrSj5uPStPU7KeylK3ELqPfpWc2Dz7UAVmGd3TNQEkNwe2KnkXAJBzVdxzQAxqbS0lABRRRQBlanDJJc5RCRtHNSaTE8bSb1K5AxmtGigBrdaKG60UAPooooAKKKKACkFLSHrQAKSGDDsePrUjM8jFnbJ/IUwGgdRzQBKDjqMmrMQIGcVWHT3NXYScJ3PegDT08Iw2njvW3ak8HoucDtzWHakIUfI4PINa1s4eEs0mSG3FVFAHUlVW0SRyQwbgVr29wTE7RRjGAMmudS5M1nHhTjP51u2fMPyLtBGcmgDVsbuR5Yoyw+7nP41qpcMJn25B9a5+zjJLtkHae1aS3JZkKp8vT60AakUrGTaHPTmrELcbSnUZz61SgbdMqhTgjmrmXXJXnj0oA1LYAOhQ44wc1e8zCARkY3YznrmsZrhyAcjA6jFW45cQlRgnr9KALXmFX27SV/lRJuPloODnOaribfIo6rtGQKnVnWaNgM5PORQBMzADBGPf0p2SqhdpPP3vamMPMm2BeMZNTq6eWwDHPegCS2l3LkkhFPfmno4EciMS6MODjrUGAsaEk/NxT4l4O2T5c/dFADoQpPy7lH8OfX1pz7tnUHJ5p5IUNk4XgZpApPlqGGGz2oAg2hYm4wRQkke5CxYnHQetTrt3uDkHHWopVTb8jYOOlAEcjry2SSOvFJHh1GOTjA9KdKA6DHXbUDE4ReMKR+dAFlvkA55HQZ6UwOEQkg4IOT+NSz7VZeBkAfjVd4y2CQQuOAOlABHKEicyg4z8uBzVqJ3ECjcM9R/8AXqoyjCoOVPI9qnCq0QLYHPQdTQBYScZCklc4PA6Yp7bsudwx1IH1qjI4aRTgjHAFOZyhXILDp+NAF9JCR83yoGwRUU/ETlVVlzj6VXWXkdNzfex0NJJIEicgANjj0oAgnt4pMSY4P8J61RaNYmdsB4xjI/CtKOdHtSrsiuOAap7hLJsVtu/j/wCvQBgajp1hdR7bq2iO7nOM8Vwut/D7TrmVmtJDET1HSvQNQDglGwFXgg9qxtSUuqhX2t1HNAHi+t+Eb7T1lZNs6IeqnnFcvcQyxNiRCDjuK9Y1vesjYcnccsAa4XVZvMmk3oPQUAc1SVYuVXOUGD6VXoAKKKKACiiigBrdaKG60UAPooooAKKKKACg9KKD0oAQU4U0U6gB6DNWosrnmq0WAcHpU8bAE5NAGlA3c+lbGksAPmX5WOG4rDtyHbH41u2DouCsilWOPpQB0emAtavGo27Tlc1qWtw7hEKMdo44rMt2SN1AYNv9O1bFk+zcrKd3VTQBdido2UsqoHXBH0rVgkgEG/ADCqEM0cskZ2ExltrMe1a0FpFG7LjejHoKALFjJE0YYNgjPWpY5sEq7blLdutRSSIkYihtyQvJJ9Ki8xGztO044oA04XiZmRjyRxmnRw5u8LKCCM8HrWLLMiMqZct3NWbe4UOcEg7TigDdaJll3wfNkcj0FLEJluBuGVLdKyoL0mFN0hBx+NXFv8LFtY7icGgDVlR1lDoPlI2jmnRcblAyvBwaqJegkDqtWY2BG1iDuwOlAErsG2IzbdvIqRcbS2TuzwMdqURpLtRfvDofalRFWH72CrenegCXIKpnPOM596ZJN+9Ctj5SQoHpUrgM7YOcjI+lQPEEkVdwAycE0AOeXAPQbRyfWopiRl9uSRxToYJZdx2so3HnHUetWJLaKaYESMABzjoT7UAVARhUJwM5PtTSN0mFXOxsEn09asPa4JKt3zUptXjRWJ5P3gPSgCvJl2XkHgYzSMA0pfJA7DNOjQMjMgwpOc9wKBHmIEZOORkdaAI8GOJjtBzzg9fwpq5dThdueME0phDSJuG0AYBJqUAxoD3Jyc9qAIi5VUAyXIxz0FSGIsqYkztBJx0phyqbnzg/dpC7KEJGB04HX60AIN0RDyHcB2HWkmcNtRu5yTUbzZuE2AnHr0NNuDsgZnOdx+mKAIJ5FRwNowOhHOeaerld5KbsjGRVIthSH+XjIFNknxEi84znOccUAMvWDg7FyoIzzya57U3VnuHjZQIx1z61u6kF8iJbZiHbDmsHVYle1fcArSNyB14oA4W8LKkwkHJOR9K4fUuNxyCzEk122tETSuqyFT0AI7CuI1X/AI+XBwcjPFAGNM245qualfriojQAUUUUAFFFFADW60UN1ooAfRRRQAUUUUAFFFFACAZNKOaSlHT8aAJUqxCitkYyfWq8f3Tn61cjVSykPhDzQBdsnRJcDk4wTnt3rpdKs7YqW3celY2knTre4aSdt+RjGOK6WwutMilWVydi5wq96AN+xt9MITYrNJxxmuptdMjkhjYIFAGTntXMadq2lOQ0aMrYxyOlag1Hz5ES3lICjoehoA6ay0+FE2MAVHKgVeisEJJTcoQ5J6YrChuHbaIzhuCSK04Rc7CpkchuenWgDbTSY5EDbye2P51BJoFsJSFJGP51VzcYCh5MYyamtkuPMDK7n39KAJU0SNJc4yRzg9aG0iCRW3DawOetWY2uFJdyN3ualJfCl35zxjpQBlJoYVA5+Y54FH9isy7w3TrnrW7GVA2vwRkrVqBIidzP8pxkUAcqbUxhfmw+48irsMTclWO4H+LvW89vaKQ4GSDxx0oZbbYJCeF7etAFaytt6ByQCvbPWtC3tkVCJiOWySR0qiwlmkPlbQmCRj0xQPtToiZPrnvQBrQLah5CuAQnINVp2iSLCBXy2RnoOOaisIGg3tMNzEelSbA7hdnABPNAFdPMeMLGHUKMDHYVV8q6VyHBba3p1FbiKyfdAUKR+PtSs5EgygIXg/SgDMgR34dSu0cjv1q2yyfZ2/eE55+lWgm6UnBHOQfem+RIJDtyFzk+4oAyTiNCWP3hjpThGH2lGAIGeOlam2J4yhjBTPpzTo7e1kWQQuI2IwBigDFjjZXb7Qo4OQc9fSnRyEEtJH8pJBB7AVsnT42ibdISvYjtVC60yYbFjkDRnqc8n1oAzR5fHHyqOPcmoQ2Ywu7BOTzVt4GRW/dNkYAPrUE0TFhuG1VGenWgCGJDJgEAEdSfr2qpP5skjLGMxj3q8xDKcZycYFUrpntA0SyAE8GgCtKgmh34AYLgZ7D1qlelmjTcR07DqK0Xi8z5XwuRliPSqF3ErlHjJ8lB3oAzbi48lSXyABkCuXu55nmSQMQFbc3PWuk1RVmtmc8E8D6VyWo7n3LbvtGOV7mgDn9dvYxcvITnA6YriryTLPIcZzx9K6XVYtrtnP3M4NczecgluoGKAMtzmo6mkqGgAooooAKKKKAGt1oobrRQA+iiigAooooAKD0opG6UAGcilFNXpTwKAFHT1qeGCRsbQabEvPGMitGFiCm7AycUAWrDR2njJLY56e1dVp3h+2AALuwI9aytPceXyw4Pauq0mZGV1VdpJGM96ANHTtBgDLv4xwOO1dLp+iWy52EtgZB9Kz7a4LMmWVSDjB78Vs2M5UKzMMdCKANu2sLZFDDkgCtSONNuMD0xmsWK4UjrgDtmr0Uo+YE8j24xQBppt6DHXmnI58xsrjHpVHe5ZcccE/WprcnDHgN/OgCZtmSxAx2B5pQoXAPA64qM5yT2xkUrEMVfGFHYmgBRguRn5ieCasIuEBP8XGah8vcpYD5jgGp3SYQbWXaFGeDQA5YiVLFuo6jpUq2ySvgtmPpio4I5JApVQS3b196uKu35cfdGMCgCa3jjVWEfI9MelTxQjjK7s8n2pkQ8sndgNgcD1qUYAJZgMkkmgBGAwCM5OMccYp5QFmbbg4xwf1phIZggB5HHsKgDliA2SwOcevbrQBaUbXO8A5GRzzmonRC8h6HAqPzmSVVHQ5GO9AkAUbSMZPBoAkSI7SwzkmpFUlHbG0Z4FNUsu4LkgjsaejfKQR7gUARG3Zhk5Axj/wCvTf7OBGMlcjt6mrkB8wHkY5wDVuPayLhW3DILZHJ7UAcpPDqVlkxSboc8g9qtWOqgmKOcBWJKg1sNH5mQcnd/CTxWVfaWJoswgBhnJAoAu+bEqbNgdRkkqegqFGtLsmPBLZAwQAaxEMtm2Zcgfd4qwtzBLgthZOtACXmltAGkiDcZxjkisKZf9MYXYOAMgkdfQ10iaiiIqyyBlJOcGkvoYLgZH3mGD/TFAHKM+7c7qdrcADpis3U9wYQphVPJPt6V0l/YmCFnQEJyCPXFc0qs8Ms9wo4JCg9zQBjatNHtIY7SoyAO5rj9QEiykxn5wnJ9zXTXSCSTM2VbsT3NctraHznRXI8zjI/nQBzupzqYHQkkg8muVuiC5DZK9c10l/EsQMZbdgdu/vXOXYwME8fzoAz5DUZ606RtzEdqZQAUUUUAFFFFADW60UN1ooAfRRRQAUUUUAFNanUxutADlX5d24Z3Y29/rTwwOBgZFMWnCgCUE546mrMB3NhiTjmqsZ2kHvU0GcnmgDodPZQ2V4JxjNdRZzEn7o3bQeK42y2749/GTwc966XTy7OkgUkA4yPrQB1VtM/nb1jBQkck9K2rC43oCVBJOePaudt3YySHkOW4HatrTZcrmEfMvUUAdJbHzGGBncOBWmjKOnHHzA1h2jEEFiF44z61qQM+1HYZJxzQBswSAKjqFOPlHFTF2eRgVXPGNvGPaqSTbeCoGecA9KchLBSj/eJJPcUAW5HG/cuNo4xUw4jDErxxiqKvnABwpJyauoDJt5yD3FAFm3UuxBIBJz0qcsz4yoOcjk8AVDGQnIL9ccHrQzR71Vi2MfnQBeto1j+V8nb2P+NLExwdw2tke+c1WR225V/lA5FS+crY7MQPwoAvFyACuFYcA/1NN3BduecYzjnNRB2z8qA5HQd6eZAQp2MHwRkHnNACO4UEqDjOAaYqYibBII+Y5P6VIFbCg4ZcZAzjFJJlysZUAHr6mgCKN8SiQnaSMc96Ugbhkdeuf602NsAHCgEcDH5UdCGA4yM7u9AEyqcDcwGefpUp2sGGH3LgjjrUD4yozuG7Jx2qSSQlcZLc7AfT3oAkUfMMM2DyPpU7OqsXVjjH3veqh5ULv+YcA5qypYH1A6n8KAJ0fcqsCNwwfpmpFcEDOSAcfWqaneygkbWOOnSpEl+YZX5Ac9e9ACXdlHcK+9MMQcH3Nctf6Y6thd47Fveux35DK3Bx0z2qlKdyEbiEJ6e3pQBwV5HMrZA8uTPIPes0+JJ7C5AkOQDnBFdvf28TxDOAeTXM6x4ehvSSzFWxkMo70AWl8SW1/GUMke88HB6A9aoaivmwslkyGMHAyP1rzjxRpWqaJJ5oJkg7OnasSHxddQyNy6g/KcGgDsNSwS8UkTIVbhwetcpq8v2ZsxOxAUrkHt6UP40aTPnIJMDG4Yz9a57UdSgnUtDKyluu4UAZ95J88jk/MeB9Kxb+QAbR1x2q1cyrGjnfvaseVyzk/wA6AGdqSndvpTaACiiigAooooAa3WihutFAD6KKKACiiigBrMAQvcjNI3AprA/ao2xkbT/MU4E59KAHDpS54600mnq2FK7RkkHd3HtQA5Qc1LFgNg9KiUYHWp4QScjtQBpWysZIwvXNdZp8jCOIq42YIKgc5zXJQOyvuXjHNdRouZLZmYru5wDQB0trKzquTlQRyR3rZsovKdTn75AOK53S8yRlQo4BDDPStq3zGVK5BB70AdDGC0+0KQegB/nWrZSAptckBO3qaxizLIrEkspxx71pI4UEdQOQPrQBqwKqyp5mdjDOR2q3Eo2EocktwQOuKqW0hMcfGGUYOe9WYmH2cbcB93QmgCRWZ3K7SGCkN7ZNXYFIbauACP1qnEziZyMSBh8xBq5GPnAzgDkEmgBbclZHUnoenvUiM8khZ0DKD1p0abVMiHI6n1qSM7oEZVIJY5X1oAeV2/ddce1EWChPOKGbJbI4GAPrTt2/5X2hjxg9BQBZVCoLK4+VCTSxjMRcgqwO3PrUbllRyAvzfKPwqZpATtYHbwwGe9AD4sE7XHGDg0bMqCwwxxkj/Gl3YHDZJ5zjpSFjllxxkZ/LrQAmVYkFApzg+gpkwaQgbwVU8gfzqRxhiQAcckDpmo0bdMX4QdST/KgBIk5LdEOTj+VIrhFAB+98xGOMULlgwAAyPlJ7UsgDIQ4wq8A5/OgBY5CYmGAWUkgnr9akO4qDuHy/xZ7d6hBCxqWIKnj3yKRiNp2sMYxk96AJpJwpcIxI4IPTNCzqAAT14x+tQSMEVCCdwzjPYYpoIYjByWHy889KALsk+1QpG49M1Wkk2tE6/PGoIA6ZNV7sEhQD0HJHQVEZMHG47V6/SgBt0NylWc84Y59arRM4DAuNue9Oa6Eis23B4wfXnFU7kExghuBncPU0ARazaw31k6MAOg9cV414l8GyRyM1u4ZWJIxwcV6nLJNI4ddwXuB/Wqs72zREONxXv60AfO2o2M+nzmOdSo7HsazJ3YjqOK9t8R21pcRqssMRBHYd68n1Wyjt52UoMEnBoAwX3YyTUB61pTWZ529uxqhNG6E5WgCM0lLSGgAooooAKKKKAGt1oobrRQA+iiigAooooAafvj6H+lA96CcOufQ0oIx70AIOlOHPWkOASAQfcUooAkHIB9OKli6dOaij7ipogSwGcUAXYGJQcZJrp9G+WMNzlV3HB6CuZjJDBh6YrqNFPkyxuOYZYihz60AdJpAVbx1U4aRdwJ6EVuQRu87wnL5GBt7cVjaRtJUMvCnarDsPSt6z3m484HaF54oA0rZT+7DqSyn5j9BWnBy+VUgN0PvVJP3so8tsBiDn1rSsuyFh8r/lQBcgAECBznedpPoaslTC3yqHI+WmRIGVgB8hO7ipY12sdr5iAOM84oAnt0SSQgKVVTjIqxGmEZlUnnn2qO0jcxtsfJA4z61NEG8tApY5X5vSgCWL/WfKSBnJ+lTwnzFQIuWVzzTGcI7BRyAAOc/WhlXzECyEMwxhe1AE4YKwQcBmPXmnhdxbJViO9V5wuGMbE84HHJ4qw6J5agLsYKBj1z3oAdkNtDrgAdaduYybGy4B2HHUCosGSRCoySACB2qaJHYtcoBtLYIPUUASIhV2G7JbofQU47VKlyOASSKYjGGWUp8wdcc9qVlCSAvkhhjjk0ADKMKrAjaM5B61HvBGxvu+9OJ+ZslfUHt06UBDsDEHefy+tADuAi4POM/QelRMwChXwMEc9qdv3IMqRFnqOKY2cNk7ic5BHagBRcCJjsVCCc5IzmoZXLuoTbuHBHtT3jKpAVYNub7vGPaoJCgkHXcx+bFAE02ZDtZdv8PXrSKULjZgLj8aiZgZcuV2rTEAZY8cljg5oAdcuixsVbH8X19qzZXPlqh6A7nHpmp7k78qoOCefpVS7fBZQQzFcHHYUAMacMBj329sVUmclhuB2qe3c1cFsFWN5uML8q9KzNRd9/yttXodvrQBTa6Yy4KkAnBrKuZPLJVeQx4x7VdnJCs24ZzwD1rAuJpIt57sc7T2oAydRdWmdDNt2kn5hXE+ILd93mLiVf7y9q6DU75hP8qA7TlielY2oTJHBJI5VPMHTPU0AcwzEZxg8VVnYE4bipp3HzYHfgiqbZJ5GQegoAikQZyvHtURqaUbR1qGgAooooAKKKKAGt1oobrRQA+iiigAooooARhkg0gPGMU401elAC0oGKSl7A+vIoAUZHI61bhUPtOcH3qvHgkcgZ7mprc4l2g59KANBVyMgjFddo0bR2x3kMd2VA9K5m2KeaFIyGH610tiGh8glgAQcj2oA6Ky+SSLHHGST710dlD5aK6vuyMEe1YliplkixtAKkgewrobNE8gMpBCgZzxn6UAXIUO6FfundjOcZrThjKSORhirZwBVK3QSEBs7l5UDmtK2KyR7hlT6UAaFqCqscEE/wAPqakjBESAAlc847etNRGzu75Dcmktg0SHPLs5JBPQUAW4cK6mAdHyQfT1qzvDr8pwQQcDpioLNhFI5K7oypC+xIqe3RBJtIOehoAlRxIHbGNo4NEe0rFtT7o5OOTSD/WEqQVVuBT4wGB+bln+UdhQBG7/AL5VXqrY49KlSTMrP/CFP4elJkrNyvIySR2AoVB2BPGevWgB8PyTIQW3jkk1IzSxrtVs87sH0qJpFEkbYKj7x9x2pXdt2HHB5P50AWFJIY9DgL9RTvMkk5CnJHpxxUCzFpPl5XoMVJA7ElSfujBPT8qAJioYRjAVS2CT3oYsZWWNt6nIBHb2qMsfLQbTuTP4moYi+8ZLAnpj1oAsFsOschKjHI9faomkV3OzIC/Ln2702WZWdYixZkG7IqMOWcEHgdwOKAJHcMWVf4SDnFVWkJnIzjHTileRfKYqSWZunt2qvGwB3SP8xx0oAtbQ0YzgnBOM96jRmW1UNg9yO4prmMyq6HJI5HeoQQ+QCw5+92oAGB2O0bcM3T0FRugUhgAWkGAB6UgO+ZkXGwH8xjrTZXeRnZgAgGF7EewoAS9k2x7mJ4G3GOgrBuptuR3Hynjua07sExfK3+sxgHtWLIjSea7KWC9AO5oAz9SlGwgqScjkdelcv4juCLUAfLO2MDviui1RmjZk3ZJxtwO/euU1MuZVNywEEZxvI60Ac3fzGztM3mXkPKriuUubiS4lLynjB49Kv6vdy3dxJJ/ATtUegFZDtgsGGCKAIJGyxxwBTWfIGcD6UHqxJqNj6UAIx9eSetR04mm0AFFFFABRRRQA1utFDdaKAH0UUUAFFFFAAaSlPSmg0ALSik/ClFAC5xT42w4PpTB1pwGTQBv2JEjKx+VSODXT6fGRDiRw5XDhvauQ00l7crjOOK6/SZN7RbhwE2HPegDqtHIDRRs/HzbGx2PaultABCAFVtowM+tc7pasJd0sYMMRzxxW6hK/dOAeeKANe1JS7jMjAErjPSrdqmZH8pwVUnBNZ1uN8sbk/dJJU1owR8OSQoJHHtQBoRkmJT5m4ngGpID+8kDjcrDAPvVaAiNVVDhAOM1KpbyioJ+/wfSgC5bny4mDDGTViD5JOCc54J4FVhvRgR3OTn0qbO4jI+XOeKAJEOyTcM7TkfSrDLsUbD8u3JHcZNRKXTKqo+UdT602WQyd8cBVA70ASBfnKqeOmSe3vUyBcMoO5l43Due1RQIBId+WwMMD1BxRGGSJkCckgEmgBVy5CSjI6delSHGd5IBXAXPrTsBXGQSD+lRqCRJGW2jIPTNADv8AVyZGwswOCOg96lmCw44DnqQP5VDGFUkDaQMr0p8z/uWzkYxjI70ACsSp37lAPGDTVfaWcFst90Ee1KZHICsigBs/LUZyMqX2uATx/KgCRXYMCQN2Pao4yTFiNflHP40xXQAYyVJz70IxEJkBHBoAhnOWVCOFA5H8qjjaKSZmdMqpyBReHnaGyxpsW1HKnDAHHHfigBHYG4uHPyrjCgUkTOLRI1IAdtxz6CoZSzuUdh0yRUzMpgVI+NoA3elADXYb3ZSPmPA780z7sYMmWwCMAZ5oaIvKzM4CJ0xxzT1cqoYDlznmgCjcKss6kMQ8ceMds1Hb2MwstxBLjJOOlX5ZXSJ1WJDIxBz3NQTTTJEsRB27STg0AcvdaVK8rHzMN6Hua878cGePZYKHXY26Q/0r1C7v/s8TXE7oWQZGeMntXnmqJ/aUkryzhZZGLDJ60AeaTAksu7GDioJMcZYHNdRf+HZ2ANu8bsxzjNc5f6fcWrBJUKNQBRfAJ+XvUDcGrLxSENuz1qu6lTgigCMnPSm048ZptABRRRQAUUUUANbrRQ3WigB9FFFABRRRQAUwjBp9Iw4oAOcA0opo6U4YoAXoKcnrTBUijp6UAaWjFReLG3R663RztJBI3qwwfSuL09tl/CzdN1dtpqlCxzj5sc0Adrpu/DAOJNwI5963YV3QxqDzswD7g1gaYgeKJgxVl6101gmYAqA7gxGT3oAtWmXAGBuLfpWjGQJP3eTjgA9zVC3GWXfwM8VoQxqkmVzyMt7GgCwsi4TILE8E46VYRVL4XlRk5puxTIqheAuTxyalVjJKQg+7xQBOmxthAbn1NTENIu1QFIOOnNRQKwIBxtHA4/nVvlTgZOGx9KAI2BJO3lh+uKTIbyl7Bu9SbSoYbskdh2zUITLqgyQuTQBaizIWYFVYnP8A9aoym8E7mzn86ecJv4HHI9KcP3eAxG0jjPagB0YJXJBKhue2aJsGYsgA5H0FPgTYGViAjHqTTAm6QleR0J7DigCNGYNhmAj5IOOpqZz9/OOAAB61EwE8uMHaCcU5grFmU8bgRgc4oAaJAcsFOc461HLKGmO1e3zZpruWck8Bec561E0mcMox6g0ASLtMeT0GFAA7+tQkny5EXlD8wB7YpEC4zu5zkYNKc7UbJyvAoAjuHBUEKF3AA0wkKm4KRnANNkaS4k3zc7ueeOanuoiEBP8ACR34oAqyPKUcZUEttHHOKc7BGhQcYHOfX1poVvsbu3BLcc9BU0hV9quecDFACXT7mGQcEc470iFcKX6jgCk3F5WyoO0cYoUEAiRR1PXpigCOVirjHIzgY9Kgu3wxiJG4jJ56ZqYod2MrgDdknoK5/wAQXws7O4u3OWkOFX07CgDkvFeppcXRs0UBI85I7muTuLZ3JaGTBIxgnpUt3K5lLABnbnP+NZ905jmy5OAAeD0oAjlhuo2w8hYoMYVqr3SGcqLgtt6Bj1qGScvISjFQo4561UnvpWjQFs4B69qAIp9Jnwzo++PrwazLi0dVGRz71dkupsAGQ47AVQnmkc8k8UAVGBGc0ypJCKjoAKKKKACiiigBrdaKG60UAPooooAKKKKACkbpS0HpQAgHFGcGgU4MQrKAuGxk45/A0AGKkX7vWowfWpFoAmtz+/jz/eH869CjGLgAg/K6446ivOkJDqfQ5r0yF9xt3RR8+0E49qAOq0tcHaynEjZXiuitmIlbAABGFHpXP6Wx8zDt80fOK6a1jLqrD+E8nNAFy2jDwkqSZBg4q/bxnzs5OD1Paq0SbDJtU7eOlaUEbKGVeRjd+FAEiks4YgAqKekRhIO7BY5GKQQM2H3YG3OBU0CuZDjlsZxjpQBNbfu3OCyKVwwz97vVgqQrN1B98Y9qjRGyd33mxnip2XeiLkcjJzQBCh3GTYAEIxmmRqUlA3cHI+lTIoyQAAwzj+lIkZjkTjk9e/NADNihWUknHJ4qebayo7LlQBg1IFAn2kjJJzkcVIyo8YBfKnjjgCgBihGVQ2SuASO5pFARWRRw3JINPQqVJwcqOKjk3NGzK5TJAOccigBkW2IM5Gew5qAB0VSpG0jGD1FTO21kVmHI6EdBTZ/9WWx/Fxg80AVNzGQEAEc8e9MZgqtkHaR3p6sQPlj7/jUbY5yTgDgUAIgCQsqAnLZJHQCpNyqjA5z2P6UwIFHXk9s05yflwNwOQMmgCIALGTIpc8KPem3uXQg5AAyCDUg5CgghgeM9qhDE7dqkL1oAYcLGI3YfMueKTKlHdgflXIp5G54tyklVORREd8BJU8E0AV42KHGdrNyD7ZqZmcSqAd3J4PaoL5x5LsoOchWGKeApRHbOVGOe/tQATOxRkVe+OnXNec+N7ozTC0jYAROCxrv7pza2k8wbDoCwJ7V5BqMjXL3M7Egyt2PWgCldRg72B3BVwCvrWHeExZJxnbjHrWpcv5FuwjztAyRWTfTRpBE7K2TnIoApTOvkxSqoHODjvVKZ1JyAcVanZFtFi7k7zVM7NpIbBxwKAIGcgNuIIJ4HpVWQ4OAatzbSvIziqcgXIIOc9aAIX9O5plOc8n0ptABRRRQAUUUUANbrRQ3WigB9FFFABRRRQAUGikNACjP4UvemDvThQAoqRfpTBwKcueBQBKqkrntXpenSA6bYoRnegwwrzdRtTPfvXq/h61L6PYNKPux7hgUAb+ilWuAWHVCOR3rp4UBQqwIzg9awNIVT5TzMd7ZG0dq623WNhggkjGM0AWo0Lom0/MODV/ZsdsHI2YJqGP77iLClSM/WrohZGctkkqOPWgBIgCNnTcvHtU8KFWjO3AOcn1oO5+VVcgcdsVNFhVJIB6nHpQArAlMDr97HrUofiPeuAOMe1MOfkbI3gAY9KnkXeRzjFACBAJmGOByDRgbVcZOTn8amKlpmlG3BGTmkKs0MeFGDkKBQBGudzOxwDnAx04pVBMSl8Yz34pVPz7Sc8Z2j6UKFESl8fKcHPJzQAmMOAnBJHB6VHKRiVNpGH61LKSGxywOC2fWok5DSAHGcn2oAgupAsDylcqBs+Uck5oliePaAQrDgqRUtvEseQM4YkgE55pssh+ZpPmP3dxoArsu2GItgSDnAqvNGA7ICSMA1bmHlpGchmIx061DtOxsD73P40ARKqvwTxnFPkSNRtYH5cc575qWNSIVTb1OSabc/POQckDjpx7UAQTMftDHqoPFVpd0iq5yEDHAHTmrMjKrbzuZuRyOKilLC1HBDdc9qAHs+2Zl2ZCjFNjG6LpsUfeJqRBvkcnoCB+lN24hICgKTk+3tQBn3W9oXAPBbIXuamALW8cZ5Y8Y9BUU6kMYzkksCfXFT6dlnkcYOzvQBzfjq8MFmLfjMylW9xXl9woeN41+U9Rg11vja7e711ow+Y4lKj61yVwxVGzgYwuaAKc8uLTDrtLcMc9RWRfSxsjQlSWTlc9BWleYZBEcnLc1lX0auxKHngYoAo3SsBuYcYA4qr1bBHTirDq6sVJ6ckZqA8HJznNAEUq8HdVGXgZHQ1enQsc54rOnOZCvYdKAIjRSmkoAKKKKACiiigBrdaKG60UAPooooAKKKKACkbgZyKWkPWgAFLSCnCgAHSpU7cUwVKnYmgCYgHd9K9G06/lazto0chVQbgO3FeeoSz84wOK6XT5XeL5epGCB6UAeoaZMj21uMEuPmz6V00MrkoCRn6V59oV4Y4URm4cjGa7O1lEr8MSc5/KgDpbFz5hzgE9eO9bFvKcgkDAGMmuetpw0qYYbR8uPetW3cOSOcrjHvQBpCJhLgHkHJParEMTAPs+ZjyBjmkhYlHzySR2596teUVjXqCORzzQBGyksXxhhj5QKfFGytk8nuMURI6hmbJzzjNWE+bjJHY0AQMoRcIN2RjFIgIiUA4OcY6CpYzjkrkZ4p2eeeMcfL0OetAEJZTM24YUjGaikUEKQSPnFPAyxGdo7E08oNi4H3CC2aACRiswYAKnAP+NQKgjEiA8dsnrVh0JciMqTnoT1FQ3DEKduCMgN60AIEdZcAEYBYd6iZVdRyT/eJ9qdnbIzAnDDrRtVJMEk7VwSO9AEZ2yAMB8o4HoKjlJiLKR8pNWRGTGEBxjnGKidNysGXLnHfrQAiLlMAhVDFh71DIweUjHA/CrSgCPHBO7lc9qrrgzOxHGCDnv6UAUlKeRI53MQwOc8U+YKVwQSDjAx1oYiSyZF+Xa2OO5pZRucL0QcDNADBhd5YYbOQBUdwzMmM/MT0PpVkrhthBLl8Aj0qtckR73I57jqeKAKNwdxlboeBn0FM81IIHweXB9vxpzoXO8HO87vrXPeL7020EcafLIxCfnQBxOqMzTTOQeGJz61RusLZqrcFjk5FW7vcjruXOD271TvXiZnD5AUcjtQBkTOFucxLvTGSTWXcgfMWyB61fQo+1lOOxrOmyfMQ8gdCaAM6Rjjvu9aTYcjkE4zT55CSAB04qaOMsyqBhgM5HpQBm3pKRhACXfgAVlnIJB696uX85a8ZlONnAIqn13Fic9R9aAENJQetFABRRRQAUUUUANbrRQ3WigB9FFFABRRRQAUmc0tN+lACil70Cno5VZFCqQ4AORkjnOR6GgBF9e1SqcDOKjX0qZORQBZj5HvWlaSsjgA4HfFZ0fbFW4OCWJxQB1ejXDSOhDEbDwPSvQtKuDJGg4BBySO9eXaO5DFjnpj8K7/w3LxtBycYoA7W0bADADG7FbtmcxuOckDkdqwbTgqc8Eckdq3rRRjqARjkd6ANGJlVQFZ9x9TWtFI8sSI7HOc5PP4VjqVIGcHtz0q1DMdiAjAzjA9aAL0akgmM5bHQVMhKvngvjoagUF1dlbYfuZSnRqCmxnztzlj1PvQA8ZCN0wCRnsalQl2VtwGAARimEgwgtt4OdooQ/vARk8jIHSgBuQ2VIOCcLgU5NzEh0IXuAe4qYrkfN1HTApIc5OeQGAI7n2oArsvRf4gOPWmz4Vn2qWOM8jpxUpwzliMcgD6VFIP3kqgA8Yx60AVmBwpyMHmo3xjCZZu/tU08Y2ooYkYwcDp7UOEEo2cDoTQApkYSInIXrx1zUcnYlmIPr3qY84PBbGCTUA24ZoyzcfdPagBVXG1vlUNkZPYCoZHQTswO0N0GKkmBDMuMhcY9qiwWKZYdDkHsKAIOCmxBgsdx+lOblHIOT1x2qRc4bocjHFNjIGASNpPOe4oATd+8ic5Xjp6mqtyP3Dl+MtjPWrCsREccMT+mailjzuBBwWytAFRgGbbwNnGB2rzH4h3gXVra3zuw2TjqK9Rl/dpISQDyTzXhHia8+1eJ55AxwJNo/CgDZn2sjEAkgdfSsTUCAu4dTnrW5MA9iXPBx271iXRY7eN4BxQBk3ACQpgEg84HasyRclh0OMj3rUugyyFd/J5Y+lZ9ymJQx+bPQ+goAox4cH65q1NJ9mspm6FhgVDYozLkDIpPE0oREhTHAyfrQBzbc5J6k0ynk5plABSUuaSgAooooAKKKKAGt1oobrRQA+iiigAooooAKaOtOPSmjrQA4UCgUooAcvX3qxGhIyBxUC471ciYGMKcjFADwB+NWIugJ6d6rKck4HfFWoh8ozgn60AbFnIEZDjA9a7fw/M4GVHGfzrg7FySuCPoea7LQ3G5Qmc989KAPStKO8LgE+orehYCPaMhuuTXN6I+CRux2FdFE23JJGcDIJ7UAaEQyAGAGOpqzbOdynrg9+lVYWVUZWOcdDVi3JKAJ0HPNAF60JZV5wCTxVoBEaQAEH/aOciqkaoqZXrkBu1T7QGbJyQcdOlAEjHavyjCk7fpToWYMrbQUBO4GmuAY2CHLE7lp6twueD1JzxigCVV3PIitjK5202MZjVsZy3B6ZqWFl3AqRxhcDuPrRIjbRx1PAoAiVD5iqOmOKgmUr5p53HjIq4VJBOeuBjvUDqQsmSRnA/GgCAAI2OgA/DNJJAXCspGNw6ce9TTr+6Axgn5cH6VJhkTETcHoD2oAq3EYWMMcAKvOKqzRLsygA4zWhOufl2g5I5zUDoFUbiT2UDpQBV8tihPb3pqQgvvcnaTg54qd1O49Ae/vQ4DHLAEgEgexoAqKSVYADJPWlkCgHYmSD371IVCyOcfLtJDe4pPLZbfoGeQ9uxoAicbFHBweT7YqvIWTBxx/jVpIQDIGywxkc1FJGzqu4nAGSfSgDE8RTrZ6VdSuSNqFj+VfPjvuuTIfvFt3PrXsXxTu/I0ZolYFp2CAjuO9eMu224Q5PUZoA7RudKUKc/Lg/Wsq7UO3GOV5ArbtcNYKzdMA49aybhdtzJhcLzQBz1zzKc8eveqk6u6AZ+YnGK0JdyuRgc8896qM5Q5A5OPwoAdpluyAYxj7xHcVz3iCbzbxuO9dbAmy1nmIIPSuH1By055oAptmkOMDAI47mlPrTaAENFB60UAFFFFABRRRQA1utFDdaKAH0UUUAFFFFAAehpopx6Ug+6CPyoABTh1pBTl60APSrEXUVAgzn2qxF94dMUATqMngVNDuIKgZ5qBRls5wavWpQJlj84NAFqzVkZTx7V12iyESoe9czC6bwCDuPTFb+kSqjLkfMPWgD0nSJMNGpxXRxbWjb1FcZpspXbg55rq7KXcCT1P40AbEL5GCB9c9sVehbCAZx07VkElYyXPvkVfhkbyohncvcGgDVjdfMZWBJqwDhj8pK53HHeqm4eSrAkEnnJq1A+GYrwSB0FAEy8knA4YmpVQFwCQFx2pkSkDoMfyqTafLYjtxQA4NyQFJywAqYsFGACSvf27CowmYzjqGHIqRDlc4HBJNAEcquEz0K9cnpUTDcehbHep5gXDHbwCMHNB3JHu45yMCgCJghGQT97OPSnMjE7mOWP3hj8qfBkNGkYG3HJPODTyhUkBmGSDk/0oArzJlwBkKOn1qKWPzHfoNv8AP2q2cF3LZBwTkd6gcYCDcBxke9AFfZlAg2k4B9xUNyrqgyxy1WSqDeQMMSC3r6cUwgFVXkknOD/OgCAgiN3AGM7T3qEjyo8gZA5I96ndXHyjAxkfjSsu1SMA5wfwFACLF5qSfewSM1WlHDkAhcZ571orGQXIYltuSQOBmqWoDy7ZmbpjaOKAPFfi1dCbUbe3LECNCxA6c15wQflHBYGut8cXIufEl7JyVUhQPpXKzrjY44+bAoA7rTg02mgEAKB+JFY98DGhVmOW5rc01B/ZwGMMUB+lYmpKztweM5oAy5wsiMT0XHPpWd5S+eWXcdxyPSrzrhcbshjz6VGquJgkYyqsOfagB2rSCCwdB1YCuDuP9a/1rs/Eb/uwpGMdK4qXlieOaAIDRSnqaQ0AIaSlNJQAUUUUAFFFFADW60UN1ooAfRRRQAUUUUAFJ160tIKAFFOXrTactAEo61NF1xkCoR29KmVSelAFlBzVhAc471XjztGDxVhOWxQBpWyYIGeQK29J3OyFj074rCtgfMOCQT0rotHXhQeMn160AdppfEi4PTrXWWIxgr6CuT0yNvOU4yua62zICnB49+cmgDVLMYxlR06VPFtQRgHg9BiqiSZRvmBwOfxqZPvIRnOePY0Aa8BBTI57HJq/ArGTgZGf/wBVZ1oMDBGSRmtEAlmIyoOMknigC5CMbic4J6U4YyOMc8ZqOLeyrsB4OcZqVULSMu7nt7c0AOGVyQ+4k547VKoTCcHGzkE0xFChyvDA8bacpBLLjtigB4Xc0ZDbQM5NBwQ6sec4B9aepYAgjk4HApg3MzBzg460ALboBJlueNoA6Zox1OMknGT0wKda5CheRk56daQgndg8E8etAET+W8yDnaRx7VFKmJGAOxsADPP1qUHdLHjqvHHpQ6gly3bp70AQDGQGXDYHOOtNKN522MYzxgfWp2+SIbyCxGNoFRRZy3Ykc5PegCuhaR5OABnBJ7epqXYRs4GSRu9MUkKtt+ZQPr0qWVz5ecA4IIX1oAVkKOVQ7lPGKx9cm8mykbPyBSxHpitlCyoCASp4Oe1cT4+v2i0q5PAAjI69KAPDNTkWe9mkLE73LZI96yZdnmqVHKvzV6fAYDqDkk+lVGUmZFGCdwA460Ad3pTMbM8Ats4rBuziYbvvg81v6RuWGQvgBlyK57Ut++XDZzxQBlSKBIccgtmrNtgAlV4ZsYNVW+UMjZLLz+FWLFwYWb0PBoAxfEUnzPGx5Fcg3Sum8QvwzE5zXNP+mKAIaQ049KbQAhpKU0lABRRRQAUUUUANbrRQ3WigB9FFFABRRRQAUlLQaAFxx70q0macoyaAJVB64qZDk8nnpUKjg88jsamjByOKALEY6HtU68EEdqiVTnOanRGIO0UAaFoQ0o9fcV0+lA5QYrnLK3JkXGQMeldbokDZXI57UAddooZsYHOOfTNb8WU6cgHkVR0mHyowBwP4jWrFCWkz2HegCeMgg7e4A5FXoPnjyBlQe1UwOeBnjtWlbAmM8Dr2FAF+02gYAP3QK0osbjggjAP41RtVIixg8EHOOtXoD87Yx0yaALW3hgCdpPJ6YqXhTyCeB1piYCgBc7sAjrmpGwHDMcqBmgB/ARv7xOCD2pVO5wOMHv7004JLMevIBpT8sn3uATn0oAcSS4BPBGfpT2T5sDjPH1pCVKhlAyRj3PNI/JJHGOOtAEqkYxzn2NIWAJzlQw6+lLt24fB2seme1RPtJAc5AOAKAGoSHJC/L2JoY4bHVgck9qc4w3LAkjJUDuKhl3bsg4GR0oAdLjcMcgrwR61CecDhuOT71KSCwXhsmojtBA6nvQAW655O07OOvWlBBGfbJp0asVOzH1HvUgQIFRu3B96AGzMqQLgDLDr6CvKPircGLSlXp5smPqK9SvziNhgBVUjgdK8V+KtxvubK3JJ2KWPOcmgDzubnJ3Y46VUUM11EAcDNWZm3HOOPY4zUFqC94qn7uePagDu7EEWchOCFGABXO6pISzPswvoDXT2CA6c5yAMbc55rmb4fPMudwBoAyIgH4OfWrlsD5EgwF9qrxxMqgE9eR+dXc7bV3YGgDitdf5AvBJbrWG3XgVq62WE6gkEckYrKYcmgCM9x3ppxkEZ/GnGmZoAQ0lKaSgAooooAKKKKAGt1oobrRQA+iiigAooooAKKKXvQAdBmngUz1p69aAJEHOasp7VBGVycip07dqALKYz7+laWnQ7ixHJx37VmxqT061r6agCqTjJNAG9p8OYl4wc4Fdto1ki7OBwM1yelqWZeOnOK7vSdpjj49setAG/Yxgg8fLxx61bwRI+MYz+lMsFWMsCGxjj0qxEpJc9D1oAsaf8ALcB8KcHIUjOcVegRc524+bNVrSM5weMnitK3T51yDxnnPXFAEtsCFYHIAwcetXYE2yBuuRx6Cqtuf3gOPQ1aiRYwFJI6+9AFoE4OSPMzww4qRfmDYwox+dV1ySMYy2MGpVIJ2qvOAfbOaAHIB5R57U7epbgcAHGRzUaqwhJDDAFKDtIbdySc8cdKAJAoGWOPlG7Of880vcAZB5zQiktyOByD0pAcODnOFxkmgCQvlCMnhjj6+tG7LsRnbjr2HrTSFwRklT6etIw4baDz0x9elAEcgwMgk989MUb1J5AwfSn8MGZvmB4XFNAVmO5cKDwc/wCeaAGpkykyL8zYFOKgbeh5pIVDSgHnBx+lDABiMZOc8fSgACkA5JHbipVU5ORgDgE9KSLqu0EjGSakyfmIPztx7AUAZmrzEh8NgEdhXgfxDuftXiGRVOFiUJXuOtPi2kOMPjkmvnbXZml1e6cnO+Rjn2oAxpySzYB29KNMiBvUwenWmysApfOccGpNIB89ycbsjFAHc2wK6ZJ09ea5u8XfdHGQOv4V1KKRowAxvJ5PrXLXwKXLv07CgCrjDoRyMc+1T6hldOVMc9cmoVUlt2MD6VPrIH2faOoGDxQB55rgP24LnhVArNbvVzUpN147DPPHNVG7cdaAIG703GOvWnt3prEtyxJJ7mgBppKU0lABRRRQAUUUUANbrRQ3WigB9FFFABRRRQAUUUUAOPJpVPrTactAE0YyQOmaschiM5x3qO0jEj4NSsCjkHigC1bOnzCQHGDjHrW5pijA3den0rn4SN2ccAVv6KdwAwOWoA7TRo0DDC5NdZpZ2qu4c9RxXN6WvzLggZ7ntXT2ICRAk5zwKAOls33YJxn86uKMyegPUVl2TjPKkADOPU1t2qeZ84GCRxQBLHGVbAOcdD61oxrtAJOG3HjHtVSJD5mDgCrcX+p6FiA3HpQBJBkhTwBUsbt/FjaoyQBzzUMEYATaQOmfbNP3FHGwLgqMZ/nQBZjZCdgQrkdTxmpF4XcAQQeCKqxTFww3Ken3R3qxEpKjcxLYBxQBN1Q5xnvS79rEAjnmocDcACQV4GT61IR+8DDgsDzQA+MqzDdnkg05FJaTpnf39Kbl9zEjnjikUkxsSTnBoAsMFWULkbRyWqGQsEPJyT09DTwgwoA+8NvPqKJfmVtoBIXv1NACOArsIRmLgAtyc45oXPmgqQwI5OO9IpDAjGTj5R70IVKtngk4UDtQAiNjaxye3FKwCksoBJ4pMDdxkHsT0pwIYKecEc47igB8ediY6D2pZCgwVJI5GaSPIGNhweBn2pp2CMmQHAyOKAOW8VyNBa3DuzKqIc+/FfPNyzSyO2TySRXt3xFuTDot2GIy/wAvBzk14jO21AB0AznFAGZcE+XtxgdRVvR42JJBIyccelVbrgAcH/CtHQs+cg2jGepoA7WdSumxnpgdBXLXjFZZNu7Ge/auvufm0hN/GOhrlbmNmdhn5sZNAFeJPMuIwTgkZpNZby4HZskgVYtQocMeoXFUtcOYN78EjPNAHm87EzyO45JzUDnJyeKmJG4ljxuNQPyaAIzTKeT1ph/SgBp60UUUAFFFFABRRRQA1utFDdaKAH0UUUAFFFORGkdUjVmdjgKoySaAG1NZ2017dw2trG0txM4jjjUZLsTgAe5Ndho3ww8UalB9pmsV0yxA3NdalILdFHqd3zY+grWtdJ8DeFrqK51TxJda1fwOsiQaPFtQMDkZlbgjI7YNeZVzWgrwovnn2inLXztovm0WoProZEXwt8aysQvh67GP7xVf5mrL/CbxnBbNdXWkx21sgLPLPeQIqDuWy/Ar6B1/4veHdI8O2OoGQ3N5eW6zxWETAyLkZw56Lg8ZPpwDXzn468f6541us6lP5VkpzHZw5ESehI/iPufwx0rwsqzLO8wleVKFOC3bUr/Jcyv67Gs4U4dbs5pP3ExXKnYxG5TkH6H0rcTThdxb0+VwMgetc9gBsEk/Sum8Ol50BLn5OPevsDnMyO3mVypQ5HFdRo0aRRDjJP6Us0AEgdccn5s1oQQYhyBzntQBu6dKuVC5OcZrpLb5bVWPr0rlNLyChKnINdOrFLcA/d60Ab2nybioJ5xXSafgxkseeoBrktNddilTnPrXRWcg2g7vm9KANgIu8N09QD2qZAcfKCO2KihPCMQAwPbnirKDK8ZLYOcdqABWwhZcDGB05zSB2LfKQTtyD6VGzFY8twNw5Panj7nOQ3GD60ATxfIVIIV+Dge9Wo8kAkcqP4e4zVWNPmVumMAN7VZC/OAGyBjkHrQA9eM7sbgcY9u1OO0uM5z2zwAaUOXUsQAM547c9KHBJGcnPP4UAKzAgEqQD3HcU6NiEbOACeRTQWJAHTIx9KUHCkYAOct6UAPLFZUUYLn15zSOSkskUn3kGc479xSZQhZDtHA49uxpdy7yNxYZ69aAGqxA+6Fyx5zmpAONhxnGcVDtzgrwOnNTHO5yeCBkY70AIu0d+R04601MKpO4FQMfQ0/b8q5XkDA7n86SKPG7kY3EEkfpQBOGKOCR7rxwRUN0+yFsjGetSmMkh+Tt5PsKq6gQ1rJgH5uMnrxQB5X8U7hjYiJcYeTdivJ5JNj/ADjIIwAK9B+J1z5l5DDggqpJzXn7E7wVxkUAUboqWIYcY4471q+HUMjqScAetZU75VmAB4ro/DEIZ03dcCgDqL9SNP3ZyvQCuQunAlZs4OQM5rstXiCWeehHP1rirsbrkqcAZzQBZgQ7AFHQ5J9qy/FmEsnRj91Mitu32NGFXj+hrmfGcmyG4VsE8AfjQBwcmNhPb1qJ8/LzxipCCy5x0HNRsCCOO1AET85pp4pWJ5ppoAbRQetFABRRRQAUUUUANbrRQ3WigB9bHhbQ28QambNb+wsAsZlae+m8qNVGM84PPPSseioqRlKDUHZ99xo9H/s34deH/wDkI6tqPiS7T/ljYR+RBn0LtyR7rTX+KE+nIYvB2haT4fToJoohNcY9DI45/KvOqK8/+yqU9cTJ1H/een/gKtH8CudrbQ0dZ1vVNbm83V9Qur2TOQZ5S+PoD0/CqAHekHf6VNJs4CZx716MIRpx5YKy8iG7jD1yKkhYBgcVDu+bFPUjFUA4HOT61teHbwWs8gbJDisRRwfQVYtm2ygjrQB1Mt23mj5gd3IroLCRnhVXYZOMmuMgbzJfm59663S1/cg9aAOrsFCFccmtoIzQbR1I5zWRpuSqgqc8ZreiRlGT3oAk02Iqi56Z610dq23r+orFthtiUE98mte0Y5GRnPSgDcsuEAc5API9cVfU/KFB4JJJ9qoWZxt3AlSeDV0fKFwARz/9agBCDkpjHfB9KdyzBkJACg4HNIcnaW4OOPYd6erBHO3Jzg4HegCeJSGK8dRyOalGQ5bAI4qKPaoyGIbdnjmrIcq5yyEgAjjigBVPHooyQPf3pyDLBThieD34pjDAY4ySMZFPxhwOhzjJ68UAALStJyMBV+72we1IwI4Gcdgacm5d2wDpj60qAhzwPvAfSgBSoCsOCSB17U12bJbHPPTjNPZRszkFs9OmKaOWYM3ykgigBSWLYXAA5OfWlV97/vPlAGMA0zjeFyMfWngkjpwOORyaAAsSgAON/BYdv/r0kCoECMWICgLnv7mnDIyTuYkDIB4xSrg4BUZHQ+tADs4QcgAdeao6nJm1HryeKuNgR5HPPT2rN1GVfIZm6gGgDw3x1cC6124LA/JhcVx0qupJONo4AFbuuzvLql9KG4eQ4/CsWYv1bp0oAqSpvb5sA5x1rr/DkaebGCCdq4FclES08a7MAtXdeGwqzYMZIxQBp61gWikEhRz9a4tkL3eecN1Fdlr8qCHYATjoPeuSwDLHgkHdQBYtF+YkDjg89q5DxqxW3weryYP4V31gE8qbOMjgA15745cB0CEENIT+lAHINjYc8EngVC/XFWHUhTgZINQtigCFvpUbdakbrTGoAZ60UpGOvekoAKKKKACiiigBrdaKG60UAPooooAKKKKAFXrzTwzFGAPGc4qOnDAVvrQAgpw6U0HIA/OnfyoActTRsAR61EAOpFTegwMZ696ANK1YB0P612misD8ucE1x+n2rTqr/APLM8ZrqtFSQXCIxPJ4oA7zR04VS3B7nvWrNdpbxBFw0hP5VW0+Pbaqx7d6yZGM14eCGBxigDf065aYHOeTXT2KZXJG4YBFcro8Sw9Rk5ziultZeVC8A9BQBvW20DB4P8qtZ3HAyyA8kH9azLRmR36A8Y71osSsecqcc5U+1AEiYMZDcHP5+1Ot2YnPJOBx6io0bOABzwSPrUsGUc44+nb2oAniI8s8EHjNWAVd/l5Xg4NQxsSD5fQ/Lz0FS8JG5yQBgZFADz8y+o6nFKSpY5+9nrjNIWyoYMTn5Rn0qSP8AdyboyRwT7dO9AApKk84Bbdik6khs5Y5OKUI29QcqQOec09VBy20AhgM568UAKMEA4AB4yTUbYkjI3EHqMelSuSZOxxj8aa2P4mxjrxjqKAImIV0IH4Zp4LSkHITA6VEwJAOefpUqjcNvAxgk56UAOUhI0UMTzzSI4DghCT1BpwPAUlWIBP1pULgdlDe9ADm/iU7QdvVjXN+KJxFp9zPnBCMQex4roLg5UZIA4BIHpXGfEmYW/h+5YYUOMDnmgDxC6fcGYg/MSc4rOnGduCc5q6zZhB3Ecng1Vf5xlSAfpQAzTiWv1B/hr0LQEwGZvl471w2h5N+5wNwGK73SA32cDcDk9qAIdeYFCRxk8cVzNnh5sknKseK6XWW8xQGyGHQCsGGIRsxB7EZxzQBYtSBZsxyDya858YsDdQpwCoLYz0zXpRXbpII688eteWeKHLau5bAwo6UAYshCg+9V/U1NIwLdM89KhPSgCM5yc9KjbrT2PamHrQAhpKWkoAKKKKACiiigBrdaKG60UAPooooAKKKKAFFGeKBQeM/SgAHQ46U7jjGaRScnHT0py0AOU4IHr096kjYdDgGkIHl+h/Wu48A/CXxH440t9S0V7AWiSNCxmn2kOADggAnowNAC/DqNL+G6s3AJU5BPavStP8PQQi3MikyJxuHerHgD4E+KdD1Frm/vNIETrgpHNIzDB9PLx+tdvqukw2LbI7qGd14fyuQp+tAGCdPMduwQ5QetYgt184sBgbs11N9IsOnyHd8xxiucRw6DHSgCaEgE7evQ1rWbhWCspPIwTWZAFC4bls1ftTiYE9TwADQBv2pO89QPX1rRUq2FPBI5xWTA/ADYA6k+lXg5255KdCR3oAvRcA88bs/hVhc4U9D0BHc+tVo0yiheOBke9XuAEIIznFAEkYyDuYEFscenrTwM5UDk8nNNXcFJJADYzjrTuPMIySdvU0AOClm6buDhalC4ZNw5JyeeBx0qOP5WGemMg+9SKTubByoOeR1oAc3CnaVBOKAQMBQSM4Jz19KDkngAKMZFPZRtyBgM+QaAGqSjn+IjpTHBMhY/NkflT5cLJu5AyB+NLIDk4OSTnJ+lADWyoGfurzx+lJk7gWU5PtwKc0RaZVXcwK8gD0pgDJIhLHIOTmgBQeM4HXmpGGUDHgdBmmr8uT3J+venOCBjJCmgBjqGj5J2sPXivNPi5OosoIFIG5923NelXBLQqygKV7dK8c+LE/majBGQoKJk47GgDgJ1RgMZytUGUgEkZHerc2GIywHPSqlwpUdcA+9AGh4ejDedJnnpiu60MFYccdTiuK8PgNFKQMAnA9Sa7vRYwY0BGMDrQBiaqmy6G0k5B6mqzptiGBjf+Yq3qyM94dpyRnH0qDP7lC3UjjjpQAXgCaaqAkZFeQ67J5ms3JAOA2K9c1SUraKMZGMA4rx2+Yte3LsQSZD/ADoAoyEDnBqI/eG4HHGakcknOOKjZtz5bJ9cUAQEcnjimnrTyetMNACGkpaSgAooooAKKKKAGt1oobrRQA+iiigAooooAVTg5o9aK9H0uz+Gmj6ba3msalq/iDUJIkkews4fs0UTkAmN5G5OOmUNAHncUbSsqRKzOxwFUZJPoBXfaB8J/FmqW5vJ9OGk6cuGa51aQW0aj1O75se4Bq/J8W59LjaLwN4d0fw1GePPiiFxc4x0Mrjn8q4XXPEOr+IJ/O1vU72/lB+U3EzOFHoAeB+FAHoB8O/Dvw2S3iDxNdeILoc/ZNEi2xfQzPwR/u4NegfCn4veEtBbVLKPQ08P6MkPnxFZXuZriUELtJPViDx2GDzXzih68ZqThlX0FAHt/iL436t4o8TWtnZKdN0B32mJTmWb0Lt2/wB0ceua9EsnT7CRnPHX1r5WtZPIureQcbHUjFfSenzGTQonjJDgKSR6UAO1cs2nPtI4OawLKTG7IPHQCuhulLWhQjhucVj/AGQxnGCjDg5HOfpQBNC+ee5OavWm7zQ3T0qmqlVHAPrV63HzKcdDQBsxyAMobpnJzV6HPPzKAefY1nWy8PvAyVxx2rYt4AYEKyxnA+6eooAuWw+XJPOOcdKvQ9QCRuzwR/hVW1UCM8HBwfY1ayRlwFzkggUASbcdevrT227iwJUlcc1GSHwW+7wcdqXJBCg8dRQBLgMT5hIAGBkdaduz8qkjpmo1Pz7s8dQDzSq7b1bauwk8e1AEyjbjAJHQ+5qQMQgVcBc5PHeoSxzt3cN0z1xT4PmUlQQTzye1ADm5VcHGCTTnjyUzkk1CDjnGRnIPpU0h6EHOBn/GgBMOk0e04JBBbPakRDtAchtwxyc9O1Kg3AbQeRgZ5JFNIK4fHDdgeRQA7LKDtXCnjj09ak4YndGw5/Hp2qPGHJK5HB2inM3J5YE459KAKtySYfnI6Z4rwXx7M03iK5LsSQAqqegFe6XrmKBicnHp3FfPOvyGfVLx84LSHGTQBkuCUzj9Kp3Ku0LdOOauTMwCkbRxzVO44iY7859KANrQVb7AMLzu55ru9PLC1cBOijmuO0FG+zRAdD8xArtowEsZBk8dcdxQBg3JAvnJBA+v51TcHKjaQNxIB7CrAYec7kcjJXNJbfvJo9wBBOTQBT8S3DQWzhWyNuenTivG2JaR2J5Yk/XmvW/GkgSzmAHPlkk+leQ+5H0oAZKjKiOceW5wDn+lV2wGIHI9elTuNwyO1VzjbmgCNqjp7UygApKWkoAKKKKACiiigBrdaKG60UAPooooAKKKKACjjGaKXPB4HNAAKcKaKcuQeO1AEgG1AT3zipkOSM1EvOcjJqVOuepoAkcnYfUc19G+Arj7X4dsySMOi5r506gjrxXuvwhkabw5b7gPkJA755oA9FOm/aMIBtDYww/nWfd6VLGJJHLPub5mPOSe9dTaKQ+xvnLqMf7NTTFHtZVIBzzgdjQBwb24Q8+varEMQ5446ip5cqwUqPvZp9uQXyADxjpQBagiwG3dMdetXYAGVQAdoJJ45qtB9xlHUdc1ahdcEZw27FAFyBwZIVDAeYSFB43HngfhVtQDtwSQTzVSFTuBPzEdD3FXIj5bqG6HBoAfvKlgwyQeBT1JPDHAxgE+lDAAjIJAwDz196VGALEkZ647UAO+6GGRzQifKoGMjkc4pCw2sy87u5FLwuwnpnmgBzOBu4ORwCPWpEYgDJGP6+lRkqEw2cj09aRm3SKOQpbIPpQBKvAV8EA8/THakU8Bv4QPX1oHzB1BJwevb0pkYUDGAxbjI6UASRFtvIJOOADipQBvck54x07+lMBy67eQBmnHIJbBIz60AOjcNuGzkqASRyOeKduGSZDnBxx/So4Tk4B44Jx1pA4jVSeD7/WgDF1+cW+lXL7sBI2x7V893KkvvBzubcQxr2/4gzrDoF23TK42n3NeGzMWzgkDHNAFeULs+7z2rPlPJxnmtKJDcXSpuwMcccn6VTvEEdygG7BP8Q70AdfoEYW1iBPIHTHWurLFdOkUg5JFc3oyEBGzngD9K6O8YJYjPB4Gc0AYKoTFM6gZwdoPrTtKX/SAG2nA5yKSIbIv3nOWwMVLpwWNmZAS2OPbNAHIePLgi3uGPACYA9s4rzFfu4I7da7/AOIM4+zyIMElgp9q4Bj68UAQsdq4NQEjt0qZipJ3HIqI4HAoAhONxplSEUw9aABvY02lpDQAUUUUAFFFFADW60UN1ooAfRRRQAUUUUAFL1pKWgBwHTFOFavh3w5rPiOcwaFpl5fyrjf5ERZUz0LN0X8SK7tPhSujoJPHfifR/D+BuNqJPtV1j/rmn9CaAPM4uGHAP1rX0TRNU1u4W20ewu72YfwQRFyPc46D613K638NvDhK6N4ev/EV4nS51eXy4c+oiX7w9mqtrHxX8VahbfZbO8i0fTx9210qIWyL7Ar8360Adn8NPAN34P8AFWm6t40utD0635U2F9Okk0u8FRtQZ5yQc54xX0rO2laNEqmK2tgx+WOONVLH2Ar4DMryyNJK7PIx3M7HJJ9c16z8LPEF9rHiG+n1i8nvLqTaTJKxZsdh7D2FAHvd54iudRnaKFTDbhiu0Hlh7n+lVi2IzjAJzjI61FAyA7hGQznqPpU3lkLnuV49hQBzNxkPJjAyaW3VgSw4IxwBVmS32u+TnuOKaY9oO0dfSgBN7b33kcnBq3CViBkLYUEZI5qpIFMoyR83QVdt/wB1IDwGUgjHP40AalsBkZ+Yj9asjyxNuVMgjI9qrW43Hkcsc1cRdkqgAbAC3JoAkHJxg7sDjrxTnAD7SFBJHboKOGCsCRnqe9SuqkqQTkjJOKAIi20LnGG46dBT2IGNwyemTQFUgN3P602RlU4wcHHNACnaA+87iwyMDgU0gCJd3ORjAqWELvHPA600qQWGQOc49aAEAAY5GexANLvKH5duV/Q0EE4/2D1z1pQpKNk5LnIwelADwFY8DAA28mhCF+VRwOcHvSLjzAwy275SD2qRAVOdo784oAYflXCAZzk59KZIzEgEcEHtT0ULnJIX7xz6+lR3TjbnpnIyBQB5z8WLr/iURQoSQ8nPqcV5LIcBSM4Azg16L8WZ28+zhQgnaWIx6V5zOmSMfd9zQBA5xgqSD2I61UhzLdQplnZnA5NWZg27AUE4x16UacrfbYXiGShzQB6FpdhOn3WViwyAB+lX9YY/2eI/lDY5PoaNI1BCkMkakyZIKkdPena6MWbN1z83HY0AYtqW8gdCAC3NSWgP2eTcfm64zTbTAhwRuIU596ntE/0aUsMZJ/AUAeY/ECZiwCqoV3/PAri3JOMjpXUeN5QbmFCckE1zMrtI5Z+uAOB6UAQsefukcVXarEhz0+9UB4zkc5zzQBD0zTT1pQMZppoASkNO7U2gAooooAKKKKAGt1oobrRQA52CIWPQDNRw3EcxwhzgZpmoEraSEelZ2jki5YditAGzRRRQAUo5PHQUlPAoA0tJ17V9Ht7qDStTvLKG62+etvM0fmbc4zg8/eP51nZLsSxJJOST3pAO3anL3oAl3FuScn1NTI/y4x+NV4/vL35qdfvD86ALKsMYHNdp8JrjyPFqpux5kZ4+lcQvB4rofATsnjDT9pxlsGgD6r08ErC52gnJq+8KtGFzz3A64zWfogDWoDc/LmtKM7jITjPFAGfc2w2F0DEAH+dZ064jYZ4HOK3Z1CggdNuazLiJQox3zQBnooJz/d+6DVqLDPuI42/jUcShypb0NXbUYz7DHP1oAu2S/MQ7Njtx1rVXajKpUMoG08dKqQxKS+RnaOKsxfez7j9aAJlEYZyUJOQM5p7iDYxwSdgJ9KQDi4bJyr8UFsqRxyAc0ADIgKs3KYG70FJ5ilyVX5QfTkU4d2PORnB6VEoHlMe54zQA8rGGBUk56j0pJAq4xyxbkfhSxjPljJwevvT9g25GR2oAiVDvz1APU/zpZAGPzdAeB0pSMKMd+tN3Hj3IoAeBtAwDgAj6U5Dkgc5XnB6YpowG2gDG6jJcwg8BkfOO+MYoAlVUEWSBlTyT796p3Ei9W5yOSKsQ8naemenrVC5OVf2YgUAeK/EO683xKzH5khQAA8A1yEzb2wowDzjtWz4tdpPEt6rnI3YrFP8AIUAQNwxYqeDjJqXSGDT7lU8nj6VWJLEAk4OTirujKApbnINAHfaDGGMY7nJ5q7rUhMZR8ELzxUHh8bnUn+4TUniNcRAjIJ60AZMDBEk2rkEdCanyF06Q4wc4GDzVZVCWzlepbGasTjbpEmPpzQB5B41dX1SNcD5VrnH54xW94v41wj0QVhNQBXk71C2NoyefTH61PIM5qu3WgBmPlxj8aaRx0p5A20w9aAGmmmnnvTTQAlFFFABRRRQA1utFDdaKAP/Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Note the eccentric, metaphyseal, geographic lesion in the proximal third of the tibia. Endosteal scalloping (white arrows), along with bone expansion, is noted (yellow arrow).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Yochum TR, Rowe LJ. Yochum and Rowe's Essentials of Skeletal Radiology, Third Edition. Philadelphia: Lippincott Williams &amp; Wilkins, 2004. Copyright &copy; 2004 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_24_28034=[""].join("\n");
var outline_f27_24_28034=null;
var title_f27_24_28035="Insomnia treatments";
var content_f27_24_28035=[" <h1 id=\"patTopicTitle\">",
"  Patient information: Insomnia treatments (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?27/24/28035/contributors\">",
"       Authors",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/24/28035/contributors\" id=\"au1847\">",
"       Michael H Bonnet, PhD",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/24/28035/contributors\" id=\"au1875\">",
"       Donna L Arand, PhD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?27/24/28035/contributors\">",
"       Section Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/24/28035/contributors\" id=\"se8034\">",
"       Ruth Benca, MD, PhD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?27/24/28035/contributors\">",
"       Deputy Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/24/28035/contributors\" id=\"de8764\">",
"       April F Eichler, MD, MPH",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"UTD.htm?27/24/28035?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      INSOMNIA OVERVIEW",
"     </span>",
"    </p>",
"    <p>",
"     Insomnia is defined as difficulty falling asleep, difficulty staying asleep, or unrefreshing sleep. In general, people with insomnia sleep less or sleep poorly despite having an adequate chance to sleep. The poor sleep causes difficulty functioning during the daytime. Insomnia is not defined by the number of hours slept because the amount of sleep needed varies from one person to another.",
"    </p>",
"    <p>",
"     In many cases, insomnia occurs when there is another problem, such as stress, pain, or a medical condition. In these cases, treatment of the underlying problem may help to improve sleep. In other cases, either the cause of insomnia is not clear or the insomnia does not get better when the co-existing problem is treated; therefore, the insomnia itself needs to be specifically addressed.",
"    </p>",
"    <p>",
"     The following is a discussion of treatments for insomnia. The diagnosis and symptoms of insomnia are discussed separately. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?2/16/2306?source=see_link\">",
"      \"Patient information: Insomnia (Beyond the Basics)\"",
"     </a>",
"     .) More detailed information about insomnia is available by subscription. (See",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/62/13290?source=see_link\">",
"      \"Treatment of insomnia\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H2\">",
"     <span class=\"h1\">",
"      BEHAVIORAL THERAPY FOR INSOMNIA",
"     </span>",
"    </p>",
"    <p>",
"     Behavioral therapy is often recommended as the initial treatment for insomnia. Behavioral changes may be recommended alone initially, or medication may be recommended along with behavioral changes. (See",
"     <a class=\"local\" href=\"#H12\">",
"      'Medicines for insomnia'",
"     </a>",
"     below.) Behavioral therapy can include sleep hygiene education, relaxation, biofeedback, stimulus control, sleep restriction, cognitive therapy, cognitive behavioral therapy, phototherapy,",
"     <span class=\"nowrap\">",
"      and/or",
"     </span>",
"     chronotherapy.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H3\">",
"     <span class=\"h2\">",
"      Sleep hygiene education",
"     </span>",
"     &nbsp;&mdash;&nbsp;Sleep hygiene teaches good sleeping habits (",
"     <a class=\"graphic graphic_table graphicRef51203 \" href=\"UTD.htm?2/57/2971\">",
"      table 1",
"     </a>",
"     ). This includes:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Sleep only as much as necessary to feel rested and then get out of bed.",
"      </li>",
"      <li>",
"       Maintain a regular sleep schedule (the same bedtime and wake time every day).",
"      </li>",
"      <li>",
"       Do not force sleep. (See",
"       <a class=\"local\" href=\"#H6\">",
"        'Stimulus control'",
"       </a>",
"       below.)",
"      </li>",
"      <li>",
"       Avoid caffeinated beverages after lunch.",
"      </li>",
"      <li>",
"       Avoid alcohol near bedtime.",
"      </li>",
"      <li>",
"       Do not smoke (particularly during the evening).",
"      </li>",
"      <li>",
"       Do not go to bed hungry.",
"      </li>",
"      <li>",
"       Adjust the bedroom environment (light, noise, temperature) so that you are comfortable before you lie down.",
"      </li>",
"      <li>",
"       Deal with concerns or worries before bedtime. Make a list of things to work on for the next day so anxiety is reduced at night.",
"      </li>",
"      <li>",
"       Exercise regularly, preferably four or more hours before bedtime.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H4\">",
"     <span class=\"h2\">",
"      Relaxation",
"     </span>",
"     &nbsp;&mdash;&nbsp;Relaxation therapy involves progressively relaxing your muscles from your head down to your feet. Here is a sample of a relaxation program: Beginning with the muscles in your face, squeeze (contract) your muscles gently for one to two seconds and then relax. Repeat several times. Use the same technique for other muscle groups, usually in the following sequence: jaw and neck, shoulders, upper arms, lower arms, fingers, chest, abdomen, buttocks, thighs, calves, and feet. Repeat this cycle for 45 minutes, if necessary. This relaxation program can promote restfulness and sleep. Relaxation therapy is sometimes combined with biofeedback.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H5\">",
"     <span class=\"h2\">",
"      Biofeedback",
"     </span>",
"     &nbsp;&mdash;&nbsp;Biofeedback uses sensors placed on your skin to track muscle tension or brain rhythms. You can see a display of your tension level or activity, allowing you to gauge your level of tension and develop strategies to reduce this tension. As an example, you may slow your breathing, progressively relax muscles, or practice deep breathing to reduce tension.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H6\">",
"     <span class=\"h2\">",
"      Stimulus control",
"     </span>",
"     &nbsp;&mdash;&nbsp;Stimulus control therapy is based on the idea that some people with insomnia have learned to associate the bedroom with staying awake rather than sleeping.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       You should spend no more than 20 minutes lying in bed trying to fall asleep.",
"      </li>",
"      <li>",
"       If you cannot fall asleep within 20 minutes, get up, go to another room and read or find another relaxing activity until you feel sleepy again. Activities such as eating, balancing your checkbook, doing housework, watching TV, or studying for a test, which \"reward\" you for staying awake, should be avoided.",
"      </li>",
"      <li>",
"       When you start to feel sleepy, you can return to bed. If you cannot fall asleep in another 20 minutes, repeat the process.",
"      </li>",
"      <li>",
"       Set an alarm clock and get up at the same time every day, including weekends.",
"      </li>",
"      <li>",
"       Do not take a nap during the day.",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     You may not sleep much on the first night. However, sleep is more likely on succeeding nights because sleepiness is increased and naps are not allowed.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H7\">",
"     <span class=\"h2\">",
"      Sleep restriction",
"     </span>",
"     &nbsp;&mdash;&nbsp;Some people with insomnia have long awakenings during the night and some try to deal with their poor sleep by staying in bed longer in the morning to \"make up\" some of their lost sleep. This additional sleep later in the morning may make it more difficult to fall asleep that night, resulting in the need to stay in bed even longer the following morning. Sleep restriction consolidates sleep and breaks this cycle.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       The first step in sleep restriction therapy is to estimate the average number of hours per night that you sleep. Decrease the total time allowed in bed per night to that average sleep time, as long as it is not less than four hours.",
"      </li>",
"      <li>",
"       A rigid bedtime and awakening time are recommended and naps are not permitted. This causes partial sleep deprivation, which increases your ability to sleep the next night.",
"      </li>",
"      <li>",
"       Once sleep has improved, you may slowly increase your time in bed to find your needed hours of sleep.",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     During the first few days to weeks, you may feel sleepy during the day and may have difficulty being alert. You can deal with this by increasing activity levels when sleepy, avoiding sedentary activities, and discussing the sleep restriction therapy with your therapist, who may need to fine tune sleep times. It is best to try sleep restriction therapy with a therapist because reducing sleep too much can produce sleepiness that can result in accidents.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H8\">",
"     <span class=\"h2\">",
"      Cognitive therapy",
"     </span>",
"     &nbsp;&mdash;&nbsp;People who are awake at night commonly become concerned that they will perform poorly the next day if they do not sleep enough. Such thoughts can initiate a cycle where being awake at night increases your anxiety, which then makes it more difficult to sleep. You may begin to blame all negative events in your life on poor sleep.",
"    </p>",
"    <p>",
"     During cognitive therapy, you work with a therapist to deal with your anxiety and negative thinking. The therapist will help you to realize that poor sleep alone cannot be the cause of all of your problems.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H9\">",
"     <span class=\"h2\">",
"      Cognitive behavioral therapy",
"     </span>",
"     &nbsp;&mdash;&nbsp;Cognitive behavioral therapy is a training course that combines several of the previously described approaches over an 8 to 10 week period.",
"    </p>",
"    <p>",
"     A sample 8-session program may include an introductory education session, followed by a session or two that focus on stimulus control and sleep restriction. These may be followed by sessions that focus on cognitive therapy and sleep hygiene. Finally, there may be sessions that review and integrate the previous work and address future problems, such as stress and relapse.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H10\">",
"     <span class=\"h2\">",
"      Phototherapy",
"     </span>",
"     &nbsp;&mdash;&nbsp;Phototherapy, also called light therapy, is an effective therapy for people whose insomnia is due to a problem called delayed sleep phase syndrome. People with this disorder have a problem with their body's \"sleep clock\" such that they have a difficult time falling asleep until much later in the evening or night than they wish (and therefore wake up later than they wish in the next morning).",
"    </p>",
"    <p>",
"     Phototherapy involves sitting in front of a specially designed light box for 30 to 40 minutes after waking up. In less severe cases, waking up consistently at a given time in the morning, followed by physical activity with exposure to bright light (eg, a walk outside), may be sufficient. Alternately, you may sit in an area with bright sunshine (eg, near a window or on a porch). The exposure to bright light at specific times helps to realign the body's sleep clock.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H11\">",
"     <span class=\"h2\">",
"      Chronotherapy",
"     </span>",
"     &nbsp;&mdash;&nbsp;Chronotherapy is also used in people with circadian rhythm sleep disorders. It involves intentionally delaying going to sleep by two to three hours on successive days until you are able to fall asleep at the desired bedtime. This can be difficult to do at home and is sometimes done in a hospital setting. After this, you must strictly enforce the newly-aligned sleep-wake schedule.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H12\">",
"     <span class=\"h1\">",
"      MEDICINES FOR INSOMNIA",
"     </span>",
"    </p>",
"    <p>",
"     Medicines to aid sleep may be recommended if insomnia interferes with your ability to function during the daytime. Discuss sleep medicines with a doctor or nurse. Consider the potential benefits (eg, improved daytime symptoms and function) versus the risks (eg, side effects and addiction) and burdens (eg, cost and effort).",
"    </p>",
"    <p>",
"     If a sleeping medicine is not effective within the first few weeks, your doctor or nurse may recommend trying a different medicine or may refer you to a sleep disorder center.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H13\">",
"     <span class=\"h2\">",
"      Sedative-hypnotic medicines",
"     </span>",
"     &nbsp;&mdash;&nbsp;Sedative-hypnotic medicines work in the brain to cause you to feel sleepy. The primary differences between the various sedative-hypnotic medicines are how quickly they begin to work and how long the effect lasts. Most clinicians select a medicine based upon your type of insomnia (ie, difficulty falling asleep or staying asleep).",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H14\">",
"     <span class=\"h3\">",
"      Benzodiazepines",
"     </span>",
"     &nbsp;&mdash;&nbsp;Benzodiazepines are an older type of prescription medicine that cause sedation, muscle relaxation, and can lower anxiety levels. Benzodiazepines that were commonly used for the treatment of insomnia include quazepam (Doral), triazolam (Halcion), estazolam (ProSom), temazepam (Restoril), flurazepam (Dalmane), and lorazepam (Ativan).",
"    </p>",
"    <p>",
"     People who take benzodiazepines should be cautious because you may be sleepy in the morning, which can affect driving safety, job performance, and decision-making. Additionally, do not take benzodiazepines with alcohol or other sedating drugs, and do not take more than your doctor or nurse recommends. Benzodiazepines are generally recommended for short-term use only.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H15\">",
"     <span class=\"h3\">",
"      Nonbenzodiazepines",
"     </span>",
"     &nbsp;&mdash;&nbsp;Nonbenzodiazepines are a class of prescription medicines that are somewhat similar to benzodiazepines. These medications may have fewer side effects compared with benzodiazepines because they work more on sleep centers and less on other areas of the brain. They tend to be short acting, so they are also less likely to produce hangover sedation in the morning. Some can also be prescribed for a longer period of time.",
"    </p>",
"    <p>",
"     Nonbenzodiazepines used to treat insomnia include zaleplon (Sonata), eszopiclone (Lunesta), zolpidem (Ambien), and zolpidem extended release (Ambien CR). Zolpidem is also available as a dissolving tablet (Edluar), an oral liquid spray (Zolpimist), and as a dissolving tablet at a lower dose for middle of the night use (Intermezzo). Do not take these medicines with alcohol or other sedating drugs, and do not take more medicine than your doctor or nurse recommends.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H16\">",
"     <span class=\"h3\">",
"      Precautions",
"     </span>",
"     &nbsp;&mdash;&nbsp;Sedative-hypnotic medicines should be used with care and certain groups should not use them at all:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Pregnant women, due to an increased risk of birth defects",
"      </li>",
"      <li>",
"       People with alcoholism",
"      </li>",
"      <li>",
"       Individuals with kidney, liver, or lung problems",
"      </li>",
"      <li>",
"       People with sleep apnea",
"      </li>",
"      <li>",
"       Individuals who need to make decisions during the night, such as clinicians on-call or single parents caring for children",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H17\">",
"     <span class=\"h3\">",
"      Side effects",
"     </span>",
"     &nbsp;&mdash;&nbsp;Sedative-hypnotic medicines can have potentially serious side effects:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Unusual behaviors such as driving, eating, or having sex after going to sleep have been reported after taking benzodiazepines and nonbenzodiazepines. You may have no memory of this behavior. There is an increased risk of these unusual behaviors if you take the sleeping medicine after drinking alcohol or taking narcotic pain medicines.",
"      </li>",
"      <li>",
"       There is a risk of impaired driving the morning after taking some of these medications. This risk is higher in women.",
"      </li>",
"      <li>",
"       Severe allergic reactions (such as anaphylaxis and angioedema) have rarely been reported, sometimes after the first dose. Studies are being conducted to determine which sedative-hypnotic medicines have these risks. You should speak to your doctor or pharmacist about these risks to determine if any precautions are needed. (See",
"       <a class=\"medical medical_patient\" href=\"UTD.htm?14/57/15250?source=see_link\">",
"        \"Patient information: Anaphylaxis symptoms and diagnosis (Beyond the Basics)\"",
"       </a>",
"       .)",
"      </li>",
"      <li>",
"       There is risk of addiction with continued use of these medications.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H18\">",
"     <span class=\"h2\">",
"      Ramelteon",
"     </span>",
"     &nbsp;&mdash;&nbsp;Ramelteon (Rozerem&reg;) is a prescription medicine approved for insomnia that works in a different brain system from the other sedative-hypnotic medications. Its benefit is greatest for people who have difficulty falling asleep. It is unlikely to cause morning sleepiness or to be habit-forming.",
"    </p>",
"    <p>",
"     The most common side effects of ramelteon are headache, sleepiness, and sore throat, although these problems occur in fewer than 1 percent of patients. You should not take ramelteon if you have liver disease or take fluvoxamine (Luvox&reg;). Ramelteon is available in the United States, but not in Europe.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H19\">",
"     <span class=\"h2\">",
"      Antidepressants",
"     </span>",
"     &nbsp;&mdash;&nbsp;In 2010, the United States Food and Drug Administration (FDA) approved the use of very low doses of doxepin, an antidepressant, as a treatment for insomnia. This new formulation, called Silenor&reg;, uses doses of 3 and 6 mg of doxepin as a specific treatment for insomnia. This medication may be most helpful for patients with difficulty staying asleep. The most common side effects of Silenor&reg; are drowsiness the next day, dry mouth, and dry eyes.",
"    </p>",
"    <p>",
"     Other antidepressants are not approved to treat insomnia, although they are sometimes used because they produce sedation. However, antidepressants may have a limited benefit unless you also have depression. Antidepressants can cause daytime sleepiness and other side effects. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?21/24/21894?source=see_link\">",
"      \"Patient information: Depression treatment options for adults (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H20\">",
"     <span class=\"h2\">",
"      Antihistamines",
"     </span>",
"     &nbsp;&mdash;&nbsp;Non-prescription sleep aids such as Nytol&reg;, Sominex&reg;, and Unisom&reg; contain an antihistamine (eg,",
"     <span class=\"nowrap\">",
"      diphenhydramine/Benadryl&reg;).",
"     </span>",
"     Some of these products also contain a pain reliever (eg, Tylenol&reg; PM, Advil&reg; PM). You should not take products containing a pain reliever every night, especially if you do not have pain.",
"    </p>",
"    <p>",
"     There is little evidence that these sleep aids are beneficial for treating insomnia. Antihistamines can cause daytime sleepiness and other side effects, such as dry mouth, blurred vision, and difficulty emptying the bladder.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H21\">",
"     <span class=\"h2\">",
"      Melatonin",
"     </span>",
"     &nbsp;&mdash;&nbsp;Melatonin is a hormone that is normally produced by a gland in the brain. &nbsp;Melatonin does not appear to be helpful in most people who have insomnia, except in people with delayed sleep phase syndrome. (See",
"     <a class=\"local\" href=\"#H10\">",
"      'Phototherapy'",
"     </a>",
"     above.)",
"    </p>",
"    <p>",
"     Melatonin appears to be safe when used for less than three months. However, melatonin is marketed as a dietary supplement; the ingredients, dose, and purity of dietary supplements are not regulated. Listed doses may be higher than that used for the treatment of insomnia (0.2 to 0.3 mg per night).",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H22\">",
"     <span class=\"h1\">",
"      ALCOHOL AND SLEEP",
"     </span>",
"    </p>",
"    <p>",
"     People commonly use alcohol as a sleep aid. However, alcohol often interferes with sleep later in the night. When used on a regular basis over the long-term, you can become dependent on alcohol and develop severe insomnia if you stop drinking alcohol. Due to numerous health risks, alcohol is not recommended at bedtime for people with insomnia.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H23\">",
"     <span class=\"h1\">",
"      ALTERNATIVE TREATMENTS FOR INSOMNIA",
"     </span>",
"    </p>",
"    <p>",
"     A recent review of complementary approaches in the treatment of insomnia concluded the following: There was some support for benefit from the use of acupressure, tai chi, and yoga; there was mixed evidence for the use of acupuncture and L-tryptophan; and, there was little support for the use of herbal medicines, such as valerian, massage, or aromatherapy.",
"    </p>",
"    <p>",
"     The potential benefits from tai chi and yoga might be related either to the procedure itself or to the activity involved. Other studies using various levels of exercise as a therapy have also shown mild positive effects that correlated with improvement in fitness levels and were independent of an improvement in mood. Most herbal products have not been tested to be sure that they are safe and effective. Therefore, these treatments are not recommended.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H24\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your healthcare provider is the best source of information for questions and concerns related to your medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H1804441004\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H2876534\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?21/58/22434?source=see_link\">",
"      Patient information: Insomnia (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?38/4/38978?source=see_link\">",
"      Patient information: Daytime sleepiness (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?19/9/19602?source=see_link\">",
"      Patient information: Jet lag (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?35/5/35921?source=see_link\">",
"      Patient information: What is a sleep study? (The Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H2876526\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?2/16/2306?source=see_link\">",
"      Patient information: Insomnia (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?14/57/15250?source=see_link\">",
"      Patient information: Anaphylaxis symptoms and diagnosis (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?21/24/21894?source=see_link\">",
"      Patient information: Depression treatment options for adults (Beyond the Basics)",
"     </a>",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H25\">",
"     <span class=\"h2\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/2/11301?source=see_link\">",
"      Classification of sleep disorders",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/36/41541?source=see_link\">",
"      Clinical features and diagnosis of insomnia",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/41/4758?source=see_link\">",
"      Overview of insomnia",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/46/13034?source=see_link\">",
"      Physiology and clinical use of melatonin",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/62/13290?source=see_link\">",
"      Treatment of insomnia",
"     </a>",
"     <br/>",
"     <br/>",
"     The following organizations also provide reliable health information.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Library of Medicine",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nlm.nih.gov/medlineplus/sleepdisorders.html\">",
"      www.nlm.nih.gov/medlineplus/sleepdisorders.html",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       American Academy of Sleep Medicine",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.aasmnet.org/\">",
"      www.aasmnet.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Heart, Lung, and Blood Institute",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nhlbi.nih.gov/health/public/sleep/index.htm\">",
"      www.nhlbi.nih.gov/health/public/sleep/index.htm",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     [",
"     <a class=\"abstract\" href=\"UTD.htm?27/24/28035/abstract/1-5\">",
"      1-5",
"     </a>",
"     ]",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 21, 2013.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"UTD.htm?27/24/28035?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <div id=\"patTopicRefHeader\">",
"    <div id=\"patTopicRefHeaderHeader\">",
"     References",
"    </div>",
"    <div id=\"patTopicRefHeaderTop\">",
"     <a href=\"#top\">",
"      <img alt=\"\" src=\"./../images/top_arrow.myextg\">",
"       Top",
"      </img>",
"     </a>",
"    </div>",
"   </div>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/24/28035/abstract/1\">",
"      Morin CM, Bootzin RR, Buysse DJ, et al. Psychological and behavioral treatment of insomnia:update of the recent evidence (1998-2004). Sleep 2006; 29:1398.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/24/28035/abstract/2\">",
"      Edinger JD, Wohlgemuth WK, Radtke RA, et al. Cognitive behavioral therapy for treatment of chronic primary insomnia: a randomized controlled trial. JAMA 2001; 285:1856.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/24/28035/abstract/3\">",
"      Buscemi N, Vandermeer B, Friesen C, et al. The efficacy and safety of drug treatments for chronic insomnia in adults: a meta-analysis of RCTs. J Gen Intern Med 2007; 22:1335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/24/28035/abstract/4\">",
"      Sarris J, Byrne GJ. A systematic review of insomnia and complementary medicine. Sleep Med Rev 2011; 15:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/24/28035/abstract/5\">",
"      Reid KJ, Baron KG, Lu B, et al. Aerobic exercise improves self-reported sleep and quality of life in older adults with insomnia. Sleep Med 2010; 11:934.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f27_24_28035=[""].join("\n");
var outline_f27_24_28035=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           INSOMNIA OVERVIEW",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H2\">",
"           BEHAVIORAL THERAPY FOR INSOMNIA",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H12\">",
"           MEDICINES FOR INSOMNIA",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H22\">",
"           ALCOHOL AND SLEEP",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H23\">",
"           ALTERNATIVE TREATMENTS FOR INSOMNIA",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H24\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#references\">",
"           REFERENCES",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"       <h1>",
"        GRAPHICS",
"       </h1>",
"       <div id=\"relatedGraphics\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          TABLES",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_table\" href=\"UTD.htm?2/57/2971\" title=\"table 1\">",
"           Rules for good sleep PI",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f27_24_28036="Repair sphincter third degr lac";
var content_f27_24_28036=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F78780&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F78780&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 546px\">",
"   <div class=\"ttl\">",
"    Repair of the anal sphincter after a third-degree perineal laceration",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 526px; height: 372px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A third degree laceration extends not only through the skin, mucous membrane, and perinal body, but includes the anal sphincter. Interrupted figure-of-eight sutures should be placed in the capsule of the sphincter muscle.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Gabbe, SG, Niebyl, JR, Simpson, JL. Closure of 2nd degree laceration. In: Obstetrics: Normal &amp; problem pregnancies, 3rd ed, Churchill Livingstone Inc., New York 1996. Copyright &copy; 1996 Elsevier.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_24_28036=[""].join("\n");
var outline_f27_24_28036=null;
var title_f27_24_28037="Pontine lesions vanishing white matter disease";
var content_f27_24_28037=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F78840&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F78840&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Neuropathology of the pons in vanishing white matter disease",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 288px; height: 432px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A transverse section of the pons reveals symmetric lesions in the areas of the central tegmental tracts (arrows), the superior central nuclei (arrowheads), and the dorsal and central parts of the basis pontis (Kliiver stain).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Van der Knaap MS, Kamphorst W, Barth PG. Phenotypic variation in leukoencephalopathy with vanishing white matter. Neurology 1998; 51:540. Copyright &copy; 1998 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_24_28037=[""].join("\n");
var outline_f27_24_28037=null;
var title_f27_24_28038="Soft tissue infections due to dog and cat bites";
var content_f27_24_28038=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Soft tissue infections due to dog and cat bites",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/24/28038/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/24/28038/contributors\">",
"     Larry M Baddour, MD, FIDSA",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/24/28038/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/24/28038/contributors\">",
"     Daniel J Sexton, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/24/28038/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/24/28038/contributors\">",
"     Elinor L Baron, MD, DTMH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?27/24/28038/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 1, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Issues related to soft tissue infections resulting from dog and cat bites will be reviewed here. Cat scratch disease, soft tissue infections due to human bites, and bites in children are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/47/23289?source=see_link\">",
"     \"Microbiology, epidemiology, clinical manifestations, and diagnosis of cat scratch disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/18/31013?source=see_link\">",
"     \"Soft tissue infections due to human bites\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/57/20377?source=see_link\">",
"     \"Initial management of animal and human bites\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;In North America, animal bites account for about 1 percent of emergency department visits and 10,000 inpatient admissions annually; approximately 1 in every 775 persons seeks emergency care for dog bites each year [",
"    <a class=\"abstract\" href=\"UTD.htm?27/24/28038/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. In a study of 769 dog bite victims evaluated over a two-year period in a community hospital emergency department, wound infection was evident in 2.5 percent of cases upon presentation, and wound infections were diagnosed in 2.1 percent of cases at follow-up [",
"    <a class=\"abstract\" href=\"UTD.htm?27/24/28038/abstract/4\">",
"     4",
"    </a>",
"    ]. Others report infection in up to one-fifth of animal bites [",
"    <a class=\"abstract\" href=\"UTD.htm?27/24/28038/abstract/5,6\">",
"     5,6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Men are bitten more often by dogs than women, while women are bitten more often by cats than men [",
"    <a class=\"abstract\" href=\"UTD.htm?27/24/28038/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. Animal bites are more common among children than adults. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/57/20377?source=see_link\">",
"     \"Initial management of animal and human bites\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The frequency of dog bite injuries varies with breed. German Shepherd and mixed breeds account for many dog bites, while sporting dogs are less commonly implicated [",
"    <a class=\"abstract\" href=\"UTD.htm?27/24/28038/abstract/1\">",
"     1",
"    </a>",
"    ]. The pit bull breed of the Staffordshire terrier has been associated with the majority of dog bite-related deaths in the United States; death usually results from exsanguination due to the number and severity of bites.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     MICROBIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The predominant pathogens in animal bite wounds are the oral flora of the biting animal and human skin flora [",
"    <a class=\"abstract\" href=\"UTD.htm?27/24/28038/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. About 85 percent of bites harbor potential pathogens, and the average wound yields five types of bacterial isolates; 60 percent have mixed aerobic and anaerobic bacteria [",
"    <a class=\"abstract\" href=\"UTD.htm?27/24/28038/abstract/9\">",
"     9",
"    </a>",
"    ]. Skin flora such as staphylococci and streptococci are isolated in about 40 percent of bites. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/24/29065?source=see_link\">",
"     \"Zoonoses from dogs\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/42/31401?source=see_link\">",
"     \"Zoonoses from cats\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Pasteurella species are isolated from 50 percent of dog bite wounds and 75 percent of cat bite wounds (",
"    <a class=\"graphic graphic_picture graphicRef70953 \" href=\"UTD.htm?36/1/36880\">",
"     picture 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?27/24/28038/abstract/9\">",
"     9",
"    </a>",
"    ]. Capnocytophaga canimorsus, a fastidious gram-negative rod, can cause bacteremia and fatal sepsis after animal bites, especially in asplenic patients or those with underlying hepatic disease. Anaerobes isolated from dog and cat bite wounds include Bacteroides, fusobacteria, Porphyromonas, Prevotella, propionibacteria and peptostreptococci [",
"    <a class=\"abstract\" href=\"UTD.htm?27/24/28038/abstract/11\">",
"     11",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/0/13321?source=see_link\">",
"     \"Pasteurella infections\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/42/9895?source=see_link\">",
"     \"Clinical features and management of sepsis in the asplenic patient\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     CLINICAL EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;A review of the circumstances related to the incident should be elicited, including whether the animal is available for observation. Cat bite wounds tend to penetrate deeply, with higher risk of associated osteomyelitis, tenosynovitis, and septic arthritis than dog bites, which are more likely to have associated crush injury and wound trauma [",
"    <a class=\"abstract\" href=\"UTD.htm?27/24/28038/abstract/12\">",
"     12",
"    </a>",
"    ]. The time to the first signs and symptoms of infection is shorter following cat bites than dog bites (median time 12 versus 24 hours) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/24/28038/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients presenting &gt;8 hours following the injury are likelier to have established infection than those presenting early. Clinical manifestations of bite wound infections may include fever, erythema, swelling, tenderness, purulent drainage and lymphangitis [",
"    <a class=\"abstract\" href=\"UTD.htm?27/24/28038/abstract/9\">",
"     9",
"    </a>",
"    ]. Subcutaneous abscesses occur in up to 20 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?27/24/28038/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Those with deep or severe wound infections and should have radiographic imaging to evaluate for subcutaneous abscess, osteomyelitis, septic arthritis or tendonitis. Pain near a bone or joint that is out of proportion to injury severity should suggest periosteal penetration with risk for osteomyelitis. Focal pain along a tendon sheath should raise suspicion for tenosynovitis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/34/4649?source=see_link\">",
"     \"Overview of osteomyelitis in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Bite wounds may also be accompanied by bacteremia, even in the do not appear grossly infected; blood cultures should be obtained in the setting of fever or other signs of systemic infection. Sepsis and its complications can also occur, particularly among immunocompromised hosts [",
"    <a class=\"abstract\" href=\"UTD.htm?27/24/28038/abstract/14,15\">",
"     14,15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of animal bites includes wound care, antibiotic therapy and vaccination [",
"    <a class=\"abstract\" href=\"UTD.htm?27/24/28038/abstract/14,16\">",
"     14,16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Wound management",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bite wounds should be irrigated copiously with sterile saline, and grossly visible debris should be removed. Superficial wound cultures obtained at the time of injury are not helpful for predicting whether infection will develop since early wounds are often colonized with potential pathogens, and it can be difficult to predict whether the wound will become infected [",
"    <a class=\"abstract\" href=\"UTD.htm?27/24/28038/abstract/14,17\">",
"     14,17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Surgical evaluation of infected animal bite wounds with abscess formation or evidence of deep infection should be pursued, especially for wounds involving the hand (",
"    <a class=\"graphic graphic_table graphicRef75020 \" href=\"UTD.htm?37/4/37964\">",
"     table 1",
"    </a>",
"    ). If debridement is needed, it should be performed cautiously to avoid unnecessarily enlarging the wound and impairing skin closure [",
"    <a class=\"abstract\" href=\"UTD.htm?27/24/28038/abstract/13\">",
"     13",
"    </a>",
"    ]. Debrided material should be sent for aerobic and anaerobic culture. In general, wounds should be left open, with approximation of wound edges to facilitate closure by secondary intention. On reevaluation within a few days, delayed primary closure can be performed as long as there are no signs of infection. Elevation of the injured area is important to accelerate healing and reduce pain due to dependent swelling.",
"   </p>",
"   <p>",
"    Complex facial bite wounds are a special exception for which primary closure by a plastic surgeon is preferable to avoid scarring [",
"    <a class=\"abstract\" href=\"UTD.htm?27/24/28038/abstract/13,18\">",
"     13,18",
"    </a>",
"    ]. Large lacerations and disfiguring wounds may also be appropriate for primary closure [",
"    <a class=\"abstract\" href=\"UTD.htm?27/24/28038/abstract/14\">",
"     14",
"    </a>",
"    ]. Subcutaneous sutures should be used sparingly, since foreign material in a contaminated wound increases the risk of infection.",
"   </p>",
"   <p>",
"    The approach to wound management is discussed in further detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/57/20377?source=see_link\">",
"     \"Initial management of animal and human bites\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Antibiotics",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Prophylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prophylactic",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/56/43912?source=see_link\">",
"     amoxicillin-clavulanate",
"    </a>",
"    has been shown to reduce the rate of infection due to animal bite wounds [",
"    <a class=\"abstract\" href=\"UTD.htm?27/24/28038/abstract/13,14,19-21\">",
"     13,14,19-21",
"    </a>",
"    ]. This was illustrated in a prospective trial of 185 patients with full thickness animal bite wounds; prophylactic antibiotics significantly reduced the infection rate among patients presenting 9 to 24 hours after injury [",
"    <a class=\"abstract\" href=\"UTD.htm?27/24/28038/abstract/19\">",
"     19",
"    </a>",
"    ]. No significant benefit was observed in patients presenting less than 9 hours following bite injury. These findings suggest that patients with more than just superficial wounds who present greater than 8 hours after a bite should receive prophylactic antibiotics.",
"   </p>",
"   <p>",
"    In addition, antibiotic prophylaxis should be administered for animal bites in the following circumstances [",
"    <a class=\"abstract\" href=\"UTD.htm?27/24/28038/abstract/6,13\">",
"     6,13",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Deep puncture wounds (especially due to cat bites)",
"     </li>",
"     <li>",
"      Moderate to severe wounds with associated crush injury",
"     </li>",
"     <li>",
"      Wounds in areas of underlying venous",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      lymphatic compromise",
"     </li>",
"     <li>",
"      Wounds on the hand(s) or in close proximity to a bone or joint (particularly the hand, as well as prosthetic joints)",
"     </li>",
"     <li>",
"      Wounds on the face or in the genital area",
"     </li>",
"     <li>",
"      Wounds requiring surgical repair",
"     </li>",
"     <li>",
"      Wounds in immunocompromised hosts",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Prophylactic oral antibiotics should be administered for three to five days, with close followup (",
"    <a class=\"graphic graphic_table graphicRef75020 \" href=\"UTD.htm?37/4/37964\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?27/24/28038/abstract/13\">",
"     13",
"    </a>",
"    ]. On followup evaluation, signs of infection should prompt further evaluation (with radiographic imaging",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    surgical consultation, if needed) and an extension of the antibiotic course.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with deep or severe wound infections should receive intravenous antibiotics; appropriate regimens are outlined in the Table (",
"    <a class=\"graphic graphic_table graphicRef63280 \" href=\"UTD.htm?26/45/27356\">",
"     table 2",
"    </a>",
"    ). Patients with complicated infections require prolonged therapy tailored to individual circumstances. For example, synovitis should be treated for up to four weeks, and osteomyelitis usually requires at least six weeks of therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?27/24/28038/abstract/13\">",
"     13",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/34/4649?source=see_link\">",
"     \"Overview of osteomyelitis in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In the absence of such complications, the duration of antibiotic therapy should be tailored to clinical improvement. In the setting of bacteremia, 10 to 14 days of parenteral therapy should be administered. Otherwise, cellulitis and skin abscess usually respond to 5 to 10 days of therapy. Intravenous therapy may be switched to outpatient oral therapy when evidence of clinical improvement is apparent (",
"    <a class=\"graphic graphic_table graphicRef75020 \" href=\"UTD.htm?37/4/37964\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?27/24/28038/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Antibiotic selection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antibiotic therapy should include empiric coverage of the expected oral animal flora. Appropriate agents are outlined in the Tables (",
"    <a class=\"graphic graphic_table graphicRef75020 \" href=\"UTD.htm?37/4/37964\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef63280 \" href=\"UTD.htm?26/45/27356\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Agents lacking in vitro activity against P. multocida should be avoided; these include first generation cephalosporins (such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/37/37462?source=see_link\">",
"     cephalexin",
"    </a>",
"    ), penicillinase-resistant penicillins (such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/11/3253?source=see_link\">",
"     dicloxacillin",
"    </a>",
"    ), macrolides (such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/29/36304?source=see_link\">",
"     erythromycin",
"    </a>",
"    ), and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/21/33104?source=see_link\">",
"     clindamycin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?27/24/28038/abstract/22\">",
"     22",
"    </a>",
"    ]. However, clindamycin may be used for anaerobic coverage if it is administered in conjunction with an additional agent that is active against P. multocida.",
"   </p>",
"   <p>",
"    Capnocytophaga species are broadly susceptible to many antimicrobial agents. Because occasional strains produce beta-lactamase, a penicillin-beta-lactamase combination or third generation cephalosporin are drugs of first choice for parenteral therapy. For oral therapy of milder infections,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/21/33104?source=see_link\">",
"     clindamycin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    , and fluoroquinolones all have activity.",
"   </p>",
"   <p>",
"    In addition to animal oral flora, human skin flora are also important pathogens, including methicillin resistant S. aureus (MRSA). Coverage for MRSA may be especially important if the patient has risk factors for colonization with community-acquired MRSA (",
"    <a class=\"graphic graphic_table graphicRef53504 \" href=\"UTD.htm?5/9/5275\">",
"     table 3",
"    </a>",
"    ). Pets can also become colonized with MRSA and transmit it via bites and scratches [",
"    <a class=\"abstract\" href=\"UTD.htm?27/24/28038/abstract/23,24\">",
"     23,24",
"    </a>",
"    ]. Risk factors and treatment of MRSA are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/7/4216?source=see_link\">",
"     \"Treatment of skin and soft tissue infections due to methicillin-resistant Staphylococcus aureus in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/48/21258?source=see_link\">",
"     \"Treatment of invasive methicillin-resistant Staphylococcus aureus infections in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/53/8026?source=see_link\">",
"     \"Epidemiology of methicillin-resistant Staphylococcus aureus infection in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Vaccination",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/18/293?source=see_link\">",
"     Tetanus immune globulin",
"    </a>",
"    and tetanus toxoid should be administered to all bite patients who have had two or fewer primary immunizations. Tetanus toxoid alone can be given to those who have completed a primary immunization series but who have not received a booster for more than five years. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/54/7014?source=see_link\">",
"     \"Tetanus-diphtheria toxoid vaccination in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Rabies prophylaxis should be considered in the setting of bites from unvaccinated pets, wild animals and in geographic areas where the prevalence of rabies is high (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/21/2393?source=see_link\">",
"     \"Rabies immune globulin and vaccine\"",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?22/15/22770?source=see_link\">",
"       \"Patient information: Animal bites (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?29/55/30578?source=see_link\">",
"       \"Patient information: Rabies (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The predominant organisms in animal bite wounds are the oral flora of the biting animal (notable pathogens include Pasteurella, Capnocytophaga, and anaerobes) as well as human skin flora (such as staphylococci and streptococci). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Microbiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Clinical manifestations of bite wound infections may include fever, erythema, swelling, tenderness, purulent drainage and lymphangitis. Complications include subcutaneous abscesses osteomyelitis, septic arthritis, tendonitis, and bacteremia. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Clinical evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Those with deep or severe wound infections and should have radiographic imaging to evaluate for subcutaneous abscess, osteomyelitis, septic arthritis, or tendonitis. Blood cultures should be obtained. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Clinical evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Bite wounds should be irrigated copiously with sterile saline, and grossly visible debris should be removed. Surgical evaluation of animal bite wounds is critical, especially for wounds involving the hand. Debrided material should be sent for aerobic and anaerobic culture (see",
"      <a class=\"local\" href=\"#H6\">",
"       'Wound management'",
"      </a>",
"      above).",
"     </li>",
"     <li>",
"      Infected animal bite wounds should be left open following debridement, with approximation of wound edges to facilitate closure by secondary intention. However, primary closure is appropriate for facial bite wounds, large lacerations, and disfiguring wounds. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Wound management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend prophylaxis with oral antibiotics for patient circumstances as outlined above (",
"      <a class=\"graphic graphic_table graphicRef75020 \" href=\"UTD.htm?37/4/37964\">",
"       table 1",
"      </a>",
"      )&nbsp;(",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). Clinical worsening despite oral prophylaxis should prompt an evaluation for wound complications and a consideration for switch therapy to intravenous treatment (",
"      <a class=\"graphic graphic_table graphicRef63280 \" href=\"UTD.htm?26/45/27356\">",
"       table 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Prophylaxis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend that patients with deep or severe wound infections receive initial therapy with intravenous rather than oral antibiotics (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). Appropriate regimens are outlined in the Table (",
"      <a class=\"graphic graphic_table graphicRef63280 \" href=\"UTD.htm?26/45/27356\">",
"       table 2",
"      </a>",
"      ). Intravenous therapy may be switched to outpatient oral therapy with evidence of clinical improvement, and the duration of antibiotic therapy should be tailored to clinical resolution of infection. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Vaccination status for tetanus and rabies should be considered. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Vaccination'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/24/28038/abstract/1\">",
"      Dire DJ. Emergency management of dog and cat bite wounds. Emerg Med Clin North Am 1992; 10:719.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/24/28038/abstract/2\">",
"      Centers for Disease Control and Prevention (CDC). Nonfatal dog bite-related injuries treated in hospital emergency departments--United States, 2001. MMWR Morb Mortal Wkly Rep 2003; 52:605.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/24/28038/abstract/3\">",
"      Weiss HB, Friedman DI, Coben JH. Incidence of dog bite injuries treated in emergency departments. JAMA 1998; 279:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/24/28038/abstract/4\">",
"      Dire DJ, Hogan DE, Riggs MW. A prospective evaluation of risk factors for infections from dog-bite wounds. Acad Emerg Med 1994; 1:258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/24/28038/abstract/5\">",
"      Callaham M. Controversies in antibiotic choices for bite wounds. Ann Emerg Med 1988; 17:1321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/24/28038/abstract/6\">",
"      Morgan M, Palmer J. Dog bites. BMJ 2007; 334:413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/24/28038/abstract/7\">",
"      MacBean CE, Taylor DM, Ashby K. Animal and human bite injuries in Victoria, 1998-2004. Med J Aust 2007; 186:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/24/28038/abstract/8\">",
"      Hon KL, Fu CC, Chor CM, et al. Issues associated with dog bite injuries in children and adolescents assessed at the emergency department. Pediatr Emerg Care 2007; 23:445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/24/28038/abstract/9\">",
"      Talan DA, Citron DM, Abrahamian FM, et al. Bacteriologic analysis of infected dog and cat bites. Emergency Medicine Animal Bite Infection Study Group. N Engl J Med 1999; 340:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/24/28038/abstract/10\">",
"      Goldstein EJ, Citron DM, Wield B, et al. Bacteriology of human and animal bite wounds. J Clin Microbiol 1978; 8:667.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/24/28038/abstract/11\">",
"      Goldstein EJ. New horizons in the bacteriology, antimicrobial susceptibility and therapy of animal bite wounds. J Med Microbiol 1998; 47:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/24/28038/abstract/12\">",
"      Goldstein EJ. Bite wounds and infection. Clin Infect Dis 1992; 14:633.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/24/28038/abstract/13\">",
"      Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management of skin and soft-tissue infections. Clin Infect Dis 2005; 41:1373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/24/28038/abstract/14\">",
"      Fleisher GR. The management of bite wounds. N Engl J Med 1999; 340:138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/24/28038/abstract/15\">",
"      Oehler RL, Velez AP, Mizrachi M, et al. Bite-related and septic syndromes caused by cats and dogs. Lancet Infect Dis 2009; 9:439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/24/28038/abstract/16\">",
"      Abrahamian FM. Dog Bites: Bacteriology, Management, and Prevention. Curr Infect Dis Rep 2000; 2:446.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/24/28038/abstract/17\">",
"      Hagan M, Goldstein E, Sanford JP. Bites from pet animals. Hosp Pract (Off Ed) 1993; 28:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/24/28038/abstract/18\">",
"      Stucker FJ, Shaw GY, Boyd S, Shockley WW. Management of animal and human bites in the head and neck. Arch Otolaryngol Head Neck Surg 1990; 116:789.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/24/28038/abstract/19\">",
"      Brakenbury PH, Muwanga C. A comparative double blind study of amoxycillin/clavulanate vs placebo in the prevention of infection after animal bites. Arch Emerg Med 1989; 6:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/24/28038/abstract/20\">",
"      Cummings P. Antibiotics to prevent infection in patients with dog bite wounds: a meta-analysis of randomized trials. Ann Emerg Med 1994; 23:535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/24/28038/abstract/21\">",
"      Callaham M. Prophylactic antibiotics in dog bite wounds: nipping at the heels of progress. Ann Emerg Med 1994; 23:577.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/24/28038/abstract/22\">",
"      Goldstein EJ, Citron DM, Richwald GA. Lack of in vitro efficacy of oral forms of certain cephalosporins, erythromycin, and oxacillin against Pasteurella multocida. Antimicrob Agents Chemother 1988; 32:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/24/28038/abstract/23\">",
"      Baptiste KE, Williams K, Willams NJ, et al. Methicillin-resistant staphylococci in companion animals. Emerg Infect Dis 2005; 11:1942.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/24/28038/abstract/24\">",
"      Sing A, Tuschak C, H&ouml;rmansdorfer S. Methicillin-resistant Staphylococcus aureus in a family and its pet cat. N Engl J Med 2008; 358:1200.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7671 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-200.131.240.2-EA0AF42627-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_24_28038=[""].join("\n");
var outline_f27_24_28038=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H13\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      MICROBIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      CLINICAL EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Wound management",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Antibiotics",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Treatment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Antibiotic selection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Vaccination",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/7671\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/7671|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?36/1/36880\" title=\"picture 1\">",
"      Pasteurella multocida microscopy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/7671|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?37/4/37964\" title=\"table 1\">",
"      Empiric oral antibiotics animal bites",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?26/45/27356\" title=\"table 2\">",
"      Empiric intravenous antibiotic therapy for animal bites",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?5/9/5275\" title=\"table 3\">",
"      Risk factors for MRSA",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/42/9895?source=related_link\">",
"      Clinical features and management of sepsis in the asplenic patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/53/8026?source=related_link\">",
"      Epidemiology of methicillin-resistant Staphylococcus aureus infection in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/57/20377?source=related_link\">",
"      Initial management of animal and human bites",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/47/23289?source=related_link\">",
"      Microbiology, epidemiology, clinical manifestations, and diagnosis of cat scratch disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/34/4649?source=related_link\">",
"      Overview of osteomyelitis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/0/13321?source=related_link\">",
"      Pasteurella infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?22/15/22770?source=related_link\">",
"      Patient information: Animal bites (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?29/55/30578?source=related_link\">",
"      Patient information: Rabies (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/21/2393?source=related_link\">",
"      Rabies immune globulin and vaccine",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/18/31013?source=related_link\">",
"      Soft tissue infections due to human bites",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/54/7014?source=related_link\">",
"      Tetanus-diphtheria toxoid vaccination in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/48/21258?source=related_link\">",
"      Treatment of invasive methicillin-resistant Staphylococcus aureus infections in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/7/4216?source=related_link\">",
"      Treatment of skin and soft tissue infections due to methicillin-resistant Staphylococcus aureus in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/42/31401?source=related_link\">",
"      Zoonoses from cats",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/24/29065?source=related_link\">",
"      Zoonoses from dogs",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f27_24_28039="Pathogenesis and diagnosis of twin-twin transfusion syndrome";
var content_f27_24_28039=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Pathogenesis and diagnosis of twin-twin transfusion syndrome",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/24/28039/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/24/28039/contributors\">",
"     Kenneth J Moise Jr, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/24/28039/contributors\">",
"     Anthony Johnson, DO",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/24/28039/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/24/28039/contributors\">",
"     Deborah Levine, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/24/28039/contributors\">",
"     Louise Wilkins-Haug, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/24/28039/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/24/28039/contributors\">",
"     Vanessa A Barss, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?27/24/28039/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 10, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Twin-twin transfusion syndrome (TTTS) is one of the most serious complications of monochorionic multiple gestations. It is associated with a high risk of",
"    <span class=\"nowrap\">",
"     fetal/neonatal",
"    </span>",
"    mortality, especially in previable gestations, and fetuses who survive are at risk of severe cardiac, neurologic, and developmental disorders.",
"   </p>",
"   <p>",
"    Historically, the diagnosis was made in neonates with intertwin weight discordance of 15 to 20 percent and a hemoglobin difference of greater than 5",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?27/24/28039/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. However, these criteria were abandoned after it was demonstrated that weight",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    hemoglobin discordance are relatively common in monochorionic twins and not sufficient to diagnose TTTS [",
"    <a class=\"abstract\" href=\"UTD.htm?27/24/28039/abstract/3\">",
"     3",
"    </a>",
"    ]. Furthermore, TTTS can occur without significant hemoglobin discordancy [",
"    <a class=\"abstract\" href=\"UTD.htm?27/24/28039/abstract/4\">",
"     4",
"    </a>",
"    ]. With advances in prenatal ultrasonography, it became clear that the cardinal finding in TTTS is a significant discrepancy in amniotic fluid volumes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     INCIDENCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence of TTTS is not clear since some fetal losses in monochorionic multifetal gestations in the first half of pregnancy may be related to undiagnosed TTTS [",
"    <a class=\"abstract\" href=\"UTD.htm?27/24/28039/abstract/5\">",
"     5",
"    </a>",
"    ]. For this reason, incidence based on data from liveborns or sonograms in the second half of pregnancy may not be accurate. Our best estimate of the incidence of TTTS is 1:40 to 1:60 twin pregnancies [",
"    <a class=\"abstract\" href=\"UTD.htm?27/24/28039/abstract/6-9\">",
"     6-9",
"    </a>",
"    ] and 9 to 15 percent of monochorionic pregnancies [",
"    <a class=\"abstract\" href=\"UTD.htm?27/24/28039/abstract/5,7\">",
"     5,7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PATHOPHYSIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no animal model for study of TTTS, but computer models have been developed [",
"    <a class=\"abstract\" href=\"UTD.htm?27/24/28039/abstract/10-12\">",
"     10-12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Unbalanced vascular anastomoses",
"    </span>",
"    &nbsp;&mdash;&nbsp;Placental intertwin vascular anastomoses play a key role in the pathophysiology of TTTS. Dichorionic twins lack vascular connections between the placentas, even when fused, and do not develop TTTS. In monochorionic twins",
"    <span class=\"nowrap\">",
"     (2/3",
"    </span>",
"    of all monozygotic twin gestations), post-delivery placental injection studies have identified four types of vascular connections:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Arteriovenous (AV)",
"     </li>",
"     <li>",
"      Veno-arterial (VA)",
"     </li>",
"     <li>",
"      Arterioarterial (AA)",
"     </li>",
"     <li>",
"      Venovenous (VV)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    AV and VA anastomoses consist of feeder vessels on the surface of the chorionic plate that descend into a common cotyledon capillary network where they anastomose. By comparison, AA and VV anastomoses are seen exclusively on the surface of the placenta. Flow in these latter two types of connections is bidirectional; the net flow is related to opposing hydrostatic pressures of each fetus.",
"   </p>",
"   <p>",
"    Although vascular connections are found in virtually all monochorionic twins [",
"    <a class=\"abstract\" href=\"UTD.htm?27/24/28039/abstract/7,13\">",
"     7,13",
"    </a>",
"    ], only 9 to 15 percent of these twin pregnancies will ultimately develop TTTS [",
"    <a class=\"abstract\" href=\"UTD.htm?27/24/28039/abstract/5,7\">",
"     5,7",
"    </a>",
"    ]. The initial process that triggers the TTTS phenotype in some monochorionic twin pregnancies but not others has not been determined. One hypothesis is that when arterial and venous connections are being established to the placental villous tree around the fifth week of gestation, overlapping vascular boundaries of each twin allow formation of various anastomotic connections in the single placenta [",
"    <a class=\"abstract\" href=\"UTD.htm?27/24/28039/abstract/14\">",
"     14",
"    </a>",
"    ]. Computer modeling has demonstrated that if the connections are unbalanced (ie, there are more AV connections in one direction than in the other), then increasing hydrostatic and osmotic forces will result in the TTTS phenotype. However, if the connections are balanced (ie, equal numbers of bidirectional anastomoses), then TTTS does not develop.",
"   </p>",
"   <p>",
"    In addition, placental injection studies have shown that AA anastomoses are protective against the development of TTTS. In two large studies of monochorionic placentas, about 95 percent had AV connections and 70 to 85 percent also had AAs anastomoses [",
"    <a class=\"abstract\" href=\"UTD.htm?27/24/28039/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. In contrast to AV anastomoses, AA anastomoses were rare to nonexistent in pregnancies with TTTS.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Cardiovascular response to circulatory imbalance",
"    </span>",
"    &nbsp;&mdash;&nbsp;The precipitating event for the development of TTTS is likely to be relative hypovolemia in one twin (called the donor twin) in response to the imbalance in placental vascular anastomoses. In an attempt to restore its intravascular volume, several vasoactive mediators are released. The donor twin's vasopressin level becomes elevated to three times the level of the other twin [",
"    <a class=\"abstract\" href=\"UTD.htm?27/24/28039/abstract/17\">",
"     17",
"    </a>",
"    ]. The donor twin's renin-angiotensin system (RAS) also appears to be upregulated, based on the finding of significant levels of renin protein and mRNA and associated renal tubular dysgenesis on histochemical investigation of donor kidneys at autopsy [",
"    <a class=\"abstract\" href=\"UTD.htm?27/24/28039/abstract/18\">",
"     18",
"    </a>",
"    ]. These hormonal derangements result in oliguria, which ultimately results in anhydramnios and the \"stuck twin\" phenotype.",
"   </p>",
"   <p>",
"    The nondonor twin experiences hypervolemia and is called the recipient twin. Hypervolemia causes its cardiac atria to stretch and release atrial natriuretic peptide (ANP) and brain natriuretic peptide (BNP). Mean ANP levels are three times higher in recipients than donors, while mean BNP levels are twice as high in recipients compared with donors [",
"    <a class=\"abstract\" href=\"UTD.htm?27/24/28039/abstract/19\">",
"     19",
"    </a>",
"    ]. These two hormones have potent natriuretic and vasodilatory properties, resulting in fetal polyuria and eventually leading to polyhydramnios in the recipient's sac.",
"   </p>",
"   <p>",
"    The cardiovascular changes in the recipient twin appear to be progressive [",
"    <a class=\"abstract\" href=\"UTD.htm?27/24/28039/abstract/20\">",
"     20",
"    </a>",
"    ]. Initially, hypervolemia is compensated by increased urine output, but eventually, donor deterioration results in elevated levels of renin and angiotensin, which pass through placental anastomoses to the recipient. Plasma endothelin-1 levels also appear to be higher in recipient fetuses than their donor siblings, possibly related to placental dysfunction on the recipient's side [",
"    <a class=\"abstract\" href=\"UTD.htm?27/24/28039/abstract/21\">",
"     21",
"    </a>",
"    ]. Both the RAS mediators and endothelin-1 contribute to hypertension in the recipient. Doppler measurements of the regurgitant jet of the tricuspid valve in the recipient twin have found systolic pressures increased 2.5-fold [",
"    <a class=\"abstract\" href=\"UTD.htm?27/24/28039/abstract/22\">",
"     22",
"    </a>",
"    ]. These changes lead to a fall in urine output, with resolution of polyhydramnios.",
"   </p>",
"   <p>",
"    Hypervolemia and abnormal concentrations of vasoactive mediators results in cardiac hypertrophy, cardiomegaly and cardiac dysfunction in the recipient twin. Acquired or functional right ventricular outflow tract abnormalities, including pulmonary stenosis and functional or anatomic atresia, have been observed in approximately 10 percent of recipient twins [",
"    <a class=\"abstract\" href=\"UTD.htm?27/24/28039/abstract/23-26\">",
"     23-26",
"    </a>",
"    ]. Hypertrophy can develop in one or both fetal cardiac ventricles. (Hypertrophy is measured with ultrasound and defined as ventricular wall or intraventricular septal thickness greater than 2 SD for gestational age). Echocardiographic studies have revealed that right-sided myocardial dysfunction is two to three-fold more common than left-sided dysfunction, which is not surprising since the right ventricle is the dominant ventricle in the fetal heart [",
"    <a class=\"abstract\" href=\"UTD.htm?27/24/28039/abstract/22\">",
"     22",
"    </a>",
"    ]. Depressed myocardial contractility and severe tricuspid regurgitation can be identified in addition to reversed a-wave on Doppler interrogation of the ductus venosus. Functional obstruction of the pulmonary artery is signified by reverse filling of the ductus arteriosus from the aortic arch [",
"    <a class=\"abstract\" href=\"UTD.htm?27/24/28039/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition, hemodynamic imbalance may impair cerebral perfusion, leading to antenatal cerebral injury [",
"    <a class=\"abstract\" href=\"UTD.htm?27/24/28039/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Finally, venous hypertension results in movement of intravascular fluid into the interstitial spaces and functional lymphatic obstruction. This leads to the development of hydrops fetalis [",
"    <a class=\"abstract\" href=\"UTD.htm?27/24/28039/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS AND DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;TTTS is usually first suspected because of characteristic findings on ultrasound examination (see below) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/24/28039/abstract/29\">",
"     29",
"    </a>",
"    ]. The mother is usually asymptomatic, but symptoms related to excessive uterine distention may occur [",
"    <a class=\"abstract\" href=\"UTD.htm?27/24/28039/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The prenatal diagnosis of TTTS is based upon ultrasonographic evidence of a single monochorionic placenta with",
"    <span class=\"nowrap\">",
"     polyhydramnios/oligohydramnios",
"    </span>",
"    sequence (POS). Before 20 weeks gestation, the maximum vertical amniotic fluid pockets for oligohydramnios and polyhydramnios are usually defined as &lt;2 cm and &gt;8 cm, respectively. After 20 weeks, the maximum vertical pocket for polyhydramnios is defined as &gt;10 cm [",
"    <a class=\"abstract\" href=\"UTD.htm?27/24/28039/abstract/10\">",
"     10",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/46/40682?source=see_link&amp;anchor=H10#H10\">",
"     \"Twin pregnancy: Prenatal issues\", section on 'Ultrasonographic assessment of chorionicity'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    When severe, oligohydramnios in the donor's sac leads to a \"stuck twin\" appearance wherein the fetus appears stuck to the uterine wall because there is no or minimal fluid in its sac and its amniotic membrane lies against its body (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef63614 graphicRef66239 \" href=\"UTD.htm?35/59/36790\">",
"     image 1A-B",
"    </a>",
"    ). In contrast, the recipient twin is freely mobile within a large volume of amniotic fluid (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef76957 graphicRef52874 graphicRef76546 graphicRef54479 graphicRef67334 \" href=\"UTD.htm?28/3/28730\">",
"     image 2A-E",
"    </a>",
"    ), which also compresses the donor twin&rsquo;s sac and can lead to shortening of the maternal cervical length (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef78079 \" href=\"UTD.htm?12/0/12289\">",
"     image 3",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Other disorders that should be considered when twin size or amniotic fluid discordancy is noted include uteroplacental insufficiency, congenital anomalies (eg, renal agenesis in suspected &ldquo;donor&rdquo; twin), umbilical cord abnormalities, and intrauterine infection. Premature rupture of membranes of one sac can cause amniotic fluid discordancy, as well.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H276251225\">",
"    <span class=\"h2\">",
"     TAPS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Twin anemia-polycythemia sequence (TAPS) is an atypical chronic form of TTTS that presents as a large intertwin hemoglobin difference, without oligohydramnios-polyhydramnios sequence [",
"    <a class=\"abstract\" href=\"UTD.htm?27/24/28039/abstract/31-33\">",
"     31-33",
"    </a>",
"    ]. Spontaneous TAPS in the absence of other clinical signs of TTTS has been reported in 3 to 6 percent of previously uncomplicated third trimester",
"    <span class=\"nowrap\">",
"     MC/DA",
"    </span>",
"    twins [",
"    <a class=\"abstract\" href=\"UTD.htm?27/24/28039/abstract/33,34\">",
"     33,34",
"    </a>",
"    ]. The reported incidence after laser therapy is 2 to 13 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?27/24/28039/abstract/35,36\">",
"     35,36",
"    </a>",
"    ]. Most cases are diagnosed in the late second or third trimester [",
"    <a class=\"abstract\" href=\"UTD.htm?27/24/28039/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Placental injection studies from TTTS pregnancies treated with laser have demonstrated that presence of residual anastomoses in those pregnancies which later developed TAPS. In the majority of cases, the residual anastomoses were very small (&lt;1 mm) unidirectional arterio-venous (AV) anastomoses without accompanying arterio-arterial anastomoses. The small residual anastomoses lead to the gradual development of anemia in one twin and polycythemia in the other [",
"    <a class=\"abstract\" href=\"UTD.htm?27/24/28039/abstract/37\">",
"     37",
"    </a>",
"    ]. The slowness of the process allows for hemodynamic compensation, which is hypothesized to be the reason for absence of amniotic fluid volume discordancy [",
"    <a class=\"abstract\" href=\"UTD.htm?27/24/28039/abstract/16\">",
"     16",
"    </a>",
"    ]. On rare occasions, TAPS may precede development of TTTS.",
"   </p>",
"   <p>",
"    Prenatally, TAPS can be diagnosed when the middle cerebral artery-peak systolic velocity (MCA-PSV) is greater than 1.5 multiples of median (MoM) in the donor twin and less than 0.8 MoM in the recipient twin [",
"    <a class=\"abstract\" href=\"UTD.htm?27/24/28039/abstract/35,38\">",
"     35,38",
"    </a>",
"    ], although criteria are not uniform across studies (some authors use MCA-PSV &lt;1.0 MoM in the recipient twin [",
"    <a class=\"abstract\" href=\"UTD.htm?27/24/28039/abstract/33\">",
"     33",
"    </a>",
"    ]). There may also be growth discordancy. Severe polycythemia can lead to fetal and placental thrombosis and hydrops fetalis in the anemic twin [",
"    <a class=\"abstract\" href=\"UTD.htm?27/24/28039/abstract/38\">",
"     38",
"    </a>",
"    ]. Postnatal diagnosis is made by presence of an intertwin hemoglobin difference of &ge;8.0",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    in conjunction with an intertwin reticulocyte ratio of &gt;1.7 (reticulocyte count of the donor twin divided by the reticulocyte count of the recipient twin) and a placental injection examination showing very small superficial AV anastomoses [",
"    <a class=\"abstract\" href=\"UTD.htm?27/24/28039/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The outcome spectrum includes delivery of two healthy neonates, the need for blood transfusion or partial exchange transfusion, and death of one or both twins. &nbsp;In one small study of 19 twin pairs with TAPS and 38 control, monochorionic twin pairs, the incidence of neonatal death and severe neonatal morbidity was similar in the TAPS group and controls (3 versus 1 percent and 24 versus 28 percent, respectively). Severe cerebral injury was detected in one infant in the TAPS group and one infant in the control group [",
"    <a class=\"abstract\" href=\"UTD.htm?27/24/28039/abstract/39\">",
"     39",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/43/9913?source=see_link&amp;anchor=H106993505#H106993505\">",
"     \"Management of twin-twin transfusion syndrome\", section on 'TAPS'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     CLASSIFICATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Classification systems have been created to provide a standardized means of describing increasing severity of TTTS.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Quintero stages",
"    </span>",
"    &nbsp;&mdash;&nbsp;Quintero has proposed five stages of disease based on findings from two-dimensional ultrasound and Doppler velocimetry in the umbilical artery and vein and ductus venosus [",
"    <a class=\"abstract\" href=\"UTD.htm?27/24/28039/abstract/40\">",
"     40",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Stage I &mdash; Oligohydramnios and polyhydramnios sequence, and the bladder of the donor twin is visible. Dopplers in both twins are normal.",
"     </li>",
"     <li>",
"      Stage II &mdash; Oligohydramnios and polyhydramnios sequence, but the bladder of the donor is not visualized. Dopplers in both twins are normal.",
"     </li>",
"     <li>",
"      Stage III &mdash; Oligohydramnios and polyhydramnios sequence, nonvisualized bladder, and abnormal Dopplers. There is",
"      <span class=\"nowrap\">",
"       absent/reversed",
"      </span>",
"      end-diastolic velocity in the umbilical artery, reversed flow in a-wave of the ductus venosus, or pulsatile flow in the umbilical vein in either fetus.",
"     </li>",
"     <li>",
"      Stage IV &mdash; One or both fetuses show signs of hydrops.",
"     </li>",
"     <li>",
"      Stage V &mdash; One or both fetuses have died.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although Quintero staging represents one method of standardization, there are several important limitations. Atypical presentations can occur; as an example, the donor twin may have both a persistent bladder and abnormal umbilical Doppler flow. In addition, although higher stages are generally associated with a worsening perinatal prognosis, the clinical presentation of a particular case does not always follow an orderly progression of stages. As an example, a stage I case may progress rapidly in several days to Stage III and regression of disease can occur in as many as 15 percent of Stage I cases and 60 percent of Stage II disease [",
"    <a class=\"abstract\" href=\"UTD.htm?27/24/28039/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Cardiovascular score",
"    </span>",
"    &nbsp;&mdash;&nbsp;A cardiovascular scoring system has been reported from Children&rsquo;s Hospital of Philadelphia (CHOP score), based on echocardiographic and peripheral Doppler findings in a study of 150 donor and recipient fetuses (",
"    <a class=\"graphic graphic_table graphicRef78353 \" href=\"UTD.htm?18/47/19195\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?27/24/28039/abstract/20\">",
"     20",
"    </a>",
"    ]. When four grades of progressively worsening cardiovascular abnormalities were compared to Quintero staging, marked differences were noted. As an example, when fetuses classified as Quintero stage II were reclassified by cardiovascular score, the spread of cardiovascular score grades from least to most severe was grade 1 (35 percent), grade 2 (30 percent), grade 3 (25 percent), and grade 4 (10 percent). However, a subsequent prospective evaluation of 158 cases of TTTS prior to laser therapy at another center failed to find an association between an increasing CHOP score and perinatal survival [",
"    <a class=\"abstract\" href=\"UTD.htm?27/24/28039/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The Cincinnati modification of the Quintero staging system is another cardiovascular scoring system [",
"    <a class=\"abstract\" href=\"UTD.htm?27/24/28039/abstract/43\">",
"     43",
"    </a>",
"    ]. This system divides Quintero stage III into A, B, and C classifications based on progressively worsening echocardiographic findings of three parameters in the recipient fetus (eg, presence and severity of atrioventricular valvular incompetence, ventricular wall thickening, and ventricular function as assessed by the Tei index). Cases are &ldquo;upstaged&rdquo; from the Quintero stage based on the presence of these fetal echocardiography findings.",
"   </p>",
"   <p>",
"    The use of different staging systems must be taken into consideration when comparing reported pregnancy outcomes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     MONITORING FOR TTTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Performance of serial ultrasound examinations to assess growth is common in twin pregnancies. The optimum frequency of these examinations has not been established, and should probably depend upon on whether placentation is monochorionic or dichorionic. Monochorionic twins, in particular, should be monitored for development of TTTS since the disorder affects 9 to 15 percent of monochorionic gestations, has high morbidity and mortality, and interventions to reduce complications of the disease are available. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/43/9913?source=see_link\">",
"     \"Management of twin-twin transfusion syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Onset of TTTS is usually gradual, but can be sudden. One study that prospectively followed 23 monochorionic twin gestations reported TTTS developed in four pregnancies at 16, 22, 24 and 29 weeks of gestation [",
"    <a class=\"abstract\" href=\"UTD.htm?27/24/28039/abstract/30\">",
"     30",
"    </a>",
"    ]. In another series of 194 monochorionic twin gestations followed prospectively, TTTS occurred in 17 and the majority of deaths occurred prior to 24 weeks of gestation [",
"    <a class=\"abstract\" href=\"UTD.htm?27/24/28039/abstract/7\">",
"     7",
"    </a>",
"    ]. However, monitoring into the third trimester appears to be necessary. The same authors subsequently reported that 13 of these fetuses developed discordant growth after 26 weeks of gestation and five of the 13 (38 percent) had twin anemia-polycythemia sequence, but no amniotic fluid discordance [",
"    <a class=\"abstract\" href=\"UTD.htm?27/24/28039/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Based on these data and our clinical experience, we establish chorionicity through ultrasound as early as possible (preferably in the late first trimester). Reversed a-wave in the ductus venosus at 11 to 13 weeks of gestation is associated with an increased risk of developing severe TTTS, as well as other complications (eg, aneuploidy, miscarriage); however, pregnancy outcome is normal in about 40 percent of monochorionic twins with this finding [",
"    <a class=\"abstract\" href=\"UTD.htm?27/24/28039/abstract/45\">",
"     45",
"    </a>",
"    ]. Further studies will be needed to assess the utility of first trimester ductus venosus Doppler examination as a screening test for TTTS before routine examination can be recommended.",
"   </p>",
"   <p>",
"    In monochorionic gestations, we perform ultrasound examination every two weeks, beginning at 16 weeks of gestation and continuing until delivery. The purpose of the 16-week ultrasound is to assess amniotic fluid volume and determine whether the fetal bladders can be visualized. At 18 weeks, we perform an anatomical survey, as well as assess amniotic fluid volume and visualization of the fetal bladders. In subsequent ultrasound examinations, we alternate a limited assessment of just amniotic fluid volume and fetal bladder visualization with a complete assessment that includes assessment of fetal growth (serially every four weeks).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;(See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/43/9913?source=see_link\">",
"     \"Management of twin-twin transfusion syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Twin-twin transfusion syndrome (TTTS) is one of the most serious complications of monochorionic multifetal gestations. It is associated with a high risk of",
"      <span class=\"nowrap\">",
"       fetal/neonatal",
"      </span>",
"      mortality, and fetuses who survive are at risk of severe cardiac, neurologic, and developmental disorders. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Unbalanced placental intertwin vascular anastomoses play a key role in the pathophysiology of TTTS. One twin becomes hypovolemic (donor twin) and the other hypervolemic (recipient twin). Subsequent cardiovascular changes in response to volume changes lead to the TTTS phenotype. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Pathophysiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The prenatal diagnosis of TTTS is based upon ultrasonographic evidence of a single monochorionic placenta with",
"      <span class=\"nowrap\">",
"       polyhydramnios/oligohydramnios",
"      </span>",
"      sequence. Before 20 weeks of gestation, the maximum vertical amniotic fluid pockets for oligohydramnios and polyhydramnios are usually defined as &lt;2 cm and &gt;8 cm, respectively. After 20 weeks, the maximum vertical pocket for polyhydramnios should be &gt;10 cm. Severe oligohydramnios results in the \"stuck twin\" appearance. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Clinical manifestations and diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest monitoring monochorionic twin pregnancies for development of TTTS with serial ultrasound examinations. Signs suggestive of TTTS are discordance in amniotic fluid volume and nonvisualization of the fetal bladder. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Monitoring for TTTS'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/24/28039/abstract/1\">",
"      Tan KL, Tan R, Tan SH, Tan AM. The twin transfusion syndrome. Clinical observations on 35 affected pairs. Clin Pediatr (Phila) 1979; 18:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/24/28039/abstract/2\">",
"      RAUSEN AR, SEKI M, STRAUSS L. TWIN TRANSFUSION SYNDROME. A REVIEW OF 19 CASES STUDIED AT ONE INSTITUTION. J Pediatr 1965; 66:613.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/24/28039/abstract/3\">",
"      Wenstrom KD, Tessen JA, Zlatnik FJ, Sipes SL. Frequency, distribution, and theoretical mechanisms of hematologic and weight discordance in monochorionic twins. Obstet Gynecol 1992; 80:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/24/28039/abstract/4\">",
"      Denbow M, Fogliani R, Kyle P, et al. Haematological indices at fetal blood sampling in monochorionic pregnancies complicated by feto-fetal transfusion syndrome. Prenat Diagn 1998; 18:941.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/24/28039/abstract/5\">",
"      Sebire NJ, Snijders RJ, Hughes K, et al. The hidden mortality of monochorionic twin pregnancies. Br J Obstet Gynaecol 1997; 104:1203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/24/28039/abstract/6\">",
"      Martin JA, Hamilton BE, Sutton PD, et al. Births: final data for 2005. Natl Vital Stat Rep 2007; 56:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/24/28039/abstract/7\">",
"      Lewi, L, Jani, J, Boes, AS, et al. The natural history of monochorionic twins and the role of prenatal ultrasound scan. Ultrasound Obstet Gynecol 2007; 30:401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/24/28039/abstract/8\">",
"      Dickinson JE, Evans SF. Obstetric and perinatal outcomes from the australian and new zealand twin-twin transfusion syndrome registry. Am J Obstet Gynecol 2000; 182:706.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/24/28039/abstract/9\">",
"      Lutfi S, Allen VM, Fahey J, et al. Twin-twin transfusion syndrome: a population-based study. Obstet Gynecol 2004; 104:1289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/24/28039/abstract/10\">",
"      Senat MV, Quarello E, Levaillant JM, et al. Determining chorionicity in twin gestations: three-dimensional (3D) multiplanar sonographic measurement of intra-amniotic membrane thickness. Ultrasound Obstet Gynecol 2006; 28:665.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/24/28039/abstract/11\">",
"      Talbert DG, Bajoria R, Sepulveda W, et al. Hydrostatic and osmotic pressure gradients produce manifestations of fetofetal transfusion syndrome in a computerized model of monochorial twin pregnancy. Am J Obstet Gynecol 1996; 174:598.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/24/28039/abstract/12\">",
"      van Gemert MJ, Sterenborg HJ. Haemodynamic model of twin-twin transfusion syndrome in monochorionic twin pregnancies. Placenta 1998; 19:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/24/28039/abstract/13\">",
"      Machin G, Still K, Lalani T. Correlations of placental vascular anatomy and clinical outcomes in 69 monochorionic twin pregnancies. Am J Med Genet 1996; 61:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/24/28039/abstract/14\">",
"      Sebire NJ, Talbert D, Fisk NM. Twin-to-twin transfusion syndrome results from dynamic asymmetrical reduction in placental anastomoses: a hypothesis. Placenta 2001; 22:383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/24/28039/abstract/15\">",
"      Denbow ML, Cox P, Taylor M, et al. Placental angioarchitecture in monochorionic twin pregnancies: relationship to fetal growth, fetofetal transfusion syndrome, and pregnancy outcome. Am J Obstet Gynecol 2000; 182:417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/24/28039/abstract/16\">",
"      Lopriore E, Deprest J, Slaghekke F, et al. Placental characteristics in monochorionic twins with and without twin anemia-polycythemia sequence. Obstet Gynecol 2008; 112:753.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/24/28039/abstract/17\">",
"      Bajoria R, Ward S, Sooranna SR. Influence of vasopressin in the pathogenesis of oligohydramnios-polyhydramnios in monochorionic twins. Eur J Obstet Gynecol Reprod Biol 2004; 113:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/24/28039/abstract/18\">",
"      Mahieu-Caputo D, Dommergues M, Delezoide AL, et al. Twin-to-twin transfusion syndrome. Role of the fetal renin-angiotensin system. Am J Pathol 2000; 156:629.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/24/28039/abstract/19\">",
"      Bajoria R, Ward S, Chatterjee R. Natriuretic peptides in the pathogenesis of cardiac dysfunction in the recipient fetus of twin-twin transfusion syndrome. Am J Obstet Gynecol 2002; 186:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/24/28039/abstract/20\">",
"      Rychik J, Tian Z, Bebbington M, et al. The twin-twin transfusion syndrome: spectrum of cardiovascular abnormality and development of a cardiovascular score to assess severity of disease. Am J Obstet Gynecol 2007; 197:392.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/24/28039/abstract/21\">",
"      Bajoria R, Sullivan M, Fisk NM. Endothelin concentrations in monochorionic twins with severe twin-twin transfusion syndrome. Hum Reprod 1999; 14:1614.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/24/28039/abstract/22\">",
"      Barrea C, Alkazaleh F, Ryan G, et al. Prenatal cardiovascular manifestations in the twin-to-twin transfusion syndrome recipients and the impact of therapeutic amnioreduction. Am J Obstet Gynecol 2005; 192:892.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/24/28039/abstract/23\">",
"      Karatza AA, Wolfenden JL, Taylor MJ, et al. Influence of twin-twin transfusion syndrome on fetal cardiovascular structure and function: prospective case-control study of 136 monochorionic twin pregnancies. Heart 2002; 88:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/24/28039/abstract/24\">",
"      Lougheed J, Sinclair BG, Fung Kee Fung K, et al. Acquired right ventricular outflow tract obstruction in the recipient twin in twin-twin transfusion syndrome. J Am Coll Cardiol 2001; 38:1533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/24/28039/abstract/25\">",
"      Simpson LL, Marx GR, Elkadry EA, D'Alton ME. Cardiac dysfunction in twin-twin transfusion syndrome: a prospective, longitudinal study. Obstet Gynecol 1998; 92:557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/24/28039/abstract/26\">",
"      Herberg U, Gross W, Bartmann P, et al. Long term cardiac follow up of severe twin to twin transfusion syndrome after intrauterine laser coagulation. Heart 2006; 92:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/24/28039/abstract/27\">",
"      Banek CS, Hecher K, Hackeloer BJ, Bartmann P. Long-term neurodevelopmental outcome after intrauterine laser treatment for severe twin-twin transfusion syndrome. Am J Obstet Gynecol 2003; 188:876.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/24/28039/abstract/28\">",
"      van den Wijngaard JP, Umur A, Krediet RT, et al. Modeling a hydropic recipient twin in twin-twin transfusion syndrome. Am J Physiol Regul Integr Comp Physiol 2005; 288:R799.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/24/28039/abstract/29\">",
"      Brown DL, Benson CB, Driscoll SG, Doubilet PM. Twin-twin transfusion syndrome: sonographic findings. Radiology 1989; 170:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/24/28039/abstract/30\">",
"      Sueters M, Middeldorp JM, Lopriore E, et al. Timely diagnosis of twin-to-twin transfusion syndrome in monochorionic twin pregnancies by biweekly sonography combined with patient instruction to report onset of symptoms. Ultrasound Obstet Gynecol 2006; 28:659.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/24/28039/abstract/31\">",
"      Lopriore E, Middeldorp JM, Oepkes D, et al. Twin anemia-polycythemia sequence in two monochorionic twin pairs without oligo-polyhydramnios sequence. Placenta 2007; 28:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/24/28039/abstract/32\">",
"      Weingertner AS, Kohler A, Kohler M, et al. Clinical and placental characteristics in four new cases of twin anemia-polycythemia sequence. Ultrasound Obstet Gynecol 2010; 35:490.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/24/28039/abstract/33\">",
"      Slaghekke F, Kist WJ, Oepkes D, et al. Twin anemia-polycythemia sequence: diagnostic criteria, classification, perinatal management and outcome. Fetal Diagn Ther 2010; 27:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/24/28039/abstract/34\">",
"      Lewi L, Jani J, Blickstein I, et al. The outcome of monochorionic diamniotic twin gestations in the era of invasive fetal therapy: a prospective cohort study. Am J Obstet Gynecol 2008; 199:514.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/24/28039/abstract/35\">",
"      Robyr R, Lewi L, Salomon LJ, et al. Prevalence and management of late fetal complications following successful selective laser coagulation of chorionic plate anastomoses in twin-to-twin transfusion syndrome. Am J Obstet Gynecol 2006; 194:796.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/24/28039/abstract/36\">",
"      Habli M, Eftekhari N, Wiebracht E, et al. Long-term maternal and subsequent pregnancy outcomes 5 years after hemolysis, elevated liver enzymes, and low platelets (HELLP) syndrome. Am J Obstet Gynecol 2009; 201:385.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/24/28039/abstract/37\">",
"      Lopriore E, Slaghekke F, Middeldorp JM, et al. Residual anastomoses in twin-to-twin transfusion syndrome treated with selective fetoscopic laser surgery: localization, size, and consequences. Am J Obstet Gynecol 2009; 201:66.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/24/28039/abstract/38\">",
"      Assaf SA, Benirschke K, Chmait RH. Spontaneous twin anemia-polycythemia sequence complicated by recipient placental vascular thrombosis and hydrops fetalis. J Matern Fetal Neonatal Med 2011; 24:549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/24/28039/abstract/39\">",
"      Lopriore E, Slaghekke F, Oepkes D, et al. Clinical outcome in neonates with twin anemia-polycythemia sequence. Am J Obstet Gynecol 2010; 203:54.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/24/28039/abstract/40\">",
"      Quintero RA, Morales WJ, Allen MH, et al. Staging of twin-twin transfusion syndrome. J Perinatol 1999; 19:550.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/24/28039/abstract/41\">",
"      Taylor MJ, Govender L, Jolly M, et al. Validation of the Quintero staging system for twin-twin transfusion syndrome. Obstet Gynecol 2002; 100:1257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/24/28039/abstract/42\">",
"      Stirnemann JJ, Nasr B, Proulx F, et al. Evaluation of the CHOP cardiovascular score as a prognostic predictor of outcome in twin-twin transfusion syndrome after laser coagulation of placental vessels in a prospective cohort. Ultrasound Obstet Gynecol 2010; 36:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/24/28039/abstract/43\">",
"      Crombleholme TM, Lim FY, Habli M, et al. Improved recipient survival with maternal nifedipine in twin-twin transfusion syndrome complicated by TTTS cardiomyopathy undergoing selective fetoscopic laser photocoagulation. Am J Obstet Gynecol 2010; 203:397.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/24/28039/abstract/44\">",
"      Lewi L, Gucciardo L, Huber A, et al. Clinical outcome and placental characteristics of monochorionic diamniotic twin pairs with early- and late-onset discordant growth. Am J Obstet Gynecol 2008; 199:511.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/24/28039/abstract/45\">",
"      Maiz N, Staboulidou I, Leal AM, et al. Ductus venosus Doppler at 11 to 13 weeks of gestation in the prediction of outcome in twin pregnancies. Obstet Gynecol 2009; 113:860.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6789 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-125.39.66.146-C1CFDD43C6-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_24_28039=[""].join("\n");
var outline_f27_24_28039=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H12\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      INCIDENCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PATHOPHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Unbalanced vascular anastomoses",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Cardiovascular response to circulatory imbalance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      CLINICAL MANIFESTATIONS AND DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H276251225\">",
"      TAPS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      CLASSIFICATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Quintero stages",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Cardiovascular score",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      MONITORING FOR TTTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"OBGYN/6789\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/6789|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?0/56/897\" title=\"diagnostic image 1A\">",
"      TTTS4",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?41/27/42417\" title=\"diagnostic image 1B\">",
"      TTTS1",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?28/21/29008\" title=\"diagnostic image 2A\">",
"      TTTS2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?6/11/6321\" title=\"diagnostic image 2B\">",
"      TTTS3",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?41/43/42687\" title=\"diagnostic image 2C\">",
"      TTTS5",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?34/1/34832\" title=\"diagnostic image 2D\">",
"      TTTS6",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?29/40/30337\" title=\"diagnostic image 2E\">",
"      TTTS7",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?12/0/12289\" title=\"diagnostic image 3\">",
"      TTTS8",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/6789|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?18/47/19195\" title=\"table 1\">",
"      Cardiovascular parameters for grading TTTS severity",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/43/9913?source=related_link\">",
"      Management of twin-twin transfusion syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/46/40682?source=related_link\">",
"      Twin pregnancy: Prenatal issues",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f27_24_28040="Acute cardiac allograft rejection: Diagnosis";
var content_f27_24_28040=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"0\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Acute cardiac allograft rejection: Diagnosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/24/28040/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/24/28040/contributors\">",
"     Howard J Eisen, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/24/28040/contributors\">",
"     Mariell Jessup, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/24/28040/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/24/28040/contributors\">",
"     Sharon A Hunt, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/24/28040/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/24/28040/contributors\">",
"     Susan B Yeon, MD, JD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?27/24/28040/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 29, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INCIDENCE AND OUTCOMES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute rejection is a common problem after heart transplantation, particularly early after transplantation. Most cases are due to cellular rejection. Antibody-mediated (noncellular) rejection is a less well understood and less easily diagnosed process, but potentially produces morbidity [",
"    <a class=\"abstract\" href=\"UTD.htm?27/24/28040/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The 2009 report from the Registry of the International Society for Heart and Lung Transplantation (ISHLT) of patients with one-year follow-up between July 2004 and July 2008 found that 21 to 30 percent were treated for rejection during the first year after transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?27/24/28040/abstract/3\">",
"     3",
"    </a>",
"    ]. This represents an underestimate for overall rejection, since the Registry does not collect data on mild rejection episodes (grade 1 R) or on antibody-mediated rejection. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'ISHLT grading system'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    In the ISHLT report, among deaths occurring between January 1992 and June 2008, acute rejection accounted for 6 percent of deaths in the first 30 days, 12 percent from 31 days to one year, 10 percent from one year to three years, and less than 2 percent at more than five years [",
"    <a class=\"abstract\" href=\"UTD.htm?27/24/28040/abstract/3\">",
"     3",
"    </a>",
"    ]. The contribution of rejection to post-transplant mortality has decreased over time [",
"    <a class=\"abstract\" href=\"UTD.htm?27/24/28040/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. This is primarily due to improvements in maintenance immunosuppression and in the diagnosis and treatment of rejection. Nevertheless, acute heart allograft rejection remains an important clinical problem.",
"   </p>",
"   <p>",
"    This topic will review the risk factors for and the clinical features and diagnostic evaluation of acute cellular rejection in the heart transplant recipient. The treatment of acute rejection is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/6/14441?source=see_link\">",
"     \"Acute cardiac allograft rejection: Treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     RISK FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although acute cellular rejection is always a potential concern in a heart transplant recipient, the likelihood of a rejection episode is influenced by several factors, particularly the time after transplantation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Time after transplantation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute cellular rejection is much more common early after a heart transplant. In a multicenter analysis by the Cardiac Transplant Research Database of 1251 patients transplanted between 1990 and 1993, the incidence of cellular rejection peaked at one month after transplant, then declined rapidly over the subsequent five months, reaching a low constant rate by the end of the first year [",
"    <a class=\"abstract\" href=\"UTD.htm?27/24/28040/abstract/5\">",
"     5",
"    </a>",
"    ]. The mean number of rejection episodes per patient in the first, second, third, and fourth years was 1.25, 0.18, 0.13 and 0.02, respectively. Newer immunosuppressive strategies have resulted in significant delays in the time that acute cellular rejection occurs [",
"    <a class=\"abstract\" href=\"UTD.htm?27/24/28040/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Type of immunosuppression",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ISHLT Registry, a nonrandomized data set, has attempted to delineate important determinants for cellular rejection in the first year following transplant. Since the data are not randomized, a cause-and-effect relationship cannot be assumed.",
"   </p>",
"   <p>",
"    Patients who at transplant discharge were receiving",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    -based immunosuppression, particularly when in combination with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    mofetil, had lower rates of treated rejection (but not ISHLT grade &gt;2R rejection) than those receiving",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    in combination with mycophenolate mofetil [",
"    <a class=\"abstract\" href=\"UTD.htm?27/24/28040/abstract/7\">",
"     7",
"    </a>",
"    ]. A similar observation was noted in the 2009 ISHLT report [",
"    <a class=\"abstract\" href=\"UTD.htm?27/24/28040/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Other",
"    </span>",
"    &nbsp;&mdash;&nbsp;Variables that appear to increase the risk of rejection include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Younger recipient [",
"      <a class=\"abstract\" href=\"UTD.htm?27/24/28040/abstract/5,8,9\">",
"       5,8,9",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Female recipient [",
"      <a class=\"abstract\" href=\"UTD.htm?27/24/28040/abstract/5,9\">",
"       5,9",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Female donor [",
"      <a class=\"abstract\" href=\"UTD.htm?27/24/28040/abstract/5,8,9\">",
"       5,8,9",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Black recipient [",
"      <a class=\"abstract\" href=\"UTD.htm?27/24/28040/abstract/9\">",
"       9",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      More HLA mismatches between the donor and recipient [",
"      <a class=\"abstract\" href=\"UTD.htm?27/24/28040/abstract/9-12\">",
"       9-12",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     CLINICAL PRESENTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because of intensive (protocol) surveillance, most cases of acute cellular rejection are diagnosed by endomyocardial biopsy at a time when the patient is asymptomatic. In a review from the Cardiac Transplant Research Database of 3367 patients experiencing 4137 episodes of cellular rejection on either surveillance or clinically indicated endomyocardial biopsy, severe hemodynamic compromise was present in only about 5 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?27/24/28040/abstract/13\">",
"     13",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Diagnosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    When symptoms do occur, they are most often manifestations of left ventricular dysfunction such as dyspnea on exertion or at rest, paroxysmal nocturnal dyspnea, orthopnea, palpitations, and syncope or near-syncope. However, the majority of patients who have significant rejection detected on routine, protocol-mandated biopsy are asymptomatic. The presence of left ventricular dysfunction can be confirmed by echocardiography which may reveal an acute decrement in systolic function or, less easily detected, a demonstrable worsening of diastolic function. Gastrointestinal symptoms, probably due to secondary hepatic congestion resulting from the increase in central venous pressure, can also be prominent and, in some cases, lead to a delay in diagnosis as other causes of gastrointestinal symptoms are pursued.",
"   </p>",
"   <p>",
"    Infrequently, acute cellular rejection presents with atrial arrhythmias, including atrial premature depolarizations, atrial fibrillation, or atrial flutter [",
"    <a class=\"abstract\" href=\"UTD.htm?27/24/28040/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. Fever and a reduction in QRS voltage on ECG, which were diagnostic features of acute cellular rejection in the first decade of heart transplantation, are rare in the calcineurin inhibitor era [",
"    <a class=\"abstract\" href=\"UTD.htm?27/24/28040/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of acute cellular rejection is established by endomyocardial biopsy, which is performed as part of routine surveillance or, on occasion, because of suggestive symptoms or echocardiographic evidence of new left ventricular dysfunction (see",
"    <a class=\"local\" href=\"#H6\">",
"     'Clinical presentation'",
"    </a>",
"    above).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Surveillance biopsy schedule",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surveillance endomyocardial biopsies are performed most frequently in the first three to six months after transplantation, the time at which acute cellular rejection is most common. Late biopsies continue to detect clinically significant episodes of rejection five years after transplantation (grade 3A or greater in 8 of 77 patients in one report), and the absence of early rejection does not predict freedom from late rejection [",
"    <a class=\"abstract\" href=\"UTD.htm?27/24/28040/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The following represents a typical biopsy schedule:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Every week for the first four weeks",
"     </li>",
"     <li>",
"      Every two weeks for the next six weeks",
"     </li>",
"     <li>",
"      Monthly for the next three to four months",
"     </li>",
"     <li>",
"      Every three months until the end of the first year",
"     </li>",
"     <li>",
"      Three to four times per year in the second year",
"     </li>",
"     <li>",
"      One to two times per year in subsequent years",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The above schedule may be modified during an attempt to wean a patient from steroids, or to make significant changes in maintenance immunosuppression. In addition, follow-up biopsies are usually obtained one to two weeks after an episode of cellular rejection is treated to assess the adequacy of therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?27/24/28040/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, the utility of continued biopsy surveillance in clinically stable patients over the long term (eg, more than one to two years posttransplant) has become controversial. A study of the Cardiac Transplant Research Database found no benefits from surveillance biopsy beyond five years post-transplant [",
"    <a class=\"abstract\" href=\"UTD.htm?27/24/28040/abstract/18\">",
"     18",
"    </a>",
"    ]. Evidence from the IMAGE study of subjects six months to five years post-transplant indicates that even if rejection is not identified until graft dysfunction occurs, intermediate-term outcomes may not be worse than with earlier detection of rejection. (See",
"    <a class=\"local\" href=\"#H17\">",
"     'Gene expression profiling'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Alternatives to surveillance biopsies have been investigated including monitoring using a gene-expression profiling test. (See",
"    <a class=\"local\" href=\"#H17\">",
"     'Gene expression profiling'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Biopsy procedure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Endomyocardial biopsies are generally performed in a specialized facility, either a cardiac catheterization laboratory or a special biopsy suite. Access is obtained through the right internal jugular vein or, less commonly, through a femoral vein. A specialized cardiac bioptome, which appears similar to bronchoscopic bioptomes, is then guided down the superior vena cava and across the right atrium and tricuspid valve into the right ventricle (using fluoroscopy or occasionally echocardiography). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/26/7592?source=see_link\">",
"     \"Endomyocardial biopsy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A minimum of three and preferably four or more evaluable specimens of endomyocardial tissue containing at least 50 percent myocardium are obtained from the right ventricular septum and submitted for pathologic assessment [",
"    <a class=\"abstract\" href=\"UTD.htm?27/24/28040/abstract/19\">",
"     19",
"    </a>",
"    ]. Most of the biopsy specimens are fixed immediately in 10 percent buffered formalin for light microscopy; tissue can also be frozen for immunohistochemical studies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;The potential complications of endomyocardial biopsy are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/26/7592?source=see_link&amp;anchor=H19#H19\">",
"     \"Endomyocardial biopsy\", section on 'Complications'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A complication that is relatively unique to cardiac transplant recipients, presumably because of the performance of biopsies in which the bioptome is repeatedly passed across the tricuspid valve, is tricuspid regurgitation (TR) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/24/28040/abstract/20\">",
"     20",
"    </a>",
"    ]. The reported prevalence of TR ranges from 47 to 98 percent and is moderate to severe in as many as one-third of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?27/24/28040/abstract/20,21\">",
"     20,21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Severe TR is most often due to a flail leaflet, which probably reflects injury to the tricuspid chordae by the bioptome [",
"    <a class=\"abstract\" href=\"UTD.htm?27/24/28040/abstract/20\">",
"     20",
"    </a>",
"    ]. Other factors that may contribute include distortion of the tricuspid valve ring due to size mismatch between the donor and recipient, and pulmonary hypertension after transplantation.",
"   </p>",
"   <p>",
"    The TR is usually well tolerated but valve replacement is occasionally required. In a review of 17 such patients in the Utah program (2 percent of all cardiac transplants), the average time to valve replacement was 77 months after transplantation and the average number of biopsies before the diagnosis of severe TR was 33 [",
"    <a class=\"abstract\" href=\"UTD.htm?27/24/28040/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Histologic findings of acute rejection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute cellular rejection is diagnosed by light microscopy of hematoxylin and eosin stained specimens on endomyocardial tissue. Morphologically, acute cellular rejection is manifested as a mononuclear inflammatory response, predominantly lymphocytic, that is infiltrating the myocardium. In more severe cases, granulocytes are also seen [",
"    <a class=\"abstract\" href=\"UTD.htm?27/24/28040/abstract/19\">",
"     19",
"    </a>",
"    ]. Significant grades of rejection are also accompanied by evidence of cardiac myocyte injury or necrosis. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'ISHLT grading system'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Immunohistologic assessment shows that the infiltrating mononuclear cells are predominantly T lymphocytes [",
"    <a class=\"abstract\" href=\"UTD.htm?27/24/28040/abstract/22\">",
"     22",
"    </a>",
"    ]. These cells are CD4 and CD8 positive [",
"    <a class=\"abstract\" href=\"UTD.htm?27/24/28040/abstract/23\">",
"     23",
"    </a>",
"    ] and express high affinity interleukin-2 receptors on their surfaces. Rejection also induces increased expression of MHC class II molecules and intercellular adhesion molecules on the surfaces of cardiac myocytes and endothelial cells [",
"    <a class=\"abstract\" href=\"UTD.htm?27/24/28040/abstract/24,25\">",
"     24,25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Occasional patients have hemodynamically significant rejection with little or no cellular infiltrate or myocyte necrosis apparent in the biopsy specimen [",
"    <a class=\"abstract\" href=\"UTD.htm?27/24/28040/abstract/26\">",
"     26",
"    </a>",
"    ]. These patients may have humoral (antibody-mediated) rejection, which is associated with antibody deposition that can be detected by immunofluorescence (IF) microscopy. A formalized description of humoral rejection has been agreed upon by the transplant community [",
"    <a class=\"abstract\" href=\"UTD.htm?27/24/28040/abstract/27\">",
"     27",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Acute antibody-mediated (humoral) rejection'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     ISHLT grading system",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cardiac transplant biopsies have been graded for acute cellular rejection according to the standardized International Society for Heart and Lung Transplantation (ISHLT) nomenclature, which was introduced in 1990 [",
"    <a class=\"abstract\" href=\"UTD.htm?27/24/28040/abstract/28,29\">",
"     28,29",
"    </a>",
"    ] and revised in 2004 [",
"    <a class=\"abstract\" href=\"UTD.htm?27/24/28040/abstract/19\">",
"     19",
"    </a>",
"    ]. However, sampling error associated with endomyocardial biopsy may result in underestimation of the severity of rejection. As a result, the absence of pathologic evidence for severe rejection in the presence of unexplained left ventricular dysfunction, heart failure, or shock should not deter treatment for rejection. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/16/25862?source=see_link\">",
"     \"Left ventricular dysfunction after orthotopic cardiac transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Acute cellular rejection",
"    </span>",
"    &nbsp;&mdash;&nbsp;The 1990 ISHLT grading system for acute cellular rejection was revised by the ISHLT in 2004 and published in 2005 [",
"    <a class=\"abstract\" href=\"UTD.htm?27/24/28040/abstract/19\">",
"     19",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Grade 0 &mdash; no rejection",
"     </li>",
"     <li>",
"      Grade 1 R, mild &mdash; Interstitial",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      perivascular infiltrate with up to one focus of myocyte damage",
"     </li>",
"     <li>",
"      Grade 2 R, moderate &mdash; two or more foci of infiltrate with associated myocyte damage",
"     </li>",
"     <li>",
"      Grade 3 R, severe &mdash; diffuse infiltrate with multifocal myocyte damage, with or without edema, hemorrhage, or vasculitis",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thus, grade 1 R includes grades 1A, 1B, and 2 in the 1990 system; grade 2 R was grade 3A; and grade 3 R was grades 3B and 4 (",
"    <a class=\"graphic graphic_table graphicRef51982 \" href=\"UTD.htm?41/50/42796\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    There is increasing recognition that there may be wide variation between pathologists and centers in the interpretation of endomyocardial biopsies. This lack of consistency as well as the costs and potential of morbidity of the biopsy procedure have motivated the search for alternative methods to detect rejection (see",
"    <a class=\"local\" href=\"#H16\">",
"     'Noninvasive detection of rejection'",
"    </a>",
"    below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Nonrejection findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are several processes that can produce cellular infiltration in the cardiac allograft and must be distinguished from acute rejection. The 2004 ISHLT revision included the following biopsy findings of nonrejection [",
"    <a class=\"abstract\" href=\"UTD.htm?27/24/28040/abstract/19\">",
"     19",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Ischemic injury &mdash; early (up to six weeks posttransplant); and late (related to allograft coronary disease)",
"     </li>",
"     <li>",
"      Quilty effect",
"     </li>",
"     <li>",
"      Infection",
"     </li>",
"     <li>",
"      Lymphoproliferative disorder",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Perioperative ischemic damage can cause myocardial necrosis as a result of donor trauma with catecholamine excess, pressor therapy during acute care, ex vivo organ ischemia, or reperfusion injury. The histologic appearance of ischemic damage early after transplant usually includes myocyte necrosis out of proportion to the cellular infiltrate, which is predominantly polymorphonuclear rather than mononuclear [",
"    <a class=\"abstract\" href=\"UTD.htm?27/24/28040/abstract/30\">",
"     30",
"    </a>",
"    ]. Later ischemic injury is related to allograft coronary disease, which is also called transplant vasculopathy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/9/18585?source=see_link\">",
"     \"Natural history and diagnosis of cardiac allograft vasculopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The Quilty effect describes the presence of one or more dense subendocardial lymphocytic infiltrates, so called because they were first seen in a patient of that name [",
"    <a class=\"abstract\" href=\"UTD.htm?27/24/28040/abstract/31\">",
"     31",
"    </a>",
"    ]. Quilty lesions differ from rejection in two respects: they extend to the endocardial surface of the heart, and they include a substantial proportion of B lymphocytes. Quilty lesions are felt to have no clinical significance.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Opportunistic infections such as cytomegalovirus (CMV) and Toxoplasma myocarditis can produce lymphocytic infiltration in the allograft myocardium. These infections can be distinguished from rejection by the presence of characteristic CMV inclusion bodies in the lymphocytes or Toxoplasma organisms in the myocardium [",
"      <a class=\"abstract\" href=\"UTD.htm?27/24/28040/abstract/32\">",
"       32",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/47/29433?source=see_link\">",
"       \"Infection in the solid organ transplant recipient\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Rarely, post-transplant lymphoproliferative disorders (PTLDs) involve the heart with myocardial infiltration of atypical lymphocytes [",
"      <a class=\"abstract\" href=\"UTD.htm?27/24/28040/abstract/33\">",
"       33",
"      </a>",
"      ]. Most PTLDs are due to malignant transformation of B lymphocytes; immunohistologic evaluation can distinguish such infiltrates from the predominantly T cell infiltrates of rejection. In addition, Epstein-Barr virus gene expression in these cells can often be detected using in situ hybridization. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/50/23338?source=see_link\">",
"       \"Treatment and prevention of post-transplant lymphoproliferative disorders\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Acute antibody-mediated (humoral) rejection",
"    </span>",
"    &nbsp;&mdash;&nbsp;The 2004 ISHLT report noted that acute antibody-mediated rejection (AMR) remains controversial [",
"    <a class=\"abstract\" href=\"UTD.htm?27/24/28040/abstract/19\">",
"     19",
"    </a>",
"    ]. A separate report from a national conference to assess AMR produced a formalized definition of the process [",
"    <a class=\"abstract\" href=\"UTD.htm?27/24/28040/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The diagnosis is based upon the following histologic features indicative of acute myocardial capillary injury [",
"    <a class=\"abstract\" href=\"UTD.htm?27/24/28040/abstract/19,34\">",
"     19,34",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      On light microscopy, myocardial capillary injury with intravascular macrophage accumulation; other findings may include intravascular thrombi and interstitial edema, hemorrhage, and neutrophilic infiltration in and around the capillaries.",
"     </li>",
"     <li>",
"      Positive immunofluorescence or immunoperoxidase staining for antibody-mediated rejection within the capillaries including immunoglobulins (IgG, IgM,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      IgA), complement (C4d, C3d,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      C1q), and CD68 staining of macrophages.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The histologic findings are accompanied in almost all patients by serum antibodies directed again HLA class I and II antigens in the donor; these antibodies may arise de novo after transplantation or be preformed due to transfusion, use of a left ventricular assist device, pregnancy, or previous transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?27/24/28040/abstract/34,35\">",
"     34,35",
"    </a>",
"    ]. Antibodies also may be formed against a variety of non-HLA antigens [",
"    <a class=\"abstract\" href=\"UTD.htm?27/24/28040/abstract/34\">",
"     34",
"    </a>",
"    ], although the role of these antibodies in AMR is not well defined.",
"   </p>",
"   <p>",
"    There is wide variation in the reported incidence of AMR among centers, as it is not routinely screened for in most centers, as is cellular rejection [",
"    <a class=\"abstract\" href=\"UTD.htm?27/24/28040/abstract/34\">",
"     34",
"    </a>",
"    ]. In a review of 587 patients at a single center, 19 percent of rejection episodes were due to vascular rejection alone, 60 percent to cellular rejection (AMR) alone, and 23 percent to mixed cellular and vascular rejection [",
"    <a class=\"abstract\" href=\"UTD.htm?27/24/28040/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    AMR may occur during the first month after transplantation, in association with antidonor antibodies, and can occur as early as two to seven days if the recipient is presensitized to donor HLA antigens, or may occur as late as months to years after transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?27/24/28040/abstract/34,36\">",
"     34,36",
"    </a>",
"    ]. Graft dysfunction is present in two-thirds of early episodes, with hemodynamic compromise (shock, hypotension, decreased cardiac output,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    a rise pulmonary capillary wedge pressure) in approximately one-half [",
"    <a class=\"abstract\" href=\"UTD.htm?27/24/28040/abstract/34,37\">",
"     34,37",
"    </a>",
"    ]. In comparison, graft dysfunction is uncommon (10 to 15 percent) with late episodes but may also be associated with hemodynamic compromise [",
"    <a class=\"abstract\" href=\"UTD.htm?27/24/28040/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     NONINVASIVE DETECTION OF REJECTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Potential noninvasive alternatives to biopsy for detection of acute rejection have been investigated. Many markers correlate with histologic evidence of rejection although data are generally limited. Evidence is strongest for gene expression profiling as discussed below. The clinical efficacy of the following markers for rejection has not been established:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Measurement of cardiac troponin T [",
"      <a class=\"abstract\" href=\"UTD.htm?27/24/28040/abstract/38\">",
"       38",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Alternations in the signal-averaged electrocardiogram. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/51/36661?source=see_link\">",
"       \"Use of the signal-averaged electrocardiogram in nonischemic heart disease and cardiac transplantation\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Intramyocardial electrograms measured during ventricular pacing [",
"      <a class=\"abstract\" href=\"UTD.htm?27/24/28040/abstract/39,40\">",
"       39,40",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Doppler echocardiography measures of diastolic",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      systolic function [",
"      <a class=\"abstract\" href=\"UTD.htm?27/24/28040/abstract/41-44\">",
"       41-44",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Myocardial acoustic alterations detected by integrated backscatter analysis that can occur in the absence of decreased contractility [",
"      <a class=\"abstract\" href=\"UTD.htm?27/24/28040/abstract/45\">",
"       45",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Imaging studies using radiolabeled lymphocytes, anti-myosin antibodies, or annexin-V, an endogenous protein that has a high affinity for apoptotic cells [",
"      <a class=\"abstract\" href=\"UTD.htm?27/24/28040/abstract/46-48\">",
"       46-48",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Cardiovascular magnetic resonance imaging [",
"      <a class=\"abstract\" href=\"UTD.htm?27/24/28040/abstract/49,50\">",
"       49,50",
"      </a>",
"      ]&nbsp;(see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/3/34874?source=see_link\">",
"       \"Clinical utility of cardiovascular magnetic resonance imaging\"",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Gene expression profiling",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gene expression profiling of mononuclear cells in peripheral blood specimens has been studied as an alternative to endomyocardial biopsy to detect",
"    <strong>",
"     cellular",
"    </strong>",
"    rejection [",
"    <a class=\"abstract\" href=\"UTD.htm?27/24/28040/abstract/51-55\">",
"     51-55",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An 11 gene PCR test was found to distinguish grade 0 (quiescence) from moderate to severe rejection (grade &ge;3A in the 1990 system classified as &ge;2 R in the 2004 system) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/24/28040/abstract/52\">",
"     52",
"    </a>",
"    ]. The test correctly identified 84 percent of moderate to severe rejection. Patients with a score &lt;30 at more than one year post-transplant were highly unlikely to have moderate to severe rejection (negative predictive value 99.6 percent). Although evidence is preliminary, this assay has been adopted clinically by several cardiac transplant programs, primarily for patients beyond the first 6 to 12 months after transplantation.",
"   </p>",
"   <p>",
"    The Invasive Monitoring Attenuation through Gene Expression (IMAGE) trial was performed as a noninferiority comparison between a commercially available gene-expression profiling test and routine biopsies for a composite primary outcome of rejection with hemodynamic compromise, graft dysfunction due to other causes, death, or retransplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?27/24/28040/abstract/56\">",
"     56",
"    </a>",
"    ]. The 602 patients were enrolled six months to five years following transplantation. A mandatory biopsy was performed for a gene-expression test score of 30 (increased to a threshold of 34 mid-trial). There was no significant difference in two-year cumulative rates of the composite outcome between the gene-expression profiling and routine biopsy groups (14.5 and 15.3 percent; HR 1.04; 95% CI 0.67 to 1.68). However this result is consistent with as high as a 68 percent increase in risk using the gene-expression profiling strategy.",
"   </p>",
"   <p>",
"    Fewer treated episodes of rejection occurred in the gene-profiling group than in the routine biopsy group (34 versus 47). Only six of 34 rejection episodes identified in the gene-profiling group were detected on the basis of the profiling test since the others were detected by heart failure symptoms or echocardiographic evidence of graft dysfunction. In the routine biopsy group, 22 of 47 rejection episodes were asymptomatic. These observations may have broader implications for post-transplant surveillance since they indicate that outcomes may not be worse if rejection is detected with graft dysfunction rather than detected early.",
"   </p>",
"   <p>",
"    Further evidence will be needed to determine the utility of this molecular diagnostic assay as a replacement for routine biopsies and its potential role in weaning immunosuppression and other aspects of long-term management of cardiac transplant recipients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?0/5/92?source=see_link\">",
"       \"Patient information: Heart transplant (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?25/36/26179?source=see_link\">",
"       \"Patient information: Heart transplantation (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Acute cellular rejection is a common problem after cardiac transplantation and is treated in about 25 percent of patients during the first year after transplantation.",
"     </li>",
"     <li>",
"      Acute cellular rejection can cause graft dysfunction and contributes to 12 percent of deaths during the period from the first month to first year after transplantation. Acute antibody-mediated rejection may also occur but its impact on morbidity and mortality is less well defined.",
"     </li>",
"     <li>",
"      Risk factors for acute cellular rejection include younger recipient, female recipient, female donor, black recipient, and greater HLA mismatches between the donor and recipient. The combination of maintenance",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      in combination with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"       mycophenolate",
"      </a>",
"      mofetil is associated with higher rates of acute rejection than the combination of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"       tacrolimus",
"      </a>",
"      with mycophenolate mofetil, although a causal relationship has not been established.",
"     </li>",
"     <li>",
"      When transplant recipients are monitored with a typical surveillance endomyocardial biopsy schedule, most cases of acute cellular rejection are asymptomatic and detected by biopsy.",
"     </li>",
"     <li>",
"      Symptoms of acute rejection include symptoms of graft dysfunction including dyspnea, orthopnea, palpitations, syncope or near-syncope, and symptoms of hepatic congestion. Atrial arrhythmias are less frequent symptoms of acute rejection. Fever and decrease in ECG voltage are rare.",
"     </li>",
"     <li>",
"      Echocardiographic evidence of acute rejection includes worsening systolic",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      diastolic function.",
"     </li>",
"     <li>",
"      Surveillance endocardial biopsies are performed most frequently during the first three to six months with fewer biopsies typically performed after the first year.",
"     </li>",
"     <li>",
"      Acute cellular rejection is graded according to the histologic appearance of endomyocardial biopsy specimen. False negative results can occur due to sampling error. Evidence of rejection should be distinguished from nonrejection alterations.",
"     </li>",
"     <li>",
"      Several noninvasive markers of acute cellular rejection have been investigated. Of these noninvasive tests, gene expression profiling is supported by the strongest evidence. A clinical trial indicated that gene expression profiling may be noninferior to routine surveillance biopsies. Further study is needed to establish the efficacy of this approach.",
"     </li>",
"     <li>",
"      Antibody mediated rejection, usually due to development of donor specific anti-HLA antibodies, can occur at any time. It is commonly accompanied by hemodynamic compromise when it occurs in the early post-transplant period. It can be diagnosed on endomyocardial biopsy and confirmed by detection of donor specific antibodies.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/24/28040/abstract/1\">",
"      Grauhan O, M&uuml;ller J, v Baeyer H, et al. Treatment of humoral rejection after heart transplantation. J Heart Lung Transplant 1998; 17:1184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/24/28040/abstract/2\">",
"      Behr TM, Feucht HE, Richter K, et al. Detection of humoral rejection in human cardiac allografts by assessing the capillary deposition of complement fragment C4d in endomyocardial biopsies. J Heart Lung Transplant 1999; 18:904.",
"     </a>",
"    </li>",
"    <li>",
"     Hertz, MI, Aurora, P, Christie, JD, et al. Scientific Registry of the International Society for Heart and Lung Transplantation: introduction to the 2009 Annual Reports. J Heart Lung Transplant 2009; 28:989. See also www.ishlt.org/registries.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/24/28040/abstract/4\">",
"      John R, Rajasinghe HA, Chen JM, et al. Long-term outcomes after cardiac transplantation: an experience based on different eras of immunosuppressive therapy. Ann Thorac Surg 2001; 72:440.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/24/28040/abstract/5\">",
"      Kubo SH, Naftel DC, Mills RM Jr, et al. Risk factors for late recurrent rejection after heart transplantation: a multiinstitutional, multivariable analysis. Cardiac Transplant Research Database Group. J Heart Lung Transplant 1995; 14:409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/24/28040/abstract/6\">",
"      Hershberger RE, Starling RC, Eisen HJ, et al. Daclizumab to prevent rejection after cardiac transplantation. N Engl J Med 2005; 352:2705.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/24/28040/abstract/7\">",
"      Kobashigawa JA, Miller LW, Russell SD, et al. Tacrolimus with mycophenolate mofetil (MMF) or sirolimus vs. cyclosporine with MMF in cardiac transplant patients: 1-year report. Am J Transplant 2006; 6:1377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/24/28040/abstract/8\">",
"      Kobashigawa JA, Kirklin JK, Naftel DC, et al. Pretransplantation risk factors for acute rejection after heart transplantation: a multiinstitutional study. The Transplant Cardiologists Research Database Group. J Heart Lung Transplant 1993; 12:355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/24/28040/abstract/9\">",
"      Jarcho J, Naftel DC, Shroyer TW, et al. Influence of HLA mismatch on rejection after heart transplantation: a multiinstitutional study. The Cardiac Transplant Research Database Group. J Heart Lung Transplant 1994; 13:583.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/24/28040/abstract/10\">",
"      Opelz G. Effect of HLA matching in heart transplantation. Collaborative Heart Transplant Study. Transplant Proc 1989; 21:794.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/24/28040/abstract/11\">",
"      DiSesa VJ, Kuo PC, Horvath KA, et al. HLA histocompatibility affects cardiac transplant rejection and may provide one basis for organ allocation. Ann Thorac Surg 1990; 49:220.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/24/28040/abstract/12\">",
"      Sheldon S, Yonan NA, Aziz TN, et al. The influence of histocompatibility on graft rejection and graft survival within a single center population of heart transplant recipients. Transplantation 1999; 68:515.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/24/28040/abstract/13\">",
"      Mills RM, Naftel DC, Kirklin JK, et al. Heart transplant rejection with hemodynamic compromise: a multiinstitutional study of the role of endomyocardial cellular infiltrate. Cardiac Transplant Research Database. J Heart Lung Transplant 1997; 16:813.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/24/28040/abstract/14\">",
"      Scott CD, Dark JH, McComb JM. Arrhythmias after cardiac transplantation. Am J Cardiol 1992; 70:1061.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/24/28040/abstract/15\">",
"      Cui G, Tung T, Kobashigawa J, et al. Increased incidence of atrial flutter associated with the rejection of heart transplantation. Am J Cardiol 2001; 88:280.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/24/28040/abstract/16\">",
"      Cooper DK, Charles RG, Rose AG, et al. Does the electrocardiogram detect early acute heart rejection. J Heart Transplant 1985; 4:546.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/24/28040/abstract/17\">",
"      Gradek WQ, D'Amico C, Smith AL, et al. Routine surveillance endomyocardial biopsy continues to detect significant rejection late after heart transplantation. J Heart Lung Transplant 2001; 20:497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/24/28040/abstract/18\">",
"      Stehlik J, Starling RC, Movsesian MA, et al. Utility of long-term surveillance endomyocardial biopsy: a multi-institutional analysis. J Heart Lung Transplant 2006; 25:1402.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/24/28040/abstract/19\">",
"      Stewart S, Winters GL, Fishbein MC, et al. Revision of the 1990 working formulation for the standardization of nomenclature in the diagnosis of heart rejection. J Heart Lung Transplant 2005; 24:1710.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/24/28040/abstract/20\">",
"      Alharethi R, Bader F, Kfoury AG, et al. Tricuspid valve replacement after cardiac transplantation. J Heart Lung Transplant 2006; 25:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/24/28040/abstract/21\">",
"      Chan MC, Giannetti N, Kato T, et al. Severe tricuspid regurgitation after heart transplantation. J Heart Lung Transplant 2001; 20:709.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/24/28040/abstract/22\">",
"      Schuurman HJ, Gmelig Meyling FH, Wijngaard PL, et al. Lymphocyte status in endomyocardial biopsies and blood after heart transplantation. J Pathol 1989; 159:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/24/28040/abstract/23\">",
"      Higuchi ML, de Assis RV, Sambiase NV, et al. Usefulness of T-cell phenotype characterization in endomyocardial biopsy fragments from human cardiac allografts. J Heart Lung Transplant 1991; 10:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/24/28040/abstract/24\">",
"      Briscoe DM, Yeung AC, Schoen FJ, et al. Predictive value of inducible endothelial cell adhesion molecule expression for acute rejection of human cardiac allografts. Transplantation 1995; 59:204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/24/28040/abstract/25\">",
"      Tanio JW, Basu CB, Albelda SM, Eisen HJ. Differential expression of the cell adhesion molecules ICAM-1, VCAM-1, and E-selectin in normal and posttransplantation myocardium. Cell adhesion molecule expression in human cardiac allografts. Circulation 1994; 89:1760.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/24/28040/abstract/26\">",
"      Costanzo-Nordin MR, Heroux AL, Radvany R, et al. Role of humoral immunity in acute cardiac allograft dysfunction. J Heart Lung Transplant 1993; 12:S143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/24/28040/abstract/27\">",
"      Takemoto SK, Zeevi A, Feng S, et al. National conference to assess antibody-mediated rejection in solid organ transplantation. Am J Transplant 2004; 4:1033.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/24/28040/abstract/28\">",
"      Winters GL, Marboe CC, Billingham ME. The International Society for Heart and Lung Transplantation grading system for heart transplant biopsy specimens: clarification and commentary. J Heart Lung Transplant 1998; 17:754.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/24/28040/abstract/29\">",
"      Billingham ME, Cary NR, Hammond ME, et al. A working formulation for the standardization of nomenclature in the diagnosis of heart and lung rejection: Heart Rejection Study Group. The International Society for Heart Transplantation. J Heart Transplant 1990; 9:587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/24/28040/abstract/30\">",
"      Fyfe B, Loh E, Winters GL, et al. Heart transplantation-associated perioperative ischemic myocardial injury. Morphological features and clinical significance. Circulation 1996; 93:1133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/24/28040/abstract/31\">",
"      Joshi A, Masek MA, Brown BW Jr, et al. \"Quilty\" revisited: a 10-year perspective. Hum Pathol 1995; 26:547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/24/28040/abstract/32\">",
"      Gonwa TA, Capehart JE, Pilcher JW, Alivizatos PA. Cytomegalovirus myocarditis as a cause of cardiac dysfunction in a heart transplant recipient. Transplantation 1989; 47:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/24/28040/abstract/33\">",
"      Eisen HJ, Hicks D, Kant JA, et al. Diagnosis of posttransplantation lymphoproliferative disorder by endomyocardial biopsy in a cardiac allograft recipient. J Heart Lung Transplant 1994; 13:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/24/28040/abstract/34\">",
"      Reed EF, Demetris AJ, Hammond E, et al. Acute antibody-mediated rejection of cardiac transplants. J Heart Lung Transplant 2006; 25:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/24/28040/abstract/35\">",
"      Joyce DL, Southard RE, Torre-Amione G, et al. Impact of left ventricular assist device (LVAD)-mediated humoral sensitization on post-transplant outcomes. J Heart Lung Transplant 2005; 24:2054.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/24/28040/abstract/36\">",
"      Taylor DO, Yowell RL, Kfoury AG, et al. Allograft coronary artery disease: clinical correlations with circulating anti-HLA antibodies and the immunohistopathologic pattern of vascular rejection. J Heart Lung Transplant 2000; 19:518.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/24/28040/abstract/37\">",
"      Michaels PJ, Espejo ML, Kobashigawa J, et al. Humoral rejection in cardiac transplantation: risk factors, hemodynamic consequences and relationship to transplant coronary artery disease. J Heart Lung Transplant 2003; 22:58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/24/28040/abstract/38\">",
"      Dengler TJ, Zimmermann R, Braun K, et al. Elevated serum concentrations of cardiac troponin T in acute allograft rejection after human heart transplantation. J Am Coll Cardiol 1998; 32:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/24/28040/abstract/39\">",
"      Bourge R, Eisen H, Hershberger R, et al. Noninvasive rejection monitoring of cardiac transplants using high resolution intramyocardial electrograms: initial US multicenter experience. Pacing Clin Electrophysiol 1998; 21:2338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/24/28040/abstract/40\">",
"      Hetzer R, Potapov EV, M&uuml;ller J, et al. Daily noninvasive rejection monitoring improves long-term survival in pediatric heart transplantation. Ann Thorac Surg 1998; 66:1343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/24/28040/abstract/41\">",
"      Moidl R, Chevtchik O, Simon P, et al. Noninvasive monitoring of peak filling rate with acoustic quantification echocardiography accurately detects acute cardiac allograft rejection. J Heart Lung Transplant 1999; 18:194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/24/28040/abstract/42\">",
"      Valantine HA, Yeoh TK, Gibbons R, et al. Sensitivity and specificity of diastolic indexes for rejection surveillance: temporal correlation with endomyocardial biopsy. J Heart Lung Transplant 1991; 10:757.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/24/28040/abstract/43\">",
"      StGoar FG, Gibbons R, Schnittger I, et al. Left ventricular diastolic function. Doppler echocardiographic changes soon after cardiac transplantation. Circulation 1990; 82:872.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/24/28040/abstract/44\">",
"      Mankad S, Murali S, Kormos RL, et al. Evaluation of the potential role of color-coded tissue Doppler echocardiography in the detection of allograft rejection in heart transplant recipients. Am Heart J 1999; 138:721.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/24/28040/abstract/45\">",
"      Angermann CE, Nassau K, Stempfle HU, et al. Recognition of acute cardiac allograft rejection from serial integrated backscatter analyses in human orthotopic heart transplant recipients. Comparison with conventional echocardiography. Circulation 1997; 95:140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/24/28040/abstract/46\">",
"      Eisen HJ, Eisenberg SB, Saffitz JE, et al. Noninvasive detection of rejection of transplanted hearts with indium-111-labeled lymphocytes. Circulation 1987; 75:868.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/24/28040/abstract/47\">",
"      Hesse B, Mortensen SA, Folke M, et al. Ability of antimyosin scintigraphy monitoring to exclude acute rejection during the first year after heart transplantation. J Heart Lung Transplant 1995; 14:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/24/28040/abstract/48\">",
"      Narula J, Acio ER, Narula N, et al. Annexin-V imaging for noninvasive detection of cardiac allograft rejection. Nat Med 2001; 7:1347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/24/28040/abstract/49\">",
"      Butler CR, Thompson R, Haykowsky M, et al. Cardiovascular magnetic resonance in the diagnosis of acute heart transplant rejection: a review. J Cardiovasc Magn Reson 2009; 11:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/24/28040/abstract/50\">",
"      Taylor AJ, Vaddadi G, Pfluger H, et al. Diagnostic performance of multisequential cardiac magnetic resonance imaging in acute cardiac allograft rejection. Eur J Heart Fail 2010; 12:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/24/28040/abstract/51\">",
"      Starling RC, Pham M, Valantine H, et al. Molecular testing in the management of cardiac transplant recipients: initial clinical experience. J Heart Lung Transplant 2006; 25:1389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/24/28040/abstract/52\">",
"      Deng MC, Eisen HJ, Mehra MR, et al. Noninvasive discrimination of rejection in cardiac allograft recipients using gene expression profiling. Am J Transplant 2006; 6:150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/24/28040/abstract/53\">",
"      Mehra MR. The emergence of genomic and proteomic biomarkers in heart transplantation. J Heart Lung Transplant 2005; 24:S213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/24/28040/abstract/54\">",
"      Marboe CC, Billingham M, Eisen H, et al. Nodular endocardial infiltrates (Quilty lesions) cause significant variability in diagnosis of ISHLT Grade 2 and 3A rejection in cardiac allograft recipients. J Heart Lung Transplant 2005; 24:S219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/24/28040/abstract/55\">",
"      Evans RW, Williams GE, Baron HM, et al. The economic implications of noninvasive molecular testing for cardiac allograft rejection. Am J Transplant 2005; 5:1553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/24/28040/abstract/56\">",
"      Pham MX, Teuteberg JJ, Kfoury AG, et al. Gene-expression profiling for rejection surveillance after cardiac transplantation. N Engl J Med 2010; 362:1890.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3519 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-218.7.204.202-35DACE4C3B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_24_28040=[""].join("\n");
var outline_f27_24_28040=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H19\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INCIDENCE AND OUTCOMES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Time after transplantation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Type of immunosuppression",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Other",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      CLINICAL PRESENTATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Surveillance biopsy schedule",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Biopsy procedure",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Complications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Histologic findings of acute rejection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      ISHLT grading system",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Acute cellular rejection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Nonrejection findings",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Acute antibody-mediated (humoral) rejection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      NONINVASIVE DETECTION OF REJECTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Gene expression profiling",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/3519\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/3519|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?41/50/42796\" title=\"table 1\">",
"      ISHLT cardiac biopsy grades",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/6/14441?source=related_link\">",
"      Acute cardiac allograft rejection: Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/3/34874?source=related_link\">",
"      Clinical utility of cardiovascular magnetic resonance imaging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/26/7592?source=related_link\">",
"      Endomyocardial biopsy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/47/29433?source=related_link\">",
"      Infection in the solid organ transplant recipient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/16/25862?source=related_link\">",
"      Left ventricular dysfunction after orthotopic cardiac transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/9/18585?source=related_link\">",
"      Natural history and diagnosis of cardiac allograft vasculopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?0/5/92?source=related_link\">",
"      Patient information: Heart transplant (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?25/36/26179?source=related_link\">",
"      Patient information: Heart transplantation (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/50/23338?source=related_link\">",
"      Treatment and prevention of post-transplant lymphoproliferative disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/51/36661?source=related_link\">",
"      Use of the signal-averaged electrocardiogram in nonischemic heart disease and cardiac transplantation",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f27_24_28041="Overview of TORCH infections";
var content_f27_24_28041=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Overview of TORCH infections",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/24/28041/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/24/28041/contributors\">",
"     Karen E Johnson, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/24/28041/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/24/28041/contributors\">",
"     Leonard E Weisman, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/24/28041/contributors\">",
"     Morven S Edwards, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/24/28041/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/24/28041/contributors\">",
"     Mary M Torchia, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?27/24/28041/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 11, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infections acquired in utero or during the birth process are a significant cause of fetal and neonatal mortality and an important contributor to early and later childhood morbidity. The original concept of the TORCH perinatal infections was to group five infections with similar presentations, including rash and ocular findings [",
"    <a class=\"abstract\" href=\"UTD.htm?27/24/28041/abstract/1\">",
"     1",
"    </a>",
"    ]. These five infections are:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Toxoplasmosis",
"     </li>",
"     <li>",
"      Other (syphilis)",
"     </li>",
"     <li>",
"      Rubella",
"     </li>",
"     <li>",
"      Cytomegalovirus (CMV)",
"     </li>",
"     <li>",
"      Herpes simplex virus (HSV)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The TORCH acronym is well recognized in the field of",
"    <span class=\"nowrap\">",
"     neonatal/perinatal",
"    </span>",
"    medicine [",
"    <a class=\"abstract\" href=\"UTD.htm?27/24/28041/abstract/2\">",
"     2",
"    </a>",
"    ]. However, there are other well-described causes of in utero infection, including enteroviruses, varicella zoster virus, and parvovirus B19. Thus, broadening the &ldquo;other&rdquo; category to include additional pathogens has been proposed [",
"    <a class=\"abstract\" href=\"UTD.htm?27/24/28041/abstract/3,4\">",
"     3,4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Given the increasing numbers of pathogens responsible for in utero and perinatal infections, the validity of indiscriminate screening of neonates or infants with findings compatible with congenital infection with &ldquo;TORCH titers&rdquo; has been questioned [",
"    <a class=\"abstract\" href=\"UTD.htm?27/24/28041/abstract/5-7\">",
"     5-7",
"    </a>",
"    ]. An alternate approach involves testing of infants with suspected congenital infections for specific pathogens based upon their clinical presentation (",
"    <a class=\"graphic graphic_table graphicRef76743 \" href=\"UTD.htm?32/26/33196\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/24/28041/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. Timely diagnosis of perinatally acquired infections is crucial to the initiation of appropriate therapy. A high index of suspicion for congenital infection and awareness of the prominent features of the most common congenital infections help to facilitate early diagnosis of congenital infection.",
"   </p>",
"   <p>",
"    An overview of the clinical features of specific TORCH infections and an approach to the infant with suspected intrauterine infection will be provided below. The individual TORCH infections are discussed in more detail separately:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/39/22137?source=see_link\">",
"       \"Toxoplasmosis and pregnancy\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/12/43208?source=see_link\">",
"       \"Congenital toxoplasmosis: Clinical features and diagnosis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/31/7672?source=see_link\">",
"       \"Congenital toxoplasmosis: Treatment, outcome, and prevention\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/61/4057?source=see_link\">",
"       \"Syphilis in pregnancy\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/31/17914?source=see_link\">",
"       \"Congenital syphilis: Clinical features and diagnosis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/11/37049?source=see_link\">",
"       \"Congenital syphilis: Evaluation, management, and prevention\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/60/6087?source=see_link\">",
"       \"Rubella in pregnancy\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/49/10010?source=see_link\">",
"       \"Congenital rubella syndrome: Clinical features and diagnosis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/63/36855?source=see_link\">",
"       \"Congenital rubella syndrome: Management, outcome, and prevention\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/21/12634?source=see_link\">",
"       \"Cytomegalovirus infection in pregnancy\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/51/36664?source=see_link\">",
"       \"Cytomegalovirus infection and disease in newborns, infants, children and adolescents\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/14/33001?source=see_link\">",
"       \"Genital herpes simplex virus infection and pregnancy\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/31/35321?source=see_link\">",
"       \"Neonatal herpes simplex virus infection: Clinical features and diagnosis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/48/40713?source=see_link\">",
"       \"Neonatal herpes simplex virus infection: Management and prevention\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/49/34585?source=see_link&amp;anchor=H16#H16\">",
"       \"Clinical manifestations and diagnosis of enterovirus and parechovirus infections\", section on 'Infections in neonates'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/29/40408?source=see_link\">",
"       \"Parvovirus B19 infection during pregnancy\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/54/22377?source=see_link&amp;anchor=H15#H15\">",
"       \"Clinical manifestations and pathogenesis of human parvovirus B19 infection\", section on 'Non-immune hydrops fetalis and intrauterine fetal death'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/28/33225?source=see_link\">",
"       \"Varicella-zoster virus infection in pregnancy\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/11/4278?source=see_link\">",
"       \"Varicella-zoster infection in the newborn\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     SCREENING FOR TORCH INFECTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The practice of screening pregnant women for TORCH infections varies geographically. In the United States, the American College of Obstetricians and Gynecologists (ACOG) recommends that pregnant women be screened for rubella and syphilis at the first prenatal visit. In other countries, pregnant women also may be screened for toxoplasmosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/1/42010?source=see_link&amp;anchor=H9#H9\">",
"     \"Initial prenatal assessment and patient education\", section on 'Routine'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/39/22137?source=see_link&amp;anchor=H7#H7\">",
"     \"Toxoplasmosis and pregnancy\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Asymptomatic infants generally are not screened for congenital infections, but some European countries and some states in the United States provide universal screening for toxoplasmosis [",
"    <a class=\"abstract\" href=\"UTD.htm?27/24/28041/abstract/8\">",
"     8",
"    </a>",
"    ]. Although identification of IgM antibodies in the newborn is suggestive of congenital infection (because IgM antibodies do not cross the placenta), indiscriminate screening for TORCH infections with the battery of &ldquo;TORCH titers&rdquo; is expensive and has a poor diagnostic yield [",
"    <a class=\"abstract\" href=\"UTD.htm?27/24/28041/abstract/5,6,9,10\">",
"     5,6,9,10",
"    </a>",
"    ]. An alternate approach involves testing of infants with suspected congenital infections for specific pathogens based upon their clinical presentation. (See",
"    <a class=\"local\" href=\"#H609355024\">",
"     'Approach to the infant with suspected intrauterine infection'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H650131395\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES OF TORCH INFECTIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Congenital toxoplasmosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Toxoplasmosis is caused by the protozoan parasite",
"    <em>",
"     Toxoplasma gondii",
"    </em>",
"    . Primary infection during pregnancy can result in congenital disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/39/22137?source=see_link\">",
"     \"Toxoplasmosis and pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Most infants with congenital toxoplasmosis are asymptomatic or without apparent abnormalities at birth. Although subclinical disease is the rule, signs present at birth may include fever, maculopapular rash, hepatosplenomegaly, microcephaly, seizures, jaundice, thrombocytopenia, and, rarely, generalized lymphadenopathy (",
"    <a class=\"graphic graphic_picture graphicRef71515 \" href=\"UTD.htm?2/28/2498\">",
"     picture 1",
"    </a>",
"    ). The so-called classic triad of congenital toxoplasmosis consists of chorioretinitis, hydrocephalus, and intracranial calcifications (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef60804 \" href=\"UTD.htm?31/3/31806\">",
"     image 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Infants with subclinical congenital toxoplasmosis who do not receive treatment have an increased risk of long-term sequelae. The most common late finding is chorioretinitis (",
"    <a class=\"graphic graphic_picture graphicRef80549 \" href=\"UTD.htm?40/39/41590\">",
"     picture 2",
"    </a>",
"    ), which can result in vision loss. Intellectual disability (mental retardation), deafness, seizures, and spasticity also can be seen in a minority of untreated children.",
"   </p>",
"   <p>",
"    The diagnosis, management, and prevention of congenital toxoplasmosis are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/12/43208?source=see_link\">",
"     \"Congenital toxoplasmosis: Clinical features and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/31/7672?source=see_link\">",
"     \"Congenital toxoplasmosis: Treatment, outcome, and prevention\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Congenital syphilis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Congenital syphilis occurs when the spirochete",
"    <em>",
"     Treponema pallidum",
"    </em>",
"    is transmitted from a pregnant woman to her fetus. Infection can result in stillbirth, hydrops fetalis, or prematurity and associated long-term morbidity. Because of this morbidity, great emphasis has been placed on routine syphilis screening of all pregnant women. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/61/4057?source=see_link&amp;anchor=H10#H10\">",
"     \"Syphilis in pregnancy\", section on 'Maternal screening'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The incidence of congenital syphilis reflects the rate of syphilis in women of childbearing age. Many congenital cases develop because the mother received no prenatal care, no penicillin treatment, or inadequate treatment before or during pregnancy.",
"   </p>",
"   <p>",
"    Most neonates with congenital syphilis are asymptomatic at birth. Overt infection can manifest in the fetus, the newborn, or later in childhood. Clinical manifestations after birth are divided arbitrarily into early (&le;2 years of age (",
"    <a class=\"graphic graphic_table graphicRef67809 \" href=\"UTD.htm?10/17/10526\">",
"     table 2",
"    </a>",
"    )) and late (&gt;2 years of age (",
"    <a class=\"graphic graphic_table graphicRef81529 \" href=\"UTD.htm?35/25/36251\">",
"     table 3",
"    </a>",
"    )).",
"   </p>",
"   <p>",
"    The diagnosis, management, and prevention of congenital syphilis are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/31/17914?source=see_link\">",
"     \"Congenital syphilis: Clinical features and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/11/37049?source=see_link\">",
"     \"Congenital syphilis: Evaluation, management, and prevention\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Congenital rubella",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rubella typically causes a mild, self-limited illness; its major impact occurs during pregnancy, when it can have devastating effects on the developing fetus.",
"   </p>",
"   <p>",
"    Congenital rubella syndrome (CRS) is rare in developed countries with established rubella immunization programs. It is no longer endemic in the United States, although an average of 5 to 6 cases are reported to the National Congenital Rubella Registry each year, usually in infants whose mothers emigrated from countries without rubella immunization programs.",
"   </p>",
"   <p>",
"    Clinical manifestations of CRS include sensorineural deafness, cataracts, cardiac malformations (eg, patent ductus arteriosus, pulmonary artery hypoplasia), and neurologic and endocrinologic sequelae. Neonatal manifestations may include growth retardation, radiolucent bone disease (not pathognomonic of congenital rubella), hepatosplenomegaly, thrombocytopenia, purpuric skin lesions (classically described as \"blueberry muffin\" lesions that represent extramedullary hematopoiesis), and hyperbilirubinemia.",
"   </p>",
"   <p>",
"    The diagnosis, management, and prevention of CRS are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/49/10010?source=see_link\">",
"     \"Congenital rubella syndrome: Clinical features and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/63/36855?source=see_link\">",
"     \"Congenital rubella syndrome: Management, outcome, and prevention\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Congenital cytomegalovirus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cytomegalovirus (CMV) is a ubiquitous virus worldwide. Despite its listing as the fourth infection in the TORCH designation, CMV has emerged as the most common congenital viral infection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h3\">",
"     Epidemiology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Primary infection and reactivation of virus can occur during pregnancy, and both can result in congenital CMV, the most common congenital viral infection. Approximately 40,000 infants are born with congenital CMV infection annually in the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?27/24/28041/abstract/11\">",
"     11",
"    </a>",
"    ]. Although the majority of congenital infections are asymptomatic, approximately 5 to 20 percent of infants born to mothers with primary CMV infection will be overtly symptomatic. These children have a mortality rate of almost 30 percent, and severe neurologic morbidity occurs in 80 percent of survivors.",
"   </p>",
"   <p>",
"    The risk of seroconversion to CMV during pregnancy averages 2.0 to 2.5 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?27/24/28041/abstract/12\">",
"     12",
"    </a>",
"    ]. Intrauterine infection occurs in 0.5 to 2 percent of all live births. Congenital infection from seropositive mothers ranges from 0.2 to 1.5 percent. In contrast, primary maternal infection during pregnancy leads to transmission in approximately 40 percent of fetuses [",
"    <a class=\"abstract\" href=\"UTD.htm?27/24/28041/abstract/13\">",
"     13",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/21/12634?source=see_link\">",
"     \"Cytomegalovirus infection in pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There generally appears to be little risk of CMV-related complications in the offspring of women infected with CMV at least six months before conception. For this group, which comprises 50 to 80 percent of the women of childbearing age, the rate of newborn CMV infection is 1 percent. These infants appear to have little significant illness or sequelae, although severe fetal cytomegalic inclusion disease after maternal reactivation of CMV during the first trimester of pregnancy has been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?27/24/28041/abstract/14,15\">",
"     14,15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Factors that can influence CMV infection during pregnancy include maternal age, parity, and gestational age [",
"    <a class=\"abstract\" href=\"UTD.htm?27/24/28041/abstract/16\">",
"     16",
"    </a>",
"    ]. Although several studies have suggested that gestational age has no apparent influence on the risk of transmission of CMV in utero [",
"    <a class=\"abstract\" href=\"UTD.htm?27/24/28041/abstract/17-20\">",
"     17-20",
"    </a>",
"    ], an increased risk of transmission was observed in late gestation in one retrospective study (36, 45, and 78 percent, for the first, second, and third trimesters, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/24/28041/abstract/21\">",
"     21",
"    </a>",
"    ]. However, sequelae appear to be more severe when infection is acquired earlier in pregnancy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h3\">",
"     Transmission",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infection requires intimate contact with a person excreting the virus in saliva, urine, or bodily fluids. Congenital CMV infection generally is the result of transplacental transmission of the virus. The virus also can be transmitted sexually, via organ transplants, via breast milk, and, rarely, via blood transfusion. Transmission is higher in households with young children or in day care centers. Excretion rates in childcare centers can be as high as 70 percent in children one to three years of age [",
"    <a class=\"abstract\" href=\"UTD.htm?27/24/28041/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h3\">",
"     Clinical manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Congenital CMV has a wide constellation of clinical symptoms, ranging from none to fulminant end-organ dysfunction.",
"   </p>",
"   <p>",
"    Approximately 90 percent of infants with congenital CMV infection are asymptomatic at birth. However, 0.5 to 15 percent of these children are at risk for development of psychomotor, hearing, neurologic, ocular, or dental abnormalities within the first few years of life [",
"    <a class=\"abstract\" href=\"UTD.htm?27/24/28041/abstract/23,24\">",
"     23,24",
"    </a>",
"    ]. Some otherwise asymptomatic infants with congenital CMV infection are identified through newborn hearing screening [",
"    <a class=\"abstract\" href=\"UTD.htm?27/24/28041/abstract/25\">",
"     25",
"    </a>",
"    ]. In particular, sensorineural hearing loss will appear in 5 to 10 percent of cases and may interfere with learning abilities (",
"    <a class=\"graphic graphic_table graphicRef51801 \" href=\"UTD.htm?14/10/14508\">",
"     table 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/24/28041/abstract/26-32\">",
"     26-32",
"    </a>",
"    ]. Hearing loss appears to be associated with increased concentrations of CMV in peripheral blood and urine [",
"    <a class=\"abstract\" href=\"UTD.htm?27/24/28041/abstract/33\">",
"     33",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/38/19050?source=see_link\">",
"     \"Etiology of hearing impairment in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Approximately 10 percent of infants with congenital CMV infection are symptomatic [",
"    <a class=\"abstract\" href=\"UTD.htm?27/24/28041/abstract/34\">",
"     34",
"    </a>",
"    ]. One study suggested that symptomatic congenital infection correlated with the amount of virus present in the amniotic fluid; infants born to mothers with &ge;10",
"    <sup>",
"     3",
"    </sup>",
"    genome equivalents in amniotic fluid by polymerase chain reaction (PCR) had a 100 percent probability of acquiring CMV, and for those with &ge;10",
"    <sup>",
"     5",
"    </sup>",
"    genome equivalents, this infection was symptomatic [",
"    <a class=\"abstract\" href=\"UTD.htm?27/24/28041/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Fifty percent of symptomatic infants present with an attenuated form of congenital infection, usually consisting of isolated splenomegaly, jaundice,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    petechiae [",
"    <a class=\"abstract\" href=\"UTD.htm?27/24/28041/abstract/34,36\">",
"     34,36",
"    </a>",
"    ]. The other 50 percent of symptomatic infants present with the syndrome of cytomegalic inclusion disease, consisting of [",
"    <a class=\"abstract\" href=\"UTD.htm?27/24/28041/abstract/37\">",
"     37",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Jaundice &ndash; 67 percent",
"     </li>",
"     <li>",
"      Hepatosplenomegaly &ndash; 60 percent",
"     </li>",
"     <li>",
"      Petechial rash &ndash; 76 percent",
"     </li>",
"     <li>",
"      Multiorgan involvement (eg, microcephaly, motor disability, chorioretinitis, cerebral calcifications (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef69239 \" href=\"UTD.htm?29/12/29902\">",
"       image 2",
"      </a>",
"      ), lethargy, respiratory distress, seizures)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Laboratory abnormalities include: abnormal blood counts (especially thrombocytopenia), hemolytic anemia, elevated transaminases, and elevated direct and indirect serum bilirubin.",
"   </p>",
"   <p>",
"    In this fulminant presentation, mortality can be up to 30 percent and occurs within a few days or weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?27/24/28041/abstract/34,38\">",
"     34,38",
"    </a>",
"    ]. In survivors, jaundice and hepatosplenomegaly may subside, but neurologic sequelae (eg, microcephaly, intellectual disability [mental retardation], hearing disorders) persist.",
"   </p>",
"   <p>",
"    More than 80 percent of infants symptomatic at birth will develop late complications that may include hearing loss, vision impairment, and varying degrees of intellectual disability and delay in psychomotor development (",
"    <a class=\"graphic graphic_table graphicRef51801 \" href=\"UTD.htm?14/10/14508\">",
"     table 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/24/28041/abstract/27\">",
"     27",
"    </a>",
"    ]. Infections acquired in late pregnancy may have less prominent signs, although severe developmental problems associated with CNS calcification, microcephaly, and hearing loss have been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?27/24/28041/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A wide range of abnormalities of the brain may be detected on cranial imaging (eg, unenhanced computed tomographic [CT] scan) (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef69239 \" href=\"UTD.htm?29/12/29902\">",
"     image 2",
"    </a>",
"    ). These abnormalities include periventricular leukomalacia and cystic abnormalities, periventricular calcifications (linear or punctate), ventriculomegaly, vasculitis, neuronal migration abnormalities, and hydranencephaly [",
"    <a class=\"abstract\" href=\"UTD.htm?27/24/28041/abstract/40,41\">",
"     40,41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Sensorineural hearing loss is detected in more than two-thirds of newborns with symptomatic congenital CMV infection [",
"    <a class=\"abstract\" href=\"UTD.htm?27/24/28041/abstract/17,38\">",
"     17,38",
"    </a>",
"    ]. Like that associated with asymptomatic infection, this hearing loss almost always is progressive, eventually producing severe to profound hearing loss in the affected ear [",
"    <a class=\"abstract\" href=\"UTD.htm?27/24/28041/abstract/40,41\">",
"     40,41",
"    </a>",
"    ]. Infants with hearing loss caused by congenital CMV infection or disease may be cognitively normal, or they may experience cognitive delays, depending upon the degree of brain involvement experienced in utero [",
"    <a class=\"abstract\" href=\"UTD.htm?27/24/28041/abstract/42,43\">",
"     42,43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Ocular abnormalities, including chorioretinitis (a posterior uveitis), retinal scars, optic atrophy, and central vision loss, also may be seen [",
"    <a class=\"abstract\" href=\"UTD.htm?27/24/28041/abstract/44\">",
"     44",
"    </a>",
"    ]. In one prospective study of 125 infants with congenital CMV, 42 of them symptomatic, visual impairment was significantly more common in the symptomatic patients (22 versus 2.4 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/24/28041/abstract/44\">",
"     44",
"    </a>",
"    ]. Moderate to severe involvement frequently bilaterally included optic atrophy, macular scars, and cortical visual impairment. Strabismus also was more frequent in those with symptomatic compared with asymptomatic congenital CMV (29 versus 1.2 percent). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/8/34951?source=see_link&amp;anchor=H5#H5\">",
"     \"Evaluation and management of strabismus in children\", section on 'Differential diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The presence of microcephaly, intracranial calcifications, or other CT scan abnormalities plus chorioretinitis correlates with a poor neurodevelopmental outcome, although the absence of these factors predicts a normal or near-normal cognitive outcome. Infants with symptomatic congenital CMV should undergo regular screening of hearing, vision, and development, with follow-up testing and referral as indicated. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/19/44344?source=see_link\">",
"     \"Evaluation of hearing impairment in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/59/24505?source=see_link\">",
"     \"Visual development and vision assessment in infants and children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h3\">",
"     Diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of congenital CMV infection or disease is accomplished by isolation of the virus in urine or saliva samples collected within the first three weeks of life. These infants often have very high titers of virus, and the culture frequently will become positive within one to three days of incubation [",
"    <a class=\"abstract\" href=\"UTD.htm?27/24/28041/abstract/17\">",
"     17",
"    </a>",
"    ]. The use of culture enhancement centrifugation systems, such as the shell vial assay (staining for early antigen production), has been substituted for traditional cell monolayer culture in many laboratories. Detection of CMV DNA in the urine and serum of newborns also using polymerase chain reaction (PCR) techniques may be used to diagnose congenital CMV infection, but these methods are less available, more expensive, and often less reliable than is traditional cell culture or shell vial culture of the urine [",
"    <a class=\"abstract\" href=\"UTD.htm?27/24/28041/abstract/45,46\">",
"     45,46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    CMV IgM antibodies in cord serum or as part of a TORCH titer panel is highly suggestive of congenital infection but should be confirmed by viral culture. Serology for CMV IgG antibody determination is not helpful because most of the general population has CMV antibody, and a positive result may only reflect passive transfer of maternal antibody to the infant. Several serologic assays with differing sensitivity and specificity are available for IgM determinations. These tests are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/25/8597?source=see_link&amp;anchor=H3#H3\">",
"     \"Diagnosis of cytomegalovirus\", section on 'Serology'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Different approaches have been evaluated to identify women at risk of transmitting CMV during pregnancy. Amniocentesis for PCR or culture is the preferred method of diagnosis, but negative results do not exclude intrauterine infection [",
"    <a class=\"abstract\" href=\"UTD.htm?27/24/28041/abstract/47\">",
"     47",
"    </a>",
"    ]. Ultrasonographic markers, including microcephaly, hepatosplenomegaly, and intracranial calcification, may suggest fetal CMV infection, but normal ultrasonography does not exclude the diagnosis. Measurement of IgM, the IgG avidity determination, and combined application of the microneutralization and avidity assays are additional approaches to making a prenatal diagnosis. These approaches are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/21/12634?source=see_link&amp;anchor=H14#H14\">",
"     \"Cytomegalovirus infection in pregnancy\", section on 'Prenatal diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38\">",
"    <span class=\"h3\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a phase II randomized, controlled multicenter clinical trial evaluating the use of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/2/34848?source=see_link\">",
"     ganciclovir",
"    </a>",
"    for the treatment of infants with symptomatic congenital CMV infection and evidence of CNS involvement, 47 infants received ganciclovir (8 to 12",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    daily in 2 divided doses for up to 6 weeks) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/24/28041/abstract/48\">",
"     48",
"    </a>",
"    ]. Ganciclovir was discontinued in eight patients because of side effects but was well tolerated in the other newborns. Decreased excretion of virus was noted during ganciclovir administration, although viruria returned promptly after cessation of therapy. Sixteen percent of the infants had stabilization or improvement in hearing at six months of follow-up. Similar results were observed in a smaller trial [",
"    <a class=\"abstract\" href=\"UTD.htm?27/24/28041/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A phase III randomized clinical trial of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/2/34848?source=see_link\">",
"     ganciclovir",
"    </a>",
"    (6",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per dose IV every 12 hours) for six weeks in neonates with virologically confirmed congenital CMV disease and neurologic involvement suggested that treatment with ganciclovir prevents hearing deterioration at six months and possibly beyond [",
"    <a class=\"abstract\" href=\"UTD.htm?27/24/28041/abstract/50\">",
"     50",
"    </a>",
"    ]. The conclusions are limited because only 42 of the 100 enrolled subjects were evaluated for the primary outcome (hearing assessment at six months) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/24/28041/abstract/51\">",
"     51",
"    </a>",
"    ]. In addition, neutropenia (absolute neutrophil count",
"    <span class=\"nowrap\">",
"     &le;1250/microL)",
"    </span>",
"    was more common among ganciclovir recipients than controls (63 versus 21 percent).",
"   </p>",
"   <p>",
"    It remains unknown whether this early and intensive administration of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/2/34848?source=see_link\">",
"     ganciclovir",
"    </a>",
"    will hasten resolution of disease, beneficially influence growth and development, decrease auditory and visual impairment, or improve intellectual outcome in these infants. Ganciclovir should not be used routinely for fear of unforeseen long-term effects, such as testicular atrophy and bone marrow suppression. However, it may be reasonable to consider in selected cases. However, anecdotal evidence does suggest that critically ill newborns, especially those who are premature and have CMV pneumonia, may benefit acutely from ganciclovir treatment. Compassionate use also may be appropriate for patients with life- or sight-threatening congenital CMV. Thus, we recommend its use only after careful consideration in selected cases.",
"   </p>",
"   <p>",
"    The treatment of newborns with asymptomatic congenital infection is not indicated. Even though these infants are at some risk for hearing loss, the side effects of therapy with currently available antiviral agents and the lack of established benefit argue against routine administration.",
"   </p>",
"   <p>",
"    The use of CMV hyperimmune globulin has not been evaluated extensively for the treatment of congenital CMV disease. However, one anecdotal report suggests some benefit [",
"    <a class=\"abstract\" href=\"UTD.htm?27/24/28041/abstract/52\">",
"     52",
"    </a>",
"    ]. Both CMV immune globulin and alpha interferon are being studied for the treatment of congenital CMV. The development of CMV vaccines also is underway [",
"    <a class=\"abstract\" href=\"UTD.htm?27/24/28041/abstract/53\">",
"     53",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H39\">",
"    <span class=\"h2\">",
"     Herpes simplex virus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Genital Herpes simplex virus (HSV) infection during pregnancy poses a significant risk to the developing fetus and newborn.",
"   </p>",
"   <p>",
"    HSV is transmitted to an infant during birth, primarily through an infected maternal genital tract. The risk of transmission is greater with primary HSV infection acquired during pregnancy, compared with reactivation of previous infection. Among mothers with primary infection, acquisition near the time of labor is the major risk factor for transmission to the neonate (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/14/33001?source=see_link\">",
"     \"Genital herpes simplex virus infection and pregnancy\"",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Most newborns with perinatally acquired HSV appear normal at birth, although many are born prematurely. HSV infection in newborns usually develops in one of three patterns, which occur with roughly equal frequency:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Localized to the skin, eyes, and mouth (SEM)",
"     </li>",
"     <li>",
"      Localized CNS disease",
"     </li>",
"     <li>",
"      Disseminated disease involving multiple organs",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The initial manifestations of CNS disease frequently are nonspecific and include temperature instability, respiratory distress, poor feeding, and lethargy; they may progress quite rapidly to hypotension, jaundice, disseminated intravascular coagulation (DIC), apnea, and shock. Vesicular skin lesions may or may not be present and develop late in some patients; the absence of skin lesions complicates recognition of the infection. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/31/35321?source=see_link\">",
"     \"Neonatal herpes simplex virus infection: Clinical features and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The diagnosis, management, and prevention of neonatal HSV infections are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/31/35321?source=see_link&amp;anchor=H11#H11\">",
"     \"Neonatal herpes simplex virus infection: Clinical features and diagnosis\", section on 'Evaluation and diagnosis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/48/40713?source=see_link\">",
"     \"Neonatal herpes simplex virus infection: Management and prevention\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H626749151\">",
"    <span class=\"h2\">",
"     Congenital varicella syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most cases of congenital varicella syndrome occur in infants whose mothers were infected between 8 and 20 weeks gestation. Characteristic findings in neonates may include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Cutaneous scars, which may be depressed and pigmented in a dermatomal distribution",
"     </li>",
"     <li>",
"      Cataracts, chorioretinitis, microphthalmos, nystagmus",
"     </li>",
"     <li>",
"      Hypoplastic limbs",
"     </li>",
"     <li>",
"      Cortical atrophy and seizures",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The clinical manifestations and diagnosis of congenital varicella syndrome are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/28/33225?source=see_link&amp;anchor=H8#H8\">",
"     \"Varicella-zoster virus infection in pregnancy\", section on 'Fetal effects of VZV infection'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/28/33225?source=see_link&amp;anchor=H1098827#H1098827\">",
"     \"Varicella-zoster virus infection in pregnancy\", section on 'Congenital varicella syndrome'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H609355024\">",
"    <span class=\"h1\">",
"     APPROACH TO THE INFANT WITH SUSPECTED INTRAUTERINE INFECTION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H609355080\">",
"    <span class=\"h2\">",
"     Overview",
"    </span>",
"    &nbsp;&mdash;&nbsp;Timely diagnosis of perinatally acquired infections is crucial to the initiation of appropriate therapy, the development of a care plan, prognosis, and family counseling. A high index of suspicion for congenital infection and awareness of the prominent features of the most common congenital infections can help to facilitate early diagnosis and tailor appropriate diagnostic evaluation (",
"    <a class=\"graphic graphic_table graphicRef76743 \" href=\"UTD.htm?32/26/33196\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H609355087\">",
"    <span class=\"h2\">",
"     Clinical suspicion",
"    </span>",
"    &nbsp;&mdash;&nbsp;In some cases, intrauterine infection may be suspected on the basis of laboratory results obtained during pregnancy (eg, positive syphilis serology with increasing titers). In the absence of suggestive maternal laboratory results, intrauterine infection may be suspected in newborns with certain clinical manifestations, or combinations of clinical manifestations including (but not limited to):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Hydrops fetalis",
"     </li>",
"     <li>",
"      Microcephaly",
"     </li>",
"     <li>",
"      Seizures",
"     </li>",
"     <li>",
"      Cataract",
"     </li>",
"     <li>",
"      Hearing loss",
"     </li>",
"     <li>",
"      Congenital heart disease",
"     </li>",
"     <li>",
"      Hepatosplenomegaly",
"     </li>",
"     <li>",
"      Jaundice",
"     </li>",
"     <li>",
"      Rash",
"     </li>",
"     <li>",
"      Thrombocytopenia",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These findings are not restricted to TORCH infections and some of the features above may occur in other infections (eg, human parvovirus, Chagas disease) and in conditions other than intrauterine infection (eg, inborn errors of metabolism, Rh incompatibility, etc). Thus, the entire clinical constellation, including maternal history and exposures must be taken into account when deciding to evaluate an infant for congenital infection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H609355103\">",
"    <span class=\"h2\">",
"     Initial evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The evaluation of a newborn with clinical findings compatible with intrauterine infection may include [",
"    <a class=\"abstract\" href=\"UTD.htm?27/24/28041/abstract/54,55\">",
"     54,55",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Review of maternal history (evidence of rubella immunity, syphilis serology, history of Herpes simplex virus (HSV), exposure to cats, etc)",
"     </li>",
"     <li>",
"      Assessment of physical stigmata consistent with various intrauterine infections &nbsp;",
"     </li>",
"     <li>",
"      Complete blood count and platelet count",
"     </li>",
"     <li>",
"      Liver function tests (particularly important in HSV infection)",
"     </li>",
"     <li>",
"      Radiographs of long bones",
"     </li>",
"     <li>",
"      Ophthalmologic evaluation",
"     </li>",
"     <li>",
"      Audiologic evaluation",
"     </li>",
"     <li>",
"      Neuroimaging [",
"      <a class=\"abstract\" href=\"UTD.htm?27/24/28041/abstract/56\">",
"       56",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Lumbar puncture",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H609355188\">",
"    <span class=\"h2\">",
"     Specific evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The results of the initial evaluation may help to determine whether evaluation for a specific pathogen (or pathogens) is warranted. Findings that are more prominent in particular infections, and may prompt evaluation for a specific pathogen, are listed in the table (",
"    <a class=\"graphic graphic_table graphicRef76743 \" href=\"UTD.htm?32/26/33196\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The diagnostic evaluation for specific infections is discussed separately:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Congenital toxoplasmosis (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/12/43208?source=see_link&amp;anchor=H11762879#H11762879\">",
"       \"Congenital toxoplasmosis: Clinical features and diagnosis\", section on 'Evaluation and diagnosis'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Congenital syphilis (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/31/17914?source=see_link&amp;anchor=H28809398#H28809398\">",
"       \"Congenital syphilis: Clinical features and diagnosis\", section on 'Approach to diagnosis'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Congenital rubella (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/49/10010?source=see_link&amp;anchor=H14#H14\">",
"       \"Congenital rubella syndrome: Clinical features and diagnosis\", section on 'Evaluation and diagnosis'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Congenital cytomegalovirus (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/51/36664?source=see_link&amp;anchor=H14#H14\">",
"       \"Cytomegalovirus infection and disease in newborns, infants, children and adolescents\", section on 'Laboratory diagnosis'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Congenital herpes simplex virus (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/31/35321?source=see_link&amp;anchor=H11#H11\">",
"       \"Neonatal herpes simplex virus infection: Clinical features and diagnosis\", section on 'Evaluation and diagnosis'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Congenital varicella (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/11/4278?source=see_link&amp;anchor=H5#H5\">",
"       \"Varicella-zoster infection in the newborn\", section on 'Diagnosis'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Congenital enterovirus infection (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/49/34585?source=see_link&amp;anchor=H18#H18\">",
"       \"Clinical manifestations and diagnosis of enterovirus and parechovirus infections\", section on 'Laboratory diagnosis'",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?32/39/33395?source=see_link\">",
"       \"Patient information: Avoiding infections in pregnancy (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topic (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?42/52/43843?source=see_link\">",
"       \"Patient information: Avoiding infections in pregnancy (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H40\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The TORCH infections (",
"      <strong>",
"       t",
"      </strong>",
"      oxoplasmosis,",
"      <strong>",
"       o",
"      </strong>",
"      ther [syphilis],",
"      <strong>",
"       r",
"      </strong>",
"      ubella,",
"      <strong>",
"       c",
"      </strong>",
"      ytomegalovirus,",
"      <strong>",
"       h",
"      </strong>",
"      erpes simplex virus) are a group of perinatal infections that may have similar clinical presentations, including rash and ocular findings. Other important causes of",
"      <span class=\"nowrap\">",
"       intrauterine/perinatal",
"      </span>",
"      infection include enteroviruses, varicella zoster virus, and parvovirus B19. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Intrauterine and perinatal infections are a significant cause of fetal and neonatal mortality and an important contributor to childhood morbidity. Awareness of the prominent clinical features of TORCH and other",
"      <span class=\"nowrap\">",
"       intrauterine/perinatal",
"      </span>",
"      infections is crucial to timely diagnosis and initiation of treatment (",
"      <a class=\"graphic graphic_table graphicRef76743 \" href=\"UTD.htm?32/26/33196\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The classic triad of congenital toxoplasmosis consists of chorioretinitis (",
"      <a class=\"graphic graphic_picture graphicRef80549 \" href=\"UTD.htm?40/39/41590\">",
"       picture 2",
"      </a>",
"      ), hydrocephalus, and intracranial calcifications (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef60804 \" href=\"UTD.htm?31/3/31806\">",
"       image 1",
"      </a>",
"      ); signs present at birth may include fever, maculopapular rash, hepatosplenomegaly, microcephaly, seizures, jaundice, thrombocytopenia, and, rarely, generalized lymphadenopathy (",
"      <a class=\"graphic graphic_picture graphicRef71515 \" href=\"UTD.htm?2/28/2498\">",
"       picture 1",
"      </a>",
"      ). However, most infants with congenital toxoplasmosis are asymptomatic or without apparent abnormalities at birth. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/12/43208?source=see_link\">",
"       \"Congenital toxoplasmosis: Clinical features and diagnosis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/31/7672?source=see_link\">",
"       \"Congenital toxoplasmosis: Treatment, outcome, and prevention\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Most neonates with congenital syphilis are asymptomatic at birth. Clinical manifestations after birth are divided arbitrarily into early (&le;2 years of age (",
"      <a class=\"graphic graphic_table graphicRef67809 \" href=\"UTD.htm?10/17/10526\">",
"       table 2",
"      </a>",
"      )) and late (&gt;2 years of age (",
"      <a class=\"graphic graphic_table graphicRef81529 \" href=\"UTD.htm?35/25/36251\">",
"       table 3",
"      </a>",
"      )). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/31/17914?source=see_link\">",
"       \"Congenital syphilis: Clinical features and diagnosis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/11/37049?source=see_link\">",
"       \"Congenital syphilis: Evaluation, management, and prevention\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Clinical manifestations of congenital rubella syndrome (CRS) include sensorineural deafness, cataracts, cardiac malformations (eg, patent ductus arteriosus, pulmonary artery hypoplasia), and neurologic and endocrinologic sequelae. Neonatal manifestations may include growth retardation, radiolucent bone disease (not pathognomonic of congenital rubella), hepatosplenomegaly, thrombocytopenia, purpuric skin lesions (classically described as \"blueberry muffin\" lesions that represent extramedullary hematopoiesis), and hyperbilirubinemia. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/49/10010?source=see_link\">",
"       \"Congenital rubella syndrome: Clinical features and diagnosis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/63/36855?source=see_link\">",
"       \"Congenital rubella syndrome: Management, outcome, and prevention\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Most infants with congenital cytomegalovirus (CMV) are asymptomatic at birth. Among symptomatic infants, clinical manifestations include hepatosplenomegaly, jaundice, petechiae, and multiorgan involvement (eg, microcephaly, motor disability, chorioretinitis, cerebral calcifications (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef69239 \" href=\"UTD.htm?29/12/29902\">",
"       image 2",
"      </a>",
"      ), lethargy, respiratory distress, seizures). Both asymptomatic and symptomatic infants with congenital CMV are at risk to develop late complications including hearing loss, vision impairment, intellectual disability, and delay in psychomotor development (",
"      <a class=\"graphic graphic_table graphicRef51801 \" href=\"UTD.htm?14/10/14508\">",
"       table 4",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H29\">",
"       'Congenital cytomegalovirus'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Most newborns with perinatally acquired herpes simplex virus appear normal at birth, although many are born prematurely. Herpes simplex virus (HSV) infection in newborns usually develops in one of three patterns: localized to the skin, eyes, and mouth; localized central nervous system (CNS) disease; and disseminated disease. The initial manifestations of CNS disease frequently are nonspecific and include temperature instability, respiratory distress, poor feeding, and lethargy; they may progress quite rapidly to hypotension, jaundice, disseminated intravascular coagulation apnea, and shock. Vesicular skin lesions may or may not be present. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/31/35321?source=see_link\">",
"       \"Neonatal herpes simplex virus infection: Clinical features and diagnosis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/48/40713?source=see_link\">",
"       \"Neonatal herpes simplex virus infection: Management and prevention\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Characteristic features of congenital varicella infection include cutaneous scars; cataracts, chorioretinitis, microphthalmos, nystagmus; hypoplastic limbs; cortical atrophy; and seizures. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/28/33225?source=see_link&amp;anchor=H8#H8\">",
"       \"Varicella-zoster virus infection in pregnancy\", section on 'Fetal effects of VZV infection'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/28/33225?source=see_link&amp;anchor=H1098827#H1098827\">",
"       \"Varicella-zoster virus infection in pregnancy\", section on 'Congenital varicella syndrome'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Timely diagnosis of perinatally acquired infections is crucial to the initiation of appropriate therapy. A high index of suspicion for congenital infection and awareness of the prominent features of the most common congenital infections can help to facilitate early diagnosis and tailor appropriate diagnostic evaluation (",
"      <a class=\"graphic graphic_table graphicRef76743 \" href=\"UTD.htm?32/26/33196\">",
"       table 1",
"      </a>",
"      ). In the absence of maternal laboratory results compatible with intrauterine infection, intrauterine infection may be suspected in newborns with certain clinical manifestations, or combinations of clinical manifestations, including hydrops fetalis, microcephaly, seizures, cataract, hearing loss, congenital heart disease, hepatosplenomegaly, jaundice,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      rash. (See",
"      <a class=\"local\" href=\"#H609355024\">",
"       'Approach to the infant with suspected intrauterine infection'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/24/28041/abstract/1\">",
"      Epps RE, Pittelkow MR, Su WP. TORCH syndrome. Semin Dermatol 1995; 14:179.",
"     </a>",
"    </li>",
"    <li>",
"     Maldonado YA, Nizet V, Klein JO, et al. Current concepts of infections of the fetus and newborn infant. In: Infectious Diseases of the Fetus and Newborn Infant, 7th ed, Remington, JS, Klein, JO, Wilson, CB, et al (Eds), Elsevier Saunders, Philadelphia 2011. p.2.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/24/28041/abstract/3\">",
"      Stamos JK, Rowley AH. Timely diagnosis of congenital infections. Pediatr Clin North Am 1994; 41:1017.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/24/28041/abstract/4\">",
"      Kinney JS, Kumar ML. Should we expand the TORCH complex? A description of clinical and diagnostic aspects of selected old and new agents. Clin Perinatol 1988; 15:727.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/24/28041/abstract/5\">",
"      Khan NA, Kazzi SN. Yield and costs of screening growth-retarded infants for torch infections. Am J Perinatol 2000; 17:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/24/28041/abstract/6\">",
"      Cullen A, Brown S, Cafferkey M, et al. Current use of the TORCH screen in the diagnosis of congenital infection. J Infect 1998; 36:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/24/28041/abstract/7\">",
"      Garland SM, Gilbert GL. Investigation of congenital infection--the TORCH screen is not a legitimate test. Paediatric Infectious Diseases Group of the Australasian Society for Infectious Diseases. Med J Aust 1993; 159:346.",
"     </a>",
"    </li>",
"    <li>",
"     National Newborn Screening and Genetics Resource Center. National newborn screening status report. file://genes-r-us.uthscsa.edu/nbsdisorders.pdf (Accessed on July 20, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/24/28041/abstract/9\">",
"      Leland D, French ML, Kleiman MB, Schreiner RL. The use of TORCH titers. Pediatrics 1983; 72:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/24/28041/abstract/10\">",
"      van der Weiden S, de Jong EP, Te Pas AB, et al. Is routine TORCH screening and urine CMV culture warranted in small for gestational age neonates? Early Hum Dev 2011; 87:103.",
"     </a>",
"    </li>",
"    <li>",
"     Coles FS. Viral Infections of the Fetus and Newborn. In: Avery's Diseases of the Newborn, 7th ed, Taeusch WH, Ballard RA (Eds), Saunders, Philadelphia 1998. p.471.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/24/28041/abstract/12\">",
"      Lazzarotto T, Varani S, Gabrielli L, et al. New advances in the diagnosis of congenital cytomegalovirus infection. Intervirology 1999; 42:390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/24/28041/abstract/13\">",
"      Stagno S, Whitley RJ. Herpesvirus infections of pregnancy. Part I: Cytomegalovirus and Epstein-Barr virus infections. N Engl J Med 1985; 313:1270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/24/28041/abstract/14\">",
"      Rousseau T, Douvier S, Reynaud I, et al. Severe fetal cytomegalic inclusion disease after documented maternal reactivation of cytomegalovirus infection during pregnancy. Prenat Diagn 2000; 20:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/24/28041/abstract/15\">",
"      Boppana SB, Fowler KB, Britt WJ, et al. Symptomatic congenital cytomegalovirus infection in infants born to mothers with preexisting immunity to cytomegalovirus. Pediatrics 1999; 104:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/24/28041/abstract/16\">",
"      Gratacap-Cavallier B, Bosson JL, Morand P, et al. Cytomegalovirus seroprevalence in French pregnant women: parity and place of birth as major predictive factors. Eur J Epidemiol 1998; 14:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/24/28041/abstract/17\">",
"      Demmler GJ. Infectious Diseases Society of America and Centers for Disease Control. Summary of a workshop on surveillance for congenital cytomegalovirus disease. Rev Infect Dis 1991; 13:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/24/28041/abstract/18\">",
"      Stagno S, Pass RF, Cloud G, et al. Primary cytomegalovirus infection in pregnancy. Incidence, transmission to fetus, and clinical outcome. JAMA 1986; 256:1904.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/24/28041/abstract/19\">",
"      Griffiths PD, Baboonian C. A prospective study of primary cytomegalovirus infection during pregnancy: final report. Br J Obstet Gynaecol 1984; 91:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/24/28041/abstract/20\">",
"      Yow MD, Williamson DW, Leeds LJ, et al. Epidemiologic characteristics of cytomegalovirus infection in mothers and their infants. Am J Obstet Gynecol 1988; 158:1189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/24/28041/abstract/21\">",
"      Bod&eacute;us M, Hubinont C, Goubau P. Increased risk of cytomegalovirus transmission in utero during late gestation. Obstet Gynecol 1999; 93:658.",
"     </a>",
"    </li>",
"    <li>",
"     American Academy of Pediatrics. Cytomegalovirus infection. In: Red Book: 2012 Report of the Committee on Infectious Diseases, 29th, Pickering LK.  (Ed), American Academy of Pediatrics, Elk Grove Village, IL 2012. p.300.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/24/28041/abstract/23\">",
"      Raynor BD. Cytomegalovirus infection in pregnancy. Semin Perinatol 1993; 17:394.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/24/28041/abstract/24\">",
"      Casteels A, Naessens A, Gordts F, et al. Neonatal screening for congenital cytomegalovirus infections. J Perinat Med 1999; 27:116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/24/28041/abstract/25\">",
"      Stehel EK, Shoup AG, Owen KE, et al. Newborn hearing screening and detection of congenital cytomegalovirus infection. Pediatrics 2008; 121:970.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/24/28041/abstract/26\">",
"      Reynolds DW, Stagno S, Stubbs KG, et al. Inapparent congenital cytomegalovirus infection with elevated cord IgM levels. Casual relation with auditory and mental deficiency. N Engl J Med 1974; 290:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/24/28041/abstract/27\">",
"      Hanshaw JB, Scheiner AP, Moxley AW, et al. School failure and deafness after \"silent\" congenital cytomegalovirus infection. N Engl J Med 1976; 295:468.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/24/28041/abstract/28\">",
"      Melish ME, Hanshaw JB. Congenital cytomegalovirus infection. Developmental progress of infants detected by routine screening. Am J Dis Child 1973; 126:190.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/24/28041/abstract/29\">",
"      Peckham CS, Chin KS, Coleman JC, et al. Cytomegalovirus infection in pregnancy: preliminary findings from a prospective study. Lancet 1983; 1:1352.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/24/28041/abstract/30\">",
"      Stagno S, Reynolds DW, Amos CS, et al. Auditory and visual defects resulting from symptomatic and subclinical congenital cytomegaloviral and toxoplasma infections. Pediatrics 1977; 59:669.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/24/28041/abstract/31\">",
"      Saigal S, Lunyk O, Larke RP, Chernesky MA. The outcome in children with congenital cytomegalovirus infection. A longitudinal follow-up study. Am J Dis Child 1982; 136:896.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/24/28041/abstract/32\">",
"      Kumar ML, Nankervis GA, Jacobs IB, et al. Congenital and postnatally acquired cytomegalovirus infections: long-term follow-up. J Pediatr 1984; 104:674.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/24/28041/abstract/33\">",
"      Boppana SB, Fowler KB, Pass RF, et al. Congenital cytomegalovirus infection: association between virus burden in infancy and hearing loss. J Pediatr 2005; 146:817.",
"     </a>",
"    </li>",
"    <li>",
"     Britt W. Cytomegalovirus. In: Infectious Diseases of the Fetus and Newborn Infant, 7th ed, Remington JS, Klein JO, Wilson CB, et al (Eds), Elsevier Saunders, Philadelphia 2011. p.706.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/24/28041/abstract/35\">",
"      Guerra B, Lazzarotto T, Quarta S, et al. Prenatal diagnosis of symptomatic congenital cytomegalovirus infection. Am J Obstet Gynecol 2000; 183:476.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/24/28041/abstract/36\">",
"      Kylat RI, Kelly EN, Ford-Jones EL. Clinical findings and adverse outcome in neonates with symptomatic congenital cytomegalovirus (SCCMV) infection. Eur J Pediatr 2006; 165:773.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/24/28041/abstract/37\">",
"      Boppana SB, Pass RF, Britt WJ, et al. Symptomatic congenital cytomegalovirus infection: neonatal morbidity and mortality. Pediatr Infect Dis J 1992; 11:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/24/28041/abstract/38\">",
"      Istas AS, Demmler GJ, Dobbins JG, Stewart JA. Surveillance for congenital cytomegalovirus disease: a report from the National Congenital Cytomegalovirus Disease Registry. Clin Infect Dis 1995; 20:665.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/24/28041/abstract/39\">",
"      Steinlin MI, Nadal D, Eich GF, et al. Late intrauterine Cytomegalovirus infection: clinical and neuroimaging findings. Pediatr Neurol 1996; 15:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/24/28041/abstract/40\">",
"      Noyola DE, Demmler GJ, Nelson CT, et al. Early predictors of neurodevelopmental outcome in symptomatic congenital cytomegalovirus infection. J Pediatr 2001; 138:325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/24/28041/abstract/41\">",
"      Boppana SB, Fowler KB, Vaid Y, et al. Neuroradiographic findings in the newborn period and long-term outcome in children with symptomatic congenital cytomegalovirus infection. Pediatrics 1997; 99:409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/24/28041/abstract/42\">",
"      Williamson WD, Demmler GJ, Percy AK, Catlin FI. Progressive hearing loss in infants with asymptomatic congenital cytomegalovirus infection. Pediatrics 1992; 90:862.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/24/28041/abstract/43\">",
"      Fowler KB, McCollister FP, Dahle AJ, et al. Progressive and fluctuating sensorineural hearing loss in children with asymptomatic congenital cytomegalovirus infection. J Pediatr 1997; 130:624.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/24/28041/abstract/44\">",
"      Coats DK, Demmler GJ, Paysse EA, et al. Ophthalmologic findings in children with congenital cytomegalovirus infection. J AAPOS 2000; 4:110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/24/28041/abstract/45\">",
"      Nelson CT, Istas AS, Wilkerson MK, Demmler GJ. PCR detection of cytomegalovirus DNA in serum as a diagnostic test for congenital cytomegalovirus infection. J Clin Microbiol 1995; 33:3317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/24/28041/abstract/46\">",
"      Demmler GJ, Buffone GJ, Schimbor CM, May RA. Detection of cytomegalovirus in urine from newborns by using polymerase chain reaction DNA amplification. J Infect Dis 1988; 158:1177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/24/28041/abstract/47\">",
"      Bod&eacute;us M, Hubinont C, Bernard P, et al. Prenatal diagnosis of human cytomegalovirus by culture and polymerase chain reaction: 98 pregnancies leading to congenital infection. Prenat Diagn 1999; 19:314.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/24/28041/abstract/48\">",
"      Whitley RJ, Cloud G, Gruber W, et al. Ganciclovir treatment of symptomatic congenital cytomegalovirus infection: results of a phase II study. National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group. J Infect Dis 1997; 175:1080.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/24/28041/abstract/49\">",
"      Nigro G, Scholz H, Bartmann U. Ganciclovir therapy for symptomatic congenital cytomegalovirus infection in infants: a two-regimen experience. J Pediatr 1994; 124:318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/24/28041/abstract/50\">",
"      Kimberlin DW, Lin CY, S&aacute;nchez PJ, et al. Effect of ganciclovir therapy on hearing in symptomatic congenital cytomegalovirus disease involving the central nervous system: a randomized, controlled trial. J Pediatr 2003; 143:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/24/28041/abstract/51\">",
"      Prober CG, Enright AM. Congenital cytomegalovirus (CMV) infections: hats off to Alabama. J Pediatr 2003; 143:4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/24/28041/abstract/52\">",
"      Nigro G, La Torre R, Anceschi MM, et al. Hyperimmunoglobulin therapy for a twin fetus with cytomegalovirus infection and growth restriction. Am J Obstet Gynecol 1999; 180:1222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/24/28041/abstract/53\">",
"      Plotkin SA. Vaccination against cytomegalovirus. Arch Virol Suppl 2001; :121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/24/28041/abstract/54\">",
"      Reef SE, Plotkin S, Cordero JF, et al. Preparing for elimination of congenital Rubella syndrome (CRS): summary of a workshop on CRS elimination in the United States. Clin Infect Dis 2000; 31:85.",
"     </a>",
"    </li>",
"    <li>",
"     Cherry JD. Rubella virus. In: Textbook of Pediatric Infectious Diseases, 6th, Feigin RD, Cherry JD, Demmler-Harrison GJ, Kaplan SL (Eds), Saunders, Philadelphia 2009. p.2271.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/24/28041/abstract/56\">",
"      Nickerson JP, Richner B, Santy K, et al. Neuroimaging of pediatric intracranial infection--part 2: TORCH, viral, fungal, and parasitic infections. J Neuroimaging 2012; 22:e52.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6011 Version 12.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-122.72.76.133-192C8F5B95-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_24_28041=[""].join("\n");
var outline_f27_24_28041=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H40\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      SCREENING FOR TORCH INFECTIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H650131395\">",
"      CLINICAL FEATURES OF TORCH INFECTIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Congenital toxoplasmosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Congenital syphilis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Congenital rubella",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Congenital cytomegalovirus",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      - Epidemiology",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      - Transmission",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      - Clinical manifestations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      - Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H38\">",
"      - Treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H39\">",
"      Herpes simplex virus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H626749151\">",
"      Congenital varicella syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H609355024\">",
"      APPROACH TO THE INFANT WITH SUSPECTED INTRAUTERINE INFECTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H609355080\">",
"      Overview",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H609355087\">",
"      Clinical suspicion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H609355103\">",
"      Initial evaluation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H609355188\">",
"      Specific evaluation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H40\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/6011\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6011|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?31/3/31806\" title=\"diagnostic image 1\">",
"      Congenital toxoplasmosis intracranial calcifications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?29/12/29902\" title=\"diagnostic image 2\">",
"      Congenital CMV cranial CT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6011|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?2/28/2498\" title=\"picture 1\">",
"      Congenital toxoplasmosis generalized manifestations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?40/39/41590\" title=\"picture 2\">",
"      Congenital toxoplasmosis chorioretinitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6011|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?32/26/33196\" title=\"table 1\">",
"      Characteristic features of congenital infections",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?10/17/10526\" title=\"table 2\">",
"      Clinical manifestations of early congenital syphilis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?35/25/36251\" title=\"table 3\">",
"      Stigmata of late congenital syphilis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?14/10/14508\" title=\"table 4\">",
"      Sequelae of congenital CMV",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/49/34585?source=related_link\">",
"      Clinical manifestations and diagnosis of enterovirus and parechovirus infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/54/22377?source=related_link\">",
"      Clinical manifestations and pathogenesis of human parvovirus B19 infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/49/10010?source=related_link\">",
"      Congenital rubella syndrome: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/63/36855?source=related_link\">",
"      Congenital rubella syndrome: Management, outcome, and prevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/31/17914?source=related_link\">",
"      Congenital syphilis: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/11/37049?source=related_link\">",
"      Congenital syphilis: Evaluation, management, and prevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/12/43208?source=related_link\">",
"      Congenital toxoplasmosis: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/31/7672?source=related_link\">",
"      Congenital toxoplasmosis: Treatment, outcome, and prevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/51/36664?source=related_link\">",
"      Cytomegalovirus infection and disease in newborns, infants, children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/21/12634?source=related_link\">",
"      Cytomegalovirus infection in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/25/8597?source=related_link\">",
"      Diagnosis of cytomegalovirus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/38/19050?source=related_link\">",
"      Etiology of hearing impairment in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/8/34951?source=related_link\">",
"      Evaluation and management of strabismus in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/19/44344?source=related_link\">",
"      Evaluation of hearing impairment in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/14/33001?source=related_link\">",
"      Genital herpes simplex virus infection and pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/1/42010?source=related_link\">",
"      Initial prenatal assessment and patient education",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/31/35321?source=related_link\">",
"      Neonatal herpes simplex virus infection: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/48/40713?source=related_link\">",
"      Neonatal herpes simplex virus infection: Management and prevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/29/40408?source=related_link\">",
"      Parvovirus B19 infection during pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?42/52/43843?source=related_link\">",
"      Patient information: Avoiding infections in pregnancy (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?32/39/33395?source=related_link\">",
"      Patient information: Avoiding infections in pregnancy (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/60/6087?source=related_link\">",
"      Rubella in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/61/4057?source=related_link\">",
"      Syphilis in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/39/22137?source=related_link\">",
"      Toxoplasmosis and pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/11/4278?source=related_link\">",
"      Varicella-zoster infection in the newborn",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/28/33225?source=related_link\">",
"      Varicella-zoster virus infection in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/59/24505?source=related_link\">",
"      Visual development and vision assessment in infants and children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f27_24_28042="Bone metabolism and renal osteodystrophy in children with chronic kidney disease";
var content_f27_24_28042=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Bone metabolism and renal osteodystrophy in children with chronic kidney disease",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/24/28042/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/24/28042/contributors\">",
"     Tarak Srivastava, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/24/28042/contributors\">",
"     Bradley A Warady, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/24/28042/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/24/28042/contributors\">",
"     Tej K Mattoo, MD, DCH, FRCP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/24/28042/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/24/28042/contributors\">",
"     Melanie S Kim, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?27/24/28042/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 14, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Abnormalities in mineral metabolism and bone structure are an almost universal finding with progressive chronic kidney disease (CKD) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/24/28042/abstract/1\">",
"     1",
"    </a>",
"    ]. The Kidney Disease: Improving Global Outcomes (KDIGO) initiative has proposed the term CKD- mineral and bone disorder (CKD-MBD) to be used to describe the broad clinical syndrome that develops as a systemic disorder as a result of the abnormalities of mineral and bone metabolism that occur in association with CKD; the term renal osteodystrophy, the topic of this review, is to be used exclusively to define alterations in bone morphology associated with CKD [",
"    <a class=\"abstract\" href=\"UTD.htm?27/24/28042/abstract/2\">",
"     2",
"    </a>",
"    ]. The changes that occur in the homeostatic mechanisms that regulate serum concentrations of calcium, phosphate, vitamin D, and parathyroid hormone (PTH) lead to the development of renal osteodystrophy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/36/2631?source=see_link\">",
"     \"Chapter 6F: Hormonal regulation of calcium and phosphate balance\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/56/36744?source=see_link\">",
"     \"Parathyroid hormone secretion and action\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In children with CKD, renal osteodystrophy results in significant complications. Many are similar to those seen in adults with CKD (eg, fractures, bone pain, and avascular necrosis) but others are unique to children (eg, growth failure and skeletal deformities).",
"   </p>",
"   <p>",
"    The prevention and management of renal osteodystrophy in children will be reviewed here. The pathogenesis of renal osteodystrophy is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/50/18218?source=see_link\">",
"     \"Pathogenesis of renal osteodystrophy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This review and its recommendations are consistent with the Kidney Disease Outcome Quality Initiative (KDOQI) clinical practice guidelines for bone metabolism and disease in children with CKD [",
"    <a class=\"abstract\" href=\"UTD.htm?27/24/28042/abstract/1\">",
"     1",
"    </a>",
"    ]. The KDOQI clinical practice guidelines for bone metabolism and disease in children with CKD, as well as other KDOQI guidelines, can be accessed through the National Kidney Foundation's web site at",
"    <a class=\"external\" href=\"file://www.kidney.org/professionals/kdoqi/guidelines.cfm\">",
"     www.kidney.org/professionals/kdoqi/guidelines.cfm",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     STAGES OF CHRONIC KIDNEY DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many of the complications of CKD (including renal osteodystrophy) can be prevented or delayed through early detection and treatment. This observation has led to the development of a staging system by the KDOQI working group that is based upon the estimated glomerular filtration rate and is independent of the primary renal diagnosis. This staging system is used to help guide management of metabolic abnormalities in children with CKD (",
"    <a class=\"graphic graphic_table graphicRef80596 \" href=\"UTD.htm?22/4/22603\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?27/24/28042/abstract/3\">",
"     3",
"    </a>",
"    ]. The CKD staging in children applies only to children greater than two years of age. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/18/26919?source=see_link\">",
"     \"Epidemiology, etiology, and course of chronic kidney disease in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Stage 1 &ndash; Normal glomerular filtration rate (GFR) &ge;90",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      per 1.73 m2",
"     </li>",
"     <li>",
"      Stage 2 &ndash; GFR between 60 to 89",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      per 1.73 m2",
"     </li>",
"     <li>",
"      Stage 3 &ndash; GFR between 30 and 59",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      per 1.73 m2",
"     </li>",
"     <li>",
"      Stage 4 &ndash; GFR between 15 and 29",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      per 1.73 m2",
"     </li>",
"     <li>",
"      Stage 5 &ndash; GFR of &lt;15",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      per 1.73 m2 or requires dialysis treatment",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Children with CKD stage 2 usually have no signs or symptoms of bone abnormalities. However, these children may have evidence of abnormalities on laboratory testing (eg, decreased serum calcitriol [1,25 dihydroxyvitamin D] and elevated serum parathyroid hormone [PTH]) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/24/28042/abstract/4\">",
"     4",
"    </a>",
"    ]. This period should be used to educate the child and family about CKD and its impact on bone metabolism. This discussion should highlight the need for laboratory monitoring and future interventions that will prevent and treat renal osteodystrophy.",
"   </p>",
"   <p>",
"    Subtle signs of renal osteodystrophy begin to be observed when the GFR decreases to 50 percent of normal (stage 3 disease). These children should be monitored for evidence of bone disease by physical examination and laboratory evaluation. Physical findings include muscle pain, weakness, and bony changes such as varus and valgus deformities of the long bones. Laboratory abnormalities of bone metabolism (eg, elevated PTH) are common in stage 3 disease and require therapeutic interventions. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Management'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     TYPES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Renal osteodystrophy consists of several different forms based on bone biopsy that include osteitis fibrosa cystica, adynamic bone disease, mixed osteodystrophy and osteomalacia. The severity of bone disease rises with increasing progression of CKD [",
"    <a class=\"abstract\" href=\"UTD.htm?27/24/28042/abstract/5,6\">",
"     5,6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pre-dialysis &ndash; In a case series of 52 children with pre-dialysis CKD, bone biopsy demonstrated increased bone turnover in 0, 13, and 29 percent, and defective mineralization in 29, 42, and 79 percent in children with CKD stage 2, 3, and",
"      <span class=\"nowrap\">",
"       4/5,",
"      </span>",
"      respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?27/24/28042/abstract/7\">",
"       7",
"      </a>",
"      ]. In children with CKD stages 3 to 4, osteitis fibrosa cystica appears to be the most common form of renal osteodystrophy as illustrated in a small study of 11 children at the start of dialysis [",
"      <a class=\"abstract\" href=\"UTD.htm?27/24/28042/abstract/6\">",
"       6",
"      </a>",
"      ]. Bone biopsy demonstrated a high bone turnover state in six patients, mixed osteodystrophy in three, and a low bone turnover state in two.",
"     </li>",
"     <li>",
"      Dialysis &ndash; In 51 children undergoing dialysis, abnormal bone histology was noted in two-thirds of the patients [",
"      <a class=\"abstract\" href=\"UTD.htm?27/24/28042/abstract/5\">",
"       5",
"      </a>",
"      ]. Histologic findings included adynamic bone disease, osteitis fibrosa cystica, mixed osteodystrophy, and osteomalacia in 27, 24, 10, and 2 percent of the cohort, respectively. There appears to be a slow shift over the years from a predominance of high bone turnover disease (ie, osteitis fibrosa cystica) to the more frequent development of low bone turnover states (ie, adynamic bone disease) in children on dialysis [",
"      <a class=\"abstract\" href=\"UTD.htm?27/24/28042/abstract/8\">",
"       8",
"      </a>",
"      ]. Unlike adults, bone density studies in children with CKD who are also on dialysis have shown acceptable bone mineral content [",
"      <a class=\"abstract\" href=\"UTD.htm?27/24/28042/abstract/9,10\">",
"       9,10",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The following is a brief review of the different forms of renal osteodystrophy. A more complete description of their pathogenesis is found separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/50/18218?source=see_link\">",
"     \"Pathogenesis of renal osteodystrophy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Osteitis fibrosa cystica",
"    </span>",
"    &nbsp;&mdash;&nbsp;Osteitis fibrosa cystica results from secondary hyperparathyroidism. Bone biopsies of affected patients demonstrate increased bone turnover activity and defective mineralization compared to normal bone (",
"    <a class=\"graphic graphic_picture graphicRef66330 \" href=\"UTD.htm?28/13/28883\">",
"     picture 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef63957 \" href=\"UTD.htm?31/5/31832\">",
"     picture 2",
"    </a>",
"    ). The aim of therapy is to prevent secondary hyperparathyroidism, thus preventing osteitis fibrosa cystica. (See",
"    <a class=\"local\" href=\"#H21\">",
"     'Parathyroid hormone'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/50/18218?source=see_link&amp;anchor=H3#H3\">",
"     \"Pathogenesis of renal osteodystrophy\", section on 'Secondary hyperparathyroidism and osteitis fibrosa'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Adynamic bone disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adynamic bone disease is characterized by low osteoblastic activity and bone formation rates (",
"    <a class=\"graphic graphic_picture graphicRef75592 \" href=\"UTD.htm?30/56/31623\">",
"     picture 3",
"    </a>",
"    ). It represents the major bone lesion seen in children who require dialysis therapy and is related to excessive suppression of the parathyroid gland (due to the administration of calcium-containing phosphate binders and vitamin D analogues) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/24/28042/abstract/5\">",
"     5",
"    </a>",
"    ]. These patients typically have a low serum intact PTH concentration (eg, &lt;100",
"    <span class=\"nowrap\">",
"     pg/mL),",
"    </span>",
"    which is frequently accompanied by an elevated serum calcium. As noted previously, adynamic bone disease is uncommon among predialysis patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/50/18218?source=see_link&amp;anchor=H13#H13\">",
"     \"Pathogenesis of renal osteodystrophy\", section on 'Adynamic bone disease'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In the past, adynamic bone disease also resulted from aluminum toxicity due to the administration of aluminum-containing phosphate binders. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/14/5352?source=see_link\">",
"     \"Aluminum toxicity in end-stage renal disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Adynamic bone disease increases the risk for fractures and metastatic calcification. This is best treated by decreasing or discontinuing the dose of the calcium-based phosphate binders",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    vitamin D therapy, which causes the intact PTH level to rise, thereby increasing bone turnover. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/50/18218?source=see_link&amp;anchor=H13#H13\">",
"     \"Pathogenesis of renal osteodystrophy\", section on 'Adynamic bone disease'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Osteomalacia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Osteomalacia is a low turnover bone lesion that is characterized by an increased volume of unmineralized bone (osteoid) (",
"    <a class=\"graphic graphic_picture graphicRef61773 \" href=\"UTD.htm?0/32/520\">",
"     picture 4",
"    </a>",
"    ). The reduction in bone turnover is the result of a decreased number of bone-forming and bone-resorbing cells, and causes an increase in the volume of unmineralized bone. In the past, this disorder resulted from aluminum toxicity due to the administration of aluminum-containing phosphate binders, which are no longer recommended. Osteomalacia is now much less common [",
"    <a class=\"abstract\" href=\"UTD.htm?27/24/28042/abstract/5\">",
"     5",
"    </a>",
"    ] and, when it occurs, is thought to reflect vitamin D deficiency. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/50/18218?source=see_link&amp;anchor=H16#H16\">",
"     \"Pathogenesis of renal osteodystrophy\", section on 'Osteomalacia'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Mixed osteodystrophy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bone lesions in patients with mixed osteodystrophy include elements of both high and low bone turnover (",
"    <a class=\"graphic graphic_picture graphicRef52703 \" href=\"UTD.htm?19/57/20376\">",
"     picture 5",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Other factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other factors that may impact on renal osteodystrophy in children include corticosteroid therapy, metabolic acidosis, hypophosphatemia (due to excessive dietary phosphate restriction or use of phosphate binders), nutritional vitamin D deficiency, medications that interfere with vitamin D metabolism (eg, anticonvulsants), and prolonged immobilization. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/21/9562?source=see_link\">",
"     \"Drugs that affect bone metabolism\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/21/26967?source=see_link\">",
"     \"Overview of rickets in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bone biopsy is the gold standard for establishing the type of renal osteodystrophy. In most clinical settings, it is not necessary to identify the specific form of renal osteodystrophy, but rather determine if bone turnover activity is high or low. In children with CKD stage 5, a combination of serum PTH and calcium test results can usually distinguish between high (eg, osteitis fibrosa cystica) and low (eg, adynamic bone disease) turnover bone disease [",
"    <a class=\"abstract\" href=\"UTD.htm?27/24/28042/abstract/11,12\">",
"     11,12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one study of children on chronic peritoneal dialysis, a serum PTH level &gt;200",
"      <span class=\"nowrap\">",
"       pg/mL",
"      </span>",
"      and a serum calcium value &lt;10",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (2.5",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"      identified patients with high turnover bone disease from secondary hyperparathyroidism with 85 percent sensitivity and 100 percent specificity [",
"      <a class=\"abstract\" href=\"UTD.htm?27/24/28042/abstract/11\">",
"       11",
"      </a>",
"      ]. Serum PTH concentrations &lt;200",
"      <span class=\"nowrap\">",
"       pg/mL",
"      </span>",
"      and serum calcium value &gt;10",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (2.5",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"      were 100 percent sensitive but only 79 percent specific for identifying patients with adynamic bone lesions.",
"     </li>",
"     <li>",
"      In another study of children on hemodialysis, all patients with a serum PTH concentration &gt;125",
"      <span class=\"nowrap\">",
"       pg/ml",
"      </span>",
"      and a serum calcium value &lt;10",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (2.5",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"      had either osteitis fibrosa or mixed osteodystrophy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Indications for bone biopsy are not well established because clinical situations have not been clearly identified for which having the histological diagnosis of bone disease is helpful. The KDOQI guidelines suggest that performance of a bone biopsy should be considered to determine the type of renal osteodystrophy and guide therapy in children with stage 5 disease in whom there are nontraumatic bone fractures, suspected aluminum exposure, or persistent hypercalcemia with a serum intact PTH between 400 and 600",
"    <span class=\"nowrap\">",
"     pg/ml",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?27/24/28042/abstract/1\">",
"     1",
"    </a>",
"    ]. The Kidney Disease Improving Global Outcomes (KDIGO) guidelines recommend bone biopsy in the setting of persistent bone pain, unexplained hypophosphatemia, and prior to initiating bisphosphonate therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?27/24/28042/abstract/13\">",
"     13",
"    </a>",
"    ]. The site of biopsy is typically the iliac crest. The specimen is obtained after the administration of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?27/38/28262?source=see_link\">",
"     tetracycline",
"    </a>",
"    markers, which are used to determine the rate of new bone formation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/43/28343?source=see_link\">",
"     \"Bone biopsy and the diagnosis of renal osteodystrophy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In children with CKD stage 3 to 4, the most likely form of renal osteodystrophy is osteitis fibrosa cystica and a bone biopsy is not routinely needed. In these patients, an elevated serum PTH concentration is indicative of increased bone turnover disease. Although the optimal targets for serum PTH remain controversial, the KDOQI working group has established target serum PTH values at different stages of CKD [",
"    <a class=\"abstract\" href=\"UTD.htm?27/24/28042/abstract/14\">",
"     14",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H21\">",
"     'Parathyroid hormone'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The goals of therapy are to prevent phosphate retention, hypovitaminosis D, and hypocalcemia. Management is focused on early detection and correction of these abnormalities because each contributes to the development of secondary hyperparathyroidism, which causes renal osteodystrophy.",
"   </p>",
"   <p>",
"    The following discussion will review the management of bone metabolism in children with CKD and is consistent with the 2005 KDOQI guidelines on bone metabolism and disease in children with chronic kidney disease. The KDOQI clinical practice guidelines for bone metabolism and disease in children with CKD, as well as other KDOQI guidelines, can be accessed through the National Kidney Foundation's web site at",
"    <a class=\"external\" href=\"file://www.kidney.org/professionals/kdoqi/guidelines.cfm\">",
"     www.kidney.org/professionals/kdoqi/guidelines.cfm",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;Serum concentrations of calcium, phosphate, and PTH should be measured on an ongoing basis in all children with CKD, even those with mild disease who often have laboratory evidence of abnormalities in bone metabolism. In a study in adults, for example, a reduction in the glomerular filtration rate (GFR) below 80",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73 m2 was associated with a reduction in the serum calcitriol level and a progressive increase in serum PTH [",
"    <a class=\"abstract\" href=\"UTD.htm?27/24/28042/abstract/4\">",
"     4",
"    </a>",
"    ]. As the GFR fell below 60",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73 m2, serum PTH rose above normal values.",
"   </p>",
"   <p>",
"    Early detection of bone metabolic abnormalities ensures that therapeutic interventions can be initiated, thereby preventing or minimizing renal osteodystrophy. Recommendations for the frequency of these measurements are based upon the stage of CKD.",
"   </p>",
"   <p>",
"    For calcium and phosphorus measurements, the KDOQI guidelines recommend [",
"    <a class=\"abstract\" href=\"UTD.htm?27/24/28042/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Stage 2 disease &ndash; Measurements at least yearly",
"     </li>",
"     <li>",
"      Stage 3 disease &ndash; Measurements at least every six months",
"     </li>",
"     <li>",
"      Stage 4 disease &ndash; Measurements at least every three months",
"     </li>",
"     <li>",
"      Stage 5 disease &ndash; Measurements at least monthly",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For PTH and alkaline phosphatase measurements, the KDOQI guidelines recommend:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Stage 2 disease &ndash; Measurements at least yearly.",
"     </li>",
"     <li>",
"      Stage 3 disease &ndash; Measurements at least every six months",
"     </li>",
"     <li>",
"      Stage 4 and 5 disease &ndash; Measurements at least every three months",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The KDOQI monitoring guidelines are similar to the guidelines proposed by the European Pediatric Dialysis Working Group (EPDWG), except that the EPDWG recommends monthly monitoring of PTH and alkaline phosphatase in Stage 5 disease [",
"    <a class=\"abstract\" href=\"UTD.htm?27/24/28042/abstract/15\">",
"     15",
"    </a>",
"    ]. If therapy is initiated to correct serum abnormalities or to treat renal osteodystrophy, the KDIGO guidelines recommend that laboratory evaluation should be performed more frequently to ensure a response to therapy or to identify the need to adjust therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?27/24/28042/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Phosphate",
"    </span>",
"    &nbsp;&mdash;&nbsp;Phosphate is a salt of oxidized phosphoric acid and is a key component of bone matrix.",
"   </p>",
"   <p>",
"    Normally, the serum phosphorus concentration is highest in infants less than three months of age. As the child ages, the normal range of phosphorus values decreases.",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      0 to 3 months of age &ndash; 4.8 to 7.4",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (1.55 to 2.39",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"     </li>",
"     <li>",
"      1 to 5 years of age &ndash; 4.5 to 6.5",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (1.45 to 2.1",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"     </li>",
"     <li>",
"      6 to 12 years of age &ndash; 3.6 to 5.8",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (1.16 to 1.87",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"     </li>",
"     <li>",
"      13 to 20 years of age &ndash; 2.3 to 4.5",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (0.74 to 1.45",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Phosphorus retention begins in the early stages of CKD and plays a central role in the development of hyperparathyroidism (",
"    <a class=\"graphic graphic_figure graphicRef68602 \" href=\"UTD.htm?28/43/29373\">",
"     figure 1",
"    </a>",
"    ). This is first mediated by a reduced production of calcitriol in the kidney, thereby removing part of the inhibitory effect of calcitriol on PTH release. The ensuing hyperparathyroidism appropriately increases urinary phosphate excretion. This adaptation is not complete, as small increments in serum phosphorus persist. In more advanced CKD, this adaptation becomes less successful, and the ensuing hyperphosphatemia promotes increasing hyperparathyroidism both by inhibition of calcitriol production and by a direct effect on the parathyroid glands. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/57/33690?source=see_link&amp;anchor=H1#H1\">",
"     \"Treatment of hyperphosphatemia in chronic kidney disease\", section on 'Background'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/50/18218?source=see_link&amp;anchor=H5#H5\">",
"     \"Pathogenesis of renal osteodystrophy\", section on 'Phosphate retention and hyperphosphatemia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The clinical correlate of these pathophysiologic changes is that a child with CKD in late stage 2 and in stage 3 disease has an elevated serum PTH but serum phosphorus level that, although increased, remains within the normal range. When the GFR falls below 30",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73 m2 (stage 4 disease), hyperphosphatemia will usually occur unless appropriate therapy is given.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Goals",
"    </span>",
"    &nbsp;&mdash;&nbsp;In children, the KDOQI practice guidelines recommend the following targeted goals for serum phosphate concentrations at different stages of CKD&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?27/24/28042/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Stages 1 to 4 (GFR between 15 and 89",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      per 1.73 m2) &ndash; The serum phosphorus should be maintained at or above the age-appropriate lower limit but no higher than the age-appropriate upper limit presented previously.",
"     </li>",
"     <li>",
"      Stage 5 (GFR &lt;15",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      per 1.73 m2 or dialysis requirement) &ndash; The serum phosphorus should be maintained between 4 to 6",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (1.29 to 1.93",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"      in children 1 to 12 years of age and between 3.5 to 5.5",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (1.13 to 1.78",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"      in adolescents.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Interventions",
"    </span>",
"    &nbsp;&mdash;&nbsp;In children with CKD, two therapeutic interventions to attain and maintain the targeted serum phosphorus concentration include restriction of dietary phosphorus and the use of calcium-based phosphate binders.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H39327940\">",
"    <span class=\"h4\">",
"     Diet",
"    </span>",
"    &nbsp;&mdash;&nbsp;In controlled studies of both children and adults, dietary phosphorus restriction results in decreased serum PTH and increased serum 1,25-dihydroxyvitamin D (calcitriol) concentrations (",
"    <a class=\"graphic graphic_figure graphicRef68602 \" href=\"UTD.htm?28/43/29373\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/24/28042/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. Conversely, an intake of phosphorus that is twice the Dietary Reference Intake (DRI) in children with CKD stage 3 increases serum PTH and decreases serum 1,25-dihydroxyvitamin D [",
"    <a class=\"abstract\" href=\"UTD.htm?27/24/28042/abstract/16\">",
"     16",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/57/33690?source=see_link\">",
"     \"Treatment of hyperphosphatemia in chronic kidney disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As a result of these studies, the 2008 KDOQI pediatric nutrition practice guidelines recommend restricting dietary phosphorus in children with CKD stages 3 to 5 who have an elevated serum PTH level and a normal serum phosphate concentration to 100 percent of the DRI for age [",
"    <a class=\"abstract\" href=\"UTD.htm?27/24/28042/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      0 to 0.5 years &ndash; 100",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"     </li>",
"     <li>",
"      0.5 to 1 year &ndash; 275",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"     </li>",
"     <li>",
"      1 to 3 years &ndash; 460",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"     </li>",
"     <li>",
"      4 to 8 years &ndash; 500",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"     </li>",
"     <li>",
"      9 to 19 years &ndash; 1250",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Dietary phosphorus should be restricted to 80 percent DRI if the serum PTH is above the target range and the serum phosphate concentration is above the age-appropriate normal range&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?27/24/28042/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      0 to 0.5 years &ndash; 80",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"     </li>",
"     <li>",
"      0.5 to 1 year &ndash; 220",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"     </li>",
"     <li>",
"      1 to 3 years &ndash; 368",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"     </li>",
"     <li>",
"      4 to 8 years &ndash; 400",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"     </li>",
"     <li>",
"      9 to 19 years &ndash; 1000",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    After the initiation of dietary restriction, serum phosphorus should be monitored at least every three months in children with CKD stages 3 and 4, and monthly in those with CKD stage 5.",
"   </p>",
"   <p>",
"    Studies in children with CKD report no association of dietary phosphorus restriction with poor linear growth [",
"    <a class=\"abstract\" href=\"UTD.htm?27/24/28042/abstract/19-22\">",
"     19-22",
"    </a>",
"    ]. However, serum phosphorus concentrations below the target range for age should be avoided because of the potential adverse effects of hypophosphatemia on linear growth.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H39327947\">",
"    <span class=\"h4\">",
"     Phosphate binders",
"    </span>",
"    &nbsp;&mdash;&nbsp;Compliance with dietary phosphate restriction in children is poor, as most of their favorite foods are rich in phosphate. Thus, despite attempts to restrict phosphorus intake, phosphate binders often become necessary to prevent phosphate absorption from the gastrointestinal tract.",
"   </p>",
"   <p>",
"    In children, several observational studies have shown that calcium-based phosphate binders are effective and safe in lowering serum phosphate and PTH levels [",
"    <a class=\"abstract\" href=\"UTD.htm?27/24/28042/abstract/23-25\">",
"     23-25",
"    </a>",
"    ]. These agents are recommended as the initial phosphate binder in children with CKD because other agents have significant side effects (such as aluminum [",
"    <a class=\"abstract\" href=\"UTD.htm?27/24/28042/abstract/26\">",
"     26",
"    </a>",
"    ]) or have not been adequately studied in children (such as",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?23/8/23684?source=see_link\">",
"     sevelamer",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/24/28042/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Phosphate binders should be taken 10 to 15 minutes before or during the meal. The effect is less when taken between meals, since most dietary phosphorus has already been absorbed.",
"   </p>",
"   <p>",
"    Phosphate binders, regardless of the agent used, have a limited phosphate-binding capacity. As examples, 1 g of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?17/38/18024?source=see_link\">",
"     calcium carbonate",
"    </a>",
"    binds 39 mg of phosphate, 1 g of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?20/51/21301?source=see_link\">",
"     calcium acetate",
"    </a>",
"    binds 45 mg of phosphate, and 400 mg of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?23/8/23684?source=see_link\">",
"     sevelamer",
"    </a>",
"    HCl binds 32 mg of phosphate. Thus, phosphate-binding compounds will be effective in lowering serum phosphate levels only if dietary phosphate restriction is continued.",
"   </p>",
"   <p>",
"    The choice among the many different calcium-containing phosphate binders, such as",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?17/38/18024?source=see_link\">",
"     calcium carbonate",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?20/51/21301?source=see_link\">",
"     calcium acetate",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?40/13/41175?source=see_link\">",
"     calcium gluconate",
"    </a>",
"    , and calcium ketoglutarate, is in large part dependent upon the patient's tolerance of the binder and the choice of the clinician. Several studies in adults have not shown an overall advantage of one preparation over another [",
"    <a class=\"abstract\" href=\"UTD.htm?27/24/28042/abstract/1\">",
"     1",
"    </a>",
"    ]. The total dose of elemental calcium should not exceed twice the DRI for calcium based on age with a maximum of 2500",
"    <span class=\"nowrap\">",
"     mg/day,",
"    </span>",
"    including the dietary calcium intake. An exception is",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?29/2/29733?source=see_link\">",
"     calcium citrate",
"    </a>",
"    , which should",
"    <strong>",
"     not",
"    </strong>",
"    be administered, since it markedly increases intestinal aluminum absorption. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/57/33690?source=see_link&amp;anchor=H8#H8\">",
"     \"Treatment of hyperphosphatemia in chronic kidney disease\", section on 'Phosphate binders'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In contrast to this general recommendation, calcium-based phosphate binders should not be used as the sole agent in patients who are hypercalcemic (serum calcium &gt;10.2",
"    <span class=\"nowrap\">",
"     mg/dL,",
"    </span>",
"    [2.55",
"    <span class=\"nowrap\">",
"     mmol/L]).",
"    </span>",
"    The preferred drug in this setting is",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?23/8/23684?source=see_link\">",
"     sevelamer",
"    </a>",
"    (Renagel&reg;), a noncalcium and nonaluminum phosphate binder [",
"    <a class=\"abstract\" href=\"UTD.htm?27/24/28042/abstract/27\">",
"     27",
"    </a>",
"    ]. It may be used alone or in conjunction with a calcium-containing phosphate binder. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/57/33690?source=see_link&amp;anchor=H8#H8\">",
"     \"Treatment of hyperphosphatemia in chronic kidney disease\", section on 'Phosphate binders'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    With the concern that calcium-containing phosphate binders may contribute to soft tissue calcification, noncalcium and nonaluminum phosphate binders, such as",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?23/8/23684?source=see_link\">",
"     sevelamer",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/37/28244?source=see_link\">",
"     lanthanum carbonate",
"    </a>",
"    , are used more frequently as initial therapy in adults. Data on these agents are limited in children. In children, an eight week randomized, open-labeled crossover study demonstrated that sevelamer was as effective as",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?20/51/21301?source=see_link\">",
"     calcium acetate",
"    </a>",
"    in reducing serum phosphorus [",
"    <a class=\"abstract\" href=\"UTD.htm?27/24/28042/abstract/9\">",
"     9",
"    </a>",
"    ]. Sevelamer was associated with a reduction in cholesterol, low-density lipoprotein cholesterol and the frequency of hypercalcemic episodes, but an increase in the frequency of metabolic acidosis. Sevelamer carbonate (Renvela&reg;) was subsequently found to be as effective as a phosphate binder compared to sevelamer HCL in 24 pediatric dialysis patients [",
"    <a class=\"abstract\" href=\"UTD.htm?27/24/28042/abstract/10\">",
"     10",
"    </a>",
"    ]. Sevelamer carbonate was also associated with an improvement in serum bicarbonate levels, such that",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?40/56/41862?source=see_link\">",
"     sodium bicarbonate",
"    </a>",
"    therapy could be discontinued. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/57/33690?source=see_link&amp;anchor=H11#H11\">",
"     \"Treatment of hyperphosphatemia in chronic kidney disease\", section on 'Sevelamer'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/57/33690?source=see_link&amp;anchor=H12#H12\">",
"     \"Treatment of hyperphosphatemia in chronic kidney disease\", section on 'Lanthanum'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The following phosphate binders should be",
"    <strong>",
"     avoided",
"    </strong>",
"    in children with CKD:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?20/36/21062?source=see_link\">",
"       Aluminum hydroxide",
"      </a>",
"      because of aluminum bone toxicity [",
"      <a class=\"abstract\" href=\"UTD.htm?27/24/28042/abstract/26\">",
"       26",
"      </a>",
"      ]. Aluminum deposition can cause low bone turnover, leading to renal osteodystrophy (eg, adynamic bone disease and osteomalacia). Aluminum usage can also be associated with neurocognitive and hematologic complications. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Types'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/14/5352?source=see_link\">",
"       \"Aluminum toxicity in end-stage renal disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Magnesium-containing antacids (such as",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?28/59/29622?source=see_link\">",
"       magnesium hydroxide",
"      </a>",
"      ) because of the risk of hypermagnesemia and the frequent development of diarrhea.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?29/2/29733?source=see_link\">",
"       Calcium citrate",
"      </a>",
"      , because it markedly increases the absorption of dietary aluminum.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H39327954\">",
"    <span class=\"h3\">",
"     Potential role for FGF23",
"    </span>",
"    &nbsp;&mdash;&nbsp;Serum FGF23 is emerging as a potential treatment target for management of CKD-MBD. FGF23 is a member of the fibroblast growth factor family and is important in phosphate regulation in the body. It inhibits the renal reabsorption of phosphate and 1-hydroxylase activity in the proximal tubule of the kidney, which results in a decrease in the 1-hydroxylaxation of 25-hydroxyvitamin D (calcidiol). In children, FGF23 increases as CKD progresses from stage 1 to 5. The rise in serum FGF23 levels precedes the development of significant hyperphosphatemia. In addition, it is elevated in patients with significant bone abnormalities regardless of the severity of the CKD [",
"    <a class=\"abstract\" href=\"UTD.htm?27/24/28042/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Case series of children with CKD have shown that serum FGF23 levels is independently associated with hyperphosphatemia, low estimated glomerular filtration rate and body mass index [",
"    <a class=\"abstract\" href=\"UTD.htm?27/24/28042/abstract/28,29\">",
"     28,29",
"    </a>",
"    ]. Although data indicate the potential role of FGF23 in the evaluation of bone metabolism as a potential treatment target for CKD-MBD, no consensus has been reached for either routine testing or a target level of FGF23 for both adults and children with CKD [",
"    <a class=\"abstract\" href=\"UTD.htm?27/24/28042/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Vitamin D",
"    </span>",
"    &nbsp;&mdash;&nbsp;In children with CKD, the homeostatic mechanisms that maintain normal serum calcium, phosphorous, and 1,25-dihydroxyvitamin D (calcitriol) concentrations are disrupted. In the early stages of CKD, impaired production of 1,25 dihydroxyvitamin D is partly due to phosphate retention. In the later stages of CKD, decreased synthesis may be due to loss of the renal enzyme required for the final step of 1-hydroxylation of 25-hydroxyvitamin D (calcidiol),",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    inhibition of production and increased degradation of 1,25 dihydroxyvitamin D by fibroblast growth factor 23 (FGF23) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/24/28042/abstract/31\">",
"     31",
"    </a>",
"    ]. In patients with CKD, low serum 25-dihydroxyvitamin D concentrations also contribute to low serum values of 1,25 dihydroxyvitamin D.",
"   </p>",
"   <p>",
"    Phosphate retention and 1,25 dihydroxyvitamin D deficiency decrease serum calcium and, as noted above, contribute directly to secondary hyperparathyroidism and renal osteodystrophy. As demonstrated by a systematic review of the literature, vitamin D therapy improves bone disease as measured by parathyroid hormone levels, regardless of formulation or route of administration [",
"    <a class=\"abstract\" href=\"UTD.htm?27/24/28042/abstract/25\">",
"     25",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/50/18218?source=see_link\">",
"     \"Pathogenesis of renal osteodystrophy\"",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H21\">",
"     'Parathyroid hormone'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The KDOQI practice guidelines recommend [",
"    <a class=\"abstract\" href=\"UTD.htm?27/24/28042/abstract/1,18\">",
"     1,18",
"    </a>",
"    ] that in children with CKD stages 2 to 4 (GFR of 15 to 89",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73 m2) and serum PTH values above the target range for the stage of CKD, serum 25-hydroxyvitamin D concentrations should be measured yearly [",
"    <a class=\"abstract\" href=\"UTD.htm?27/24/28042/abstract/1,18\">",
"     1,18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Serum 25-hydroxyvitamin D levels indicative of",
"    <span class=\"nowrap\">",
"     deficiency/insufficiency",
"    </span>",
"    in children with CKD stages 2 and 4 are as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Severe vitamin D deficiency: &lt;5",
"      <span class=\"nowrap\">",
"       ng/mL",
"      </span>",
"     </li>",
"     <li>",
"      Mild vitamin D deficiency: 5 to 15",
"      <span class=\"nowrap\">",
"       ng/mL",
"      </span>",
"     </li>",
"     <li>",
"      Vitamin D insufficiency: 16 to 30",
"      <span class=\"nowrap\">",
"       ng/mL",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Deficiency of 25-hydroxyvitamin D is common in children with CKD as illustrated by the following retrospective studies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a study from a single center in Florida of 258 patients (mean age 12.3 years) with CKD of all stages (but predominantly Stages 1 and 2 [83 percent]) with an estimated mean GFR 106 &plusmn; 51",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      per 1.73m2, 60 percent of patients had serum 25-hydroxyvitamin D concentrations &lt;30",
"      <span class=\"nowrap\">",
"       ng/mL",
"      </span>",
"      (75",
"      <span class=\"nowrap\">",
"       nmol/L),",
"      </span>",
"      and 28 percent had vitamin D deficiency defined as 25-hydroxyvitamin D &lt;20",
"      <span class=\"nowrap\">",
"       ng/mL",
"      </span>",
"      (50",
"      <span class=\"nowrap\">",
"       nmol/L)",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?27/24/28042/abstract/32\">",
"       32",
"      </a>",
"      ]. Children with more advanced CKD, non-Caucasian ethnicity, and overweight or obese habitus were more likely to have 25-hydroxyvitamin D deficiency and elevated PTH.",
"     </li>",
"     <li>",
"      In a study from a single center in Chicago of children with CKD (stages 1 through 5), the prevalence of 25-hydroxyvitamin D deficiency defined as a level &lt;15",
"      <span class=\"nowrap\">",
"       ng/mL",
"      </span>",
"      (38",
"      <span class=\"nowrap\">",
"       nmol/L)",
"      </span>",
"      ranged from 20 to 75 percent during the decade between 1987 and 1996 [",
"      <a class=\"abstract\" href=\"UTD.htm?27/24/28042/abstract/33\">",
"       33",
"      </a>",
"      ]. In a group of 88 children from the same center who were seen from 2005 to 2006, the prevalence was 39 percent. Lack of sunlight exposure and ethnicity with dark complexion were risk factors for 25-hydroxyvitamin D deficiency as lower levels of 25-hydroxyvitamin D were observed in black and Hispanic children compared to white patients and during the winter months.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Management of 25-OH vitamin D deficiency",
"    </span>",
"    &nbsp;&mdash;&nbsp;The KDOQI guidelines recommend that treatment with ergocalciferol or cholecalciferol should be started when the serum 25-hydroxyvitamin D is &lt;30",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    (75",
"    <span class=\"nowrap\">",
"     nmol/L).",
"    </span>",
"   </p>",
"   <p>",
"    Evidence to support this recommendation includes the following studies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a small randomized, placebo-controlled clinical study, ergocalciferol therapy delayed the onset of secondary hyperparathyroidism in children with 25-hydroxyvitamin D deficiency defined as &lt;30",
"      <span class=\"nowrap\">",
"       ng/mL",
"      </span>",
"      [75",
"      <span class=\"nowrap\">",
"       nmol/L]",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?27/24/28042/abstract/34\">",
"       34",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a prospective study from a single center in Detroit of 57 children with CKD stages 2 through 4, 44 (77 percent) had 25-hydroxyvitamin D concentrations &lt;30",
"      <span class=\"nowrap\">",
"       ng/mL",
"      </span>",
"      (75",
"      <span class=\"nowrap\">",
"       nmol/L).",
"      </span>",
"      In these patients, the mean PTH concentration was 120",
"      <span class=\"nowrap\">",
"       ng/mL,",
"      </span>",
"      which after three months of ergocalciferol treatment decreased to 80",
"      <span class=\"nowrap\">",
"       pg/mL",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?27/24/28042/abstract/35\">",
"       35",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In another prospective study in Indian children, correction of 25-hydroxyvitamin D deficiency with cholecalciferol therapy led to a median reduction in PTH of 38 percent in CKD stage 2, 25 percent in CKD stage 3, and 15 percent in CKD stage 4 [",
"      <a class=\"abstract\" href=\"UTD.htm?27/24/28042/abstract/36\">",
"       36",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Ergocalciferol dosing is dependent on serum 25-hydroxyvitamin D (25-[OH]D) levels as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Serum 25(OH)D level 16 to 30",
"      <span class=\"nowrap\">",
"       ng/mL:",
"      </span>",
"      2000 international units",
"      <span class=\"nowrap\">",
"       (IU)/day",
"      </span>",
"      for three months or 50,000 IU every month for three months.",
"     </li>",
"     <li>",
"      Serum 25(OH)D level 5 to 15",
"      <span class=\"nowrap\">",
"       ng/mL:",
"      </span>",
"      4000",
"      <span class=\"nowrap\">",
"       IU/day",
"      </span>",
"      for 12 weeks or 50,000 IU every other week for 12 weeks.",
"     </li>",
"     <li>",
"      Serum 25(OH)D level &lt;5",
"      <span class=\"nowrap\">",
"       ng/mL:",
"      </span>",
"      8000",
"      <span class=\"nowrap\">",
"       IU/day",
"      </span>",
"      for four weeks then 4000",
"      <span class=\"nowrap\">",
"       IU/day",
"      </span>",
"      for two months for total therapy of three months. Alternatively, 50,000",
"      <span class=\"nowrap\">",
"       IU/week",
"      </span>",
"      for four weeks followed by 50,000 IU two",
"      <span class=\"nowrap\">",
"       times/month",
"      </span>",
"      for a total therapy of three months.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    During ergocalciferol therapy, laboratory monitoring includes measurement of 25(OH)D, total calcium and phosphorus levels one month following initiation of therapy, every three months during therapy, and with any dose change. Once the serum (OH) D level is &gt;30",
"    <span class=\"nowrap\">",
"     ng/mL,",
"    </span>",
"    a maintenance dose between 200 and 1000",
"    <span class=\"nowrap\">",
"     IU/day",
"    </span>",
"    is given.",
"   </p>",
"   <p>",
"    There is a suggestion that cholecalciferol may be more potent in raising and maintaining serum 25-hydroxyvitamin D concentrations compared with ergocalciferol [",
"    <a class=\"abstract\" href=\"UTD.htm?27/24/28042/abstract/37\">",
"     37",
"    </a>",
"    ]. The response of PTH reduction with ergocalciferol or cholecalciferol supplementation appears to be blunted with advancing CKD stages [",
"    <a class=\"abstract\" href=\"UTD.htm?27/24/28042/abstract/34,36\">",
"     34,36",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4786570\">",
"    <span class=\"h3\">",
"     Elevated PTH and normal 25-OH vitamin D",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4786680\">",
"    <span class=\"h4\">",
"     CKD stage 2 to 4",
"    </span>",
"    &nbsp;&mdash;&nbsp;In children with CKD stage 2 to 4, active vitamin D analogue (eg, calcitriol) should be considered if all of the following criteria are met:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Serum 25-hydroxyvitamin D (25[OH]D) is &gt;30",
"      <span class=\"nowrap\">",
"       ng/mL",
"      </span>",
"      (75",
"      <span class=\"nowrap\">",
"       nmol/L)",
"      </span>",
"     </li>",
"     <li>",
"      Serum PTH is above the target range",
"     </li>",
"     <li>",
"      Serum calcium level is &lt;10",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (2.37",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"     </li>",
"     <li>",
"      Serum phosphorus level is less than the age appropriate upper limits for the stage of CKD",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In adults with CKD and secondary hyperparathyroidism, randomized controlled trials have shown that active vitamin D analogue therapy suppresses serum PTH secretion and improves bone disease in patients with CKD stages 3 through 5. In children, calcitriol (1,25-dihydroxyvitamin D) has been reported in observational studies to decrease serum PTH concentrations and improve the linear growth of children with CKD [",
"    <a class=\"abstract\" href=\"UTD.htm?27/24/28042/abstract/38,39\">",
"     38,39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The recommended starting dose for calcitriol is based on the body weight of the child:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Weight &lt;10 kg &ndash; 0.05 microgram every other day",
"     </li>",
"     <li>",
"      Weight between 10 and 20 kg &ndash; 0.1 to 0.15 microgram per day",
"     </li>",
"     <li>",
"      Weight &gt;20 kg &ndash; 0.25 microgram per day",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The use of calcitriol in patients with an elevation of serum calcium or phosphorus can lead to soft tissue calcification due to an increase in the calcium phosphate product. The increased gastrointestinal absorption of calcium and phosphorus that occurs with calcitriol usage can also contribute to soft tissue calcification. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/58/32681?source=see_link\">",
"     \"Management of secondary hyperparathyroidism and mineral metabolism abnormalities in adult predialysis patients with chronic kidney disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/36/38474?source=see_link\">",
"     \"Management of secondary hyperparathyroidism and mineral metabolism abnormalities in dialysis patients\"",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H26\">",
"     'Soft tissue and vascular calcification'",
"    </a>",
"    below.) &nbsp;",
"   </p>",
"   <p>",
"    Once active vitamin D therapy is started, serum calcium and phosphorus concentrations should be measured after one month of therapy for three months and at least every three months thereafter. Serum PTH should be measured at least every three months. The dose of calcitriol should be held if hypercalcemia develops or the serum PTH falls below the target range for the stage of CKD. If hyperphosphatemia develops or persists, the dose of vitamin D should be decreased, and phosphate binder usage and dietary phosphate restriction intensified.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4786687\">",
"    <span class=\"h4\">",
"     CKD stage 5",
"    </span>",
"    &nbsp;&mdash;&nbsp;In children with CKD stage 5 disease (GFR &lt;15",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73 m2) and serum PTH &gt;300",
"    <span class=\"nowrap\">",
"     pg/mL,",
"    </span>",
"    calcitriol should be administered to reduce the serum PTH to 200 to 300",
"    <span class=\"nowrap\">",
"     pg/mL",
"    </span>",
"    according to the KDOQI guidelines, although the optimal target remains controversial [",
"    <a class=\"abstract\" href=\"UTD.htm?27/24/28042/abstract/14\">",
"     14",
"    </a>",
"    ]. For instance, data from the International Pediatric Peritoneal Dialysis Network (IPPN) supported a PTH target range of 100 to 300",
"    <span class=\"nowrap\">",
"     pg/mL",
"    </span>",
"    in children on peritoneal dialysis [",
"    <a class=\"abstract\" href=\"UTD.htm?27/24/28042/abstract/40\">",
"     40",
"    </a>",
"    ]. Once calcitriol is started, serum calcium and phosphorus concentrations should be measured every two weeks for one month and at least monthly thereafter. Serum PTH should be measured monthly for three months and then at least every three months. Serum PTH concentrations &lt;100",
"    <span class=\"nowrap\">",
"     ng/L",
"    </span>",
"    should be avoided to prevent adynamic bone disease. Based upon the laboratory results, dosing of calcitriol should be appropriately adjusted. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Adynamic bone disease'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H496449353\">",
"    <span class=\"h3\">",
"     Other vitamin D analogues",
"    </span>",
"    &nbsp;&mdash;&nbsp;More selective vitamin D analogues, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/14/37093?source=see_link\">",
"     alfacalcidol",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?30/33/31254?source=see_link\">",
"     paricalcitol",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?27/24/28042/abstract/41\">",
"     41",
"    </a>",
"    ], or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/12/44229?source=see_link\">",
"     doxercalciferol",
"    </a>",
"    , have been developed to reduce the risk of hypercalcemia and hyperphosphatemia. In one small controlled double-blinded study of 29 pediatric hemodialysis patients, paricalcitol was superior to placebo in terms of decreasing PTH levels, but there was no difference between the two treatments with respect to the serum calcium, phosphorus, or calcium phosphate product [",
"    <a class=\"abstract\" href=\"UTD.htm?27/24/28042/abstract/42\">",
"     42",
"    </a>",
"    ]. In adult patients, the one clinical trial that directly compared paricalcitol to calcitriol found no significant differences between the two agents. Similar comparative data are lacking in children. As a result, there is no convincing evidence supporting the use of one specific vitamin D analogue over another. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/36/38474?source=see_link&amp;anchor=H18#H18\">",
"     \"Management of secondary hyperparathyroidism and mineral metabolism abnormalities in dialysis patients\", section on 'Vitamin D derivatives'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In adults, calcimimetics (only",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/23/26998?source=see_link\">",
"     cinacalcet",
"    </a>",
"    is available) have been increasingly used to suppress PTH secretion and decrease the risk of hypercalcemia associated with calcitriol. These agents, which increase the sensitivity of the calcium-sensing receptor (CaSR) in the parathyroid gland to calcium, have not been adequately studied in the pediatric population. The use of calcimimetics has been anecdotal in children with severe",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    refractory hyperparathyroidism. Two small observational studies with a total of 15 children on dialysis and one with severe CKD reported a decrease of 61 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?27/24/28042/abstract/43\">",
"     43",
"    </a>",
"    ] and 74 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?27/24/28042/abstract/44\">",
"     44",
"    </a>",
"    ] in serum PTH levels with calcimimetic therapy. However, calcimimetics are not part of standard care, and should only be given in the research setting. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/58/32681?source=see_link&amp;anchor=H18#H18\">",
"     \"Management of secondary hyperparathyroidism and mineral metabolism abnormalities in adult predialysis patients with chronic kidney disease\", section on 'Cinacalcet'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/36/38474?source=see_link&amp;anchor=H25#H25\">",
"     \"Management of secondary hyperparathyroidism and mineral metabolism abnormalities in dialysis patients\", section on 'Calcimimetics'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Calcium",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Hypocalcemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;The total serum calcium should be maintained within a normal range for the laboratory used, generally between 8.8 and 9.7",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (2.2 to 2.37",
"    <span class=\"nowrap\">",
"     mmol/L).",
"    </span>",
"    With progressive loss of kidney function, phosphate retention and 1,25-dihydroxyvitamin D deficiency can result in hypocalcemia if appropriate therapy is not given.",
"   </p>",
"   <p>",
"    For children with CKD stages 2 to 5, the 2008 KDOQI pediatric nutrition guidelines suggest that the total calcium intake (nutritional sources and phosphate binders) be in the range of 100 to 200 percent of the daily reference intake (DRI) for age (",
"    <a class=\"graphic graphic_table graphicRef52366 \" href=\"UTD.htm?13/11/13501\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/24/28042/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Symptomatic hypocalcemia should initially be treated with parenteral",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?18/63/19446?source=see_link\">",
"     calcium chloride",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?27/24/28042/abstract/1\">",
"     1",
"    </a>",
"    ]. Long-term therapy requires appropriate management of hyperphosphatemia and vitamin D deficiency, as described above. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/37/44632?source=see_link\">",
"     \"Treatment of hypocalcemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Hypercalcemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children with CKD who are treated with vitamin D therapy and calcium-containing phosphate binders may develop hypercalcemia. If the total serum calcium value exceeds 10.2",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (2.55",
"    <span class=\"nowrap\">",
"     mmol/L),",
"    </span>",
"    the dose of calcium-based phosphate binders should be reduced",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    therapy changed to",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?23/8/23684?source=see_link\">",
"     sevelamer",
"    </a>",
"    . Vitamin D therapy should also be discontinued until the serum calcium returns to the targeted range and then restarted with an appropriate dose adjustment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Parathyroid hormone",
"    </span>",
"    &nbsp;&mdash;&nbsp;High bone turnover seen in osteitis fibrosa and mixed osteodystrophy is a result of secondary hyperparathyroidism. The pathogenesis of secondary hyperparathyroidism in CKD is mediated via several complex and interactive pathways. The major factor stimulating parathyroid gland function is hyperphosphatemia, which initially acts by decreasing serum 1,25-dihydroxyvitamin D; the fall in calcitriol diminishes its suppressive effect on the parathyroid gland, leading to hyperparathyroidism. In the late stages, hyperphosphatemia itself can directly increase PTH release. Hypocalcemia, if it develops, is an additional stimulus to PTH secretion. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/50/18218?source=see_link&amp;anchor=H3#H3\">",
"     \"Pathogenesis of renal osteodystrophy\", section on 'Secondary hyperparathyroidism and osteitis fibrosa'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The serum PTH concentration is inversely correlated with kidney function and is almost always elevated when the glomerular filtration rate falls below 60",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73 m2 [",
"    <a class=\"abstract\" href=\"UTD.htm?27/24/28042/abstract/5\">",
"     5",
"    </a>",
"    ]. Although the optimal serum PTH values in children with CKD are uncertain, the KDOQI guidelines recommend targeted levels of serum intact PTH at different stages of CKD as follows&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?27/24/28042/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Stage 2 and 3 disease &ndash; 35 to 70",
"      <span class=\"nowrap\">",
"       pg/mL",
"      </span>",
"     </li>",
"     <li>",
"      Stage 4 disease &ndash; 70 to 110",
"      <span class=\"nowrap\">",
"       pg/mL",
"      </span>",
"     </li>",
"     <li>",
"      Stage 5 disease &ndash; 200 to 300",
"      <span class=\"nowrap\">",
"       pg/mL",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In contrast to KDOQI, KDIGO suggests that PTH levels be maintained in the range of approximately two to nine times the upper normal limit in patients with CKD stage 5D [",
"    <a class=\"abstract\" href=\"UTD.htm?27/24/28042/abstract/13\">",
"     13",
"    </a>",
"    ]. Data from the International Pediatric Peritoneal Dialysis Network (IPPN) supports a PTH target range of 100 to 300",
"    <span class=\"nowrap\">",
"     pg/mL",
"    </span>",
"    in children on peritoneal dialysis [",
"    <a class=\"abstract\" href=\"UTD.htm?27/24/28042/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The management and prevention of secondary hyperparathyroidism is complex and requires frequent monitoring and adjustment of therapy. The initial step is to correct phosphate retention by dietary restriction usually combined with either calcium-containing phosphate binders",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?23/8/23684?source=see_link\">",
"     sevelamer",
"    </a>",
"    . (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Phosphate'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    This is followed by either calcium supplementation",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    vitamin D therapy. In the early stages of CKD, the clinician should also assess and replenish 25-hydroxyvitamin D (if the level is low) with oral ergocalciferol or cholecalciferol prior to initiating therapy with calcitriol. (See",
"    <a class=\"local\" href=\"#H18\">",
"     'Calcium'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H15\">",
"     'Vitamin D'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    In most children with stage 5 disease, the combination of dietary phosphate restriction, phosphate binders, and active vitamin D therapy is required to maintain a normal age-appropriate serum phosphate value and a serum PTH concentration that is no more than two to four times normal. The European Pediatric Dialysis Working Group (EPDWG) has developed a management algorithm to target a serum calcium phosphorous product below 60",
"    <span class=\"nowrap\">",
"     mg(2)/dL(2)",
"    </span>",
"    (",
"    <a class=\"graphic graphic_algorithm graphicRef62785 \" href=\"UTD.htm?16/26/16815\">",
"     algorithm 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/24/28042/abstract/15\">",
"     15",
"    </a>",
"    ]. As noted above, anecdotal experience in children suggests that calcimimetic therapy may be beneficial as well. Severe secondary hyperparathyroidism requiring parathyroidectomy is rare in children.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Aluminum in chronic kidney disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Aluminum-related disorders in CKD, although now extremely rare, can present with the findings of hypercalcemia, osteomalacia, microcytic anemia, and dialysis encephalopathy. The purpose of monitoring the plasma aluminum level in the late stages of CKD is to identify excessive aluminum intake or absorption that might have occurred so that corrective measures can be taken. To prevent aluminum toxicity, the regular administration of aluminum, historically provided most commonly in the form of phosphate binders, should be avoided and, in hemodialysis patients, the dialysate concentration of aluminum should be maintained at &lt;10",
"    <span class=\"nowrap\">",
"     mcg/L",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?27/24/28042/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/14/5352?source=see_link\">",
"     \"Aluminum toxicity in end-stage renal disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients who are ingesting aluminum-containing phosphate binders or medications such as",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?8/4/8261?source=see_link\">",
"     sucralfate",
"    </a>",
"    that contain aluminum should not receive citrate simultaneously as the latter medication enhances the gastrointestinal absorption of aluminum. Serum aluminum levels should be measured yearly in patients with Stage 5 CKD, and the baseline level of serum aluminum should be &lt;20",
"    <span class=\"nowrap\">",
"     mcg/L.",
"    </span>",
"    In a cross-sectional study of 41 children on dialysis, children with low turnover bone disease had higher serum aluminum levels [",
"    <a class=\"abstract\" href=\"UTD.htm?27/24/28042/abstract/45\">",
"     45",
"    </a>",
"    ]. A",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/0/37894?source=see_link\">",
"     deferoxamine",
"    </a>",
"    (DFO) test should be performed if there are elevated serum aluminum levels (&gt;60",
"    <span class=\"nowrap\">",
"     mcg/L),",
"    </span>",
"    clinical signs and symptoms of aluminum toxicity, or prior to parathyroid surgery if the patient has had aluminum exposure [",
"    <a class=\"abstract\" href=\"UTD.htm?27/24/28042/abstract/1\">",
"     1",
"    </a>",
"    ]. To help avoid toxicity, the DFO test should",
"    <strong>",
"     not",
"    </strong>",
"    be performed in patients with serum aluminum levels above 200",
"    <span class=\"nowrap\">",
"     mcg/L.",
"    </span>",
"    (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/14/5352?source=see_link\">",
"     \"Aluminum toxicity in end-stage renal disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The sequelae of renal osteodystrophy in children include growth retardation, musculoskeletal deformities, and soft tissue calcification [",
"    <a class=\"abstract\" href=\"UTD.htm?27/24/28042/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Growth failure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Growth failure in children with CKD is multifactorial in origin. Potential contributing factors in addition to renal osteodystrophy include chronic metabolic acidosis, anorexia and inadequate caloric intake and inadequate unbound insulin-like growth factor. The relative importance of these factors in growth failure is uncertain. However, treatment is aimed at correcting all correctable abnormalities.",
"   </p>",
"   <p>",
"    KDIGO recommends that infants with CKD stages 2 to 5D should have their length measured at least quarterly, while children with CKD stages 2 to 5D should be assessed for linear growth at least annually [",
"    <a class=\"abstract\" href=\"UTD.htm?27/24/28042/abstract/13\">",
"     13",
"    </a>",
"    ]. Similarly, the 2008 KDOQI pediatric nutrition guidelines recommend that assessments of dietary intake, height, weight, head circumference, and age percentiles for weight, body mass index (BMI) and height age percentile (or weight, BMI, and height velocity SDS for age [z score]) be performed at least twice as frequently as one would perform them in a healthy child of the same age, and more frequently in high risk infants and children. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/14/31976?source=see_link&amp;anchor=H5#H5\">",
"     \"Measurement of growth in children\", section on 'Z-scores'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There is evidence of increased growth after interventions such as vitamin D therapy and normalization of serum PTH concentrations [",
"    <a class=\"abstract\" href=\"UTD.htm?27/24/28042/abstract/38,39\">",
"     38,39",
"    </a>",
"    ]. In children and adolescents with CKD stages 2 to 5D and related height deficits, treatment with recombinant human growth hormone has been recommended when additional growth is desired, after first addressing malnutrition and biochemical abnormalities of CKD&ndash;MBD [",
"    <a class=\"abstract\" href=\"UTD.htm?27/24/28042/abstract/13\">",
"     13",
"    </a>",
"    ]. The KDOQI pediatric nutrition guidelines recommend that recombinant human growth hormone be considered in children with CKD if height SDS is &lt;-1.88 or height for age is &lt;3rd percentile, or if height velocity for age is SDS &lt;-1.88 or height velocity for age is &lt;3rd percentile, despite adequate treatment for nutritional deficiencies and metabolic abnormalities. The data supporting the use of growth hormone therapy in CKD is presented separately. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Management'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/14/27881?source=see_link\">",
"     \"Growth hormone treatment in children with chronic kidney disease and postrenal transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Musculoskeletal deformities",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children with renal osteodystrophy are at increased risk for nontraumatic fractures. In addition, other skeletal deformities may develop, given that these children can be vitamin D deficient, hyperphosphatemic,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    acidotic. The deformities are similar to those seen in children with vitamin D deficiency rickets. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/21/26967?source=see_link\">",
"     \"Overview of rickets in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In children with CKD, the growth plate is vulnerable to injury with disruption of the connection between the epiphyseal plate and the metaphysis [",
"    <a class=\"abstract\" href=\"UTD.htm?27/24/28042/abstract/46\">",
"     46",
"    </a>",
"    ]. This abnormality, along with hyperparathyroid erosions of bone, puts the child at an increased risk for slipped epiphysis and genu valgum. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/42/23209?source=see_link\">",
"     \"Slipped capital femoral epiphysis (SCFE)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Soft tissue and vascular calcification",
"    </span>",
"    &nbsp;&mdash;&nbsp;Soft tissue calcifications (also called calcinosis) can lead to long-term morbidity in patients with CKD. The sites include vascular, ocular, periarticular, and visceral calcifications and may be severe enough to produce calciphylaxis. Most of the data on this subject have been derived from studies in adults and are presented separately. The following discussion will emphasize the more limited data related to children. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/20/17738?source=see_link\">",
"     \"Vascular calcification in chronic kidney disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/42/15017?source=see_link\">",
"     \"Calciphylaxis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/16/8456?source=see_link\">",
"     \"Eye disorders associated with chronic kidney disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Soft tissue calcification can involve the vasculature, including the coronary arteries [",
"    <a class=\"abstract\" href=\"UTD.htm?27/24/28042/abstract/47-50\">",
"     47-50",
"    </a>",
"    ]. It is unclear how frequently this occurs, as illustrated by the following studies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one study using electron beam computerized tomography (CT) of 39 dialysis patients (age 7 to 30 years, mean 19 years), coronary artery calcification (CAC) was present in 14 of the 16 dialysis patients who were over 20 years of age, but not in any of the younger dialysis patients. It was present in only 3 of 60 normal subjects who were 20 to 30 years of age [",
"      <a class=\"abstract\" href=\"UTD.htm?27/24/28042/abstract/48\">",
"       48",
"      </a>",
"      ]. In addition to older age, patients with CAC had been dialyzed longer (14 versus 4 years) and had a significantly higher calcium phosphate product (65 versus 56",
"      <span class=\"nowrap\">",
"       mg2/dL2).",
"      </span>",
"     </li>",
"     <li>",
"      In a study of 39 young adults (19 to 39 years old) with childhood onset of CKD, CAC was present in 92 percent with all exceeding the 95th age and gender specific percentile for calcium scores [",
"      <a class=\"abstract\" href=\"UTD.htm?27/24/28042/abstract/51\">",
"       51",
"      </a>",
"      ]. The risk factors consisted of elevated C-reactive protein, hyperparathyroidism, elevated calcium-phosphate product and hyperhomocysteinemia [",
"      <a class=\"abstract\" href=\"UTD.htm?27/24/28042/abstract/51\">",
"       51",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      These findings were confirmed in yet another small study with 11 children (age 11 to 24 years, median age 19.3 years), which also used electron beam CT to detect CAC [",
"      <a class=\"abstract\" href=\"UTD.htm?27/24/28042/abstract/50\">",
"       50",
"      </a>",
"      ]. In this study, 7 of 11 (64 percent) patients had CAC, which correlated with the dose of elemental calcium and calcitriol.",
"     </li>",
"     <li>",
"      In contrast, only 8 of 53 (15 percent) patients had coronary artery calcification in a study of 53 children with end-stage kidney disease [",
"      <a class=\"abstract\" href=\"UTD.htm?27/24/28042/abstract/52\">",
"       52",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    As noted above, the etiology of soft tissue calcification is multifactorial in children. This was addressed in a retrospective autopsy review of 120 children with CKD from 1960 to 1983, 60 percent of whom had soft tissue calcification [",
"    <a class=\"abstract\" href=\"UTD.htm?27/24/28042/abstract/47\">",
"     47",
"    </a>",
"    ]. On multiple logistic regression analysis, the use of vitamin D or its analogues, the peak calcium phosphate product, the age at onset of kidney failure, and male sex were associated with calcinosis. Vitamin D therapy showed the strongest independent association with calcinosis.",
"   </p>",
"   <p>",
"    Vascular calcification is accelerated in children on hemodialysis [",
"    <a class=\"abstract\" href=\"UTD.htm?27/24/28042/abstract/53\">",
"     53",
"    </a>",
"    ], is associated with abnormalities of circulating calcification inhibitors [",
"    <a class=\"abstract\" href=\"UTD.htm?27/24/28042/abstract/54\">",
"     54",
"    </a>",
"    ], and worsens with severity of mineral bone abnormalities including elevation of FGF23 and dialysis duration [",
"    <a class=\"abstract\" href=\"UTD.htm?27/24/28042/abstract/55-57\">",
"     55-57",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Phosphate'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    In a single study of 61 children on dialysis, it was noted that serum 1,25-dihydroxyvitamin D levels had a U-shaped distribution for both carotid intima-media thickness and vascular calcification scores [",
"    <a class=\"abstract\" href=\"UTD.htm?27/24/28042/abstract/58\">",
"     58",
"    </a>",
"    ]. Specifically, children with both low and high serum 1,25-dihydroxyvitamin D levels were at increased risk for increased carotid intima-media thickness and increased vascular calcification scores. In contrast, there was no correlation between the serum 25-hydroxyvitamin D level and the same outcomes [",
"    <a class=\"abstract\" href=\"UTD.htm?27/24/28042/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In another study with 85 children on dialysis, it was found that children with serum PTH levels &gt;2 times upper limit of normal (ULN) had greater carotid intima-media thickness, cardiac calcification, and stiffer vessels in comparison with children with serum PTH levels &lt;2x ULN who had measurements comparable to normal children [",
"    <a class=\"abstract\" href=\"UTD.htm?27/24/28042/abstract/55\">",
"     55",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In an attempt to minimize the risk of soft tissue and vascular calcification, the KDOQI guidelines recommend that the calcium phosphate product be maintained below the following values [",
"    <a class=\"abstract\" href=\"UTD.htm?27/24/28042/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Less than 55",
"      <span class=\"nowrap\">",
"       mg2/dL2",
"      </span>",
"      in children older than 12 years of age",
"     </li>",
"     <li>",
"      Less than 65",
"      <span class=\"nowrap\">",
"       mg2/dL2",
"      </span>",
"      in children younger than 12 years of age",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This is best achieved by maintaining the serum level of phosphate within the age specific target range and keeping the serum calcium between 8.8 and 9.7",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (2.2 to 2.37",
"    <span class=\"nowrap\">",
"     mmol/L).",
"    </span>",
"    (See",
"    <a class=\"local\" href=\"#H17\">",
"     'Management of 25-OH vitamin D deficiency'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H21\">",
"     'Parathyroid hormone'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?24/17/24850?source=see_link\">",
"       \"Patient information: Bone problems caused by kidney disease (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In children with chronic kidney disease (CKD), abnormalities in bone metabolism occur early and are universal. If untreated, these patients will develop renal osteodystrophy and CKD- mineral and bone disorder (CKD-MBD) as their CKD progresses.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Renal osteodystrophy can present as several different pathologic forms and includes osteitis fibrosa, adynamic bone disease, osteomalacia, and mixed osteodystrophy. Osteitis fibrosa cystica results from secondary hyperparathyroidism, and is the form of bone disease seen in children with mild to moderate CKD. The other forms are seen in children with severe CKD, and are often due to therapeutic interventions (eg, excess suppression of the parathyroid gland from calcium-containing phosphate binders and vitamin D analogues). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Types'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/50/18218?source=see_link\">",
"       \"Pathogenesis of renal osteodystrophy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The Kidney Disease Outcome Quality Initiative (KDOQI), Kidney Disease: Improving Global Outcomes (KDIGO), and The European Pediatric Dialysis Working Group (EPDWG) provide guidelines to care for children with CKD who are at risk for developing renal osteodystrophy. These guidelines specifically outline measures to detect and treat abnormalities of bone metabolism and secondary hyperparathyroidism. The KDOQI clinical practice guidelines for bone metabolism and disease in children with CKD, as well as other KDOQI guidelines, can be accessed through the National Kidney Foundation's web site at",
"      <a class=\"external\" href=\"file://www.kidney.org/professionals/kdoqi/guidelines.cfm\">",
"       www.kidney.org/professionals/kdoqi/guidelines.cfm",
"      </a>",
"      .",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Our own clinical practice is consistent with the KDOQI guidelines in the management of bone metabolic abnormalities in children with CKD and includes the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Management (frequency of monitoring and therapeutic interventions) is based upon the child's level of kidney function (",
"      <a class=\"graphic graphic_table graphicRef80596 \" href=\"UTD.htm?22/4/22603\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Stages of chronic kidney disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Therapy focuses on the prevention of phosphate retention and hypovitaminosis D because these are the main contributors to the development of secondary hyperparathyroidism, which results in renal osteodystrophy. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest that serum concentrations of calcium, phosphate, and parathyroid hormone should be measured on an ongoing basis in all children with stages 2 to 5 of CKD&nbsp;(",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Monitoring'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In children with an elevated serum PTH",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      phosphate level, we recommend reducing the PTH",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      phosphate concentration with dietary restriction of phosphorus and the use of phosphate binders, if necessary&nbsp;(",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ).",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?29/2/29733?source=see_link\">",
"       Calcium citrate",
"      </a>",
"      ,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?20/36/21062?source=see_link\">",
"       aluminum hydroxide",
"      </a>",
"      , and magnesium-containing antacids should",
"      <strong>",
"       not",
"      </strong>",
"      be used as phosphate binders because of their adverse side effects. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Phosphate'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In children with CKD stage 2 to 4, if serum PTH is above the target range, 25-hydroxyvitamin D concentration should be measured. If the 25-hydroxyvitamin D level is &lt;30",
"      <span class=\"nowrap\">",
"       ng/mL",
"      </span>",
"      (75",
"      <span class=\"nowrap\">",
"       nmol/L),",
"      </span>",
"      we suggest that ergocalciferol or cholecalciferol be given (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). If the level is &gt;30",
"      <span class=\"nowrap\">",
"       ng/mL",
"      </span>",
"      (75",
"      <span class=\"nowrap\">",
"       nmol/L)",
"      </span>",
"      and the serum calcium level is &lt;10",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (2.37",
"      <span class=\"nowrap\">",
"       mmol/L),",
"      </span>",
"      we recommend calcitriol therapy (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Vitamin D'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In children with CKD stage 5 and PTH levels &gt;300",
"      <span class=\"nowrap\">",
"       pg/mL,",
"      </span>",
"      we suggest that calcitriol should be administered until serum PTH is reduced to a range between 200 to 300",
"      <span class=\"nowrap\">",
"       pg/mL",
"      </span>",
"      (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ), although the optimal target range remains controversial. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Vitamin D'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Serum calcium should be maintained within a normal range for the laboratory used, generally between 8.8 and 9.7",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (2.2 to 2.37",
"      <span class=\"nowrap\">",
"       mmol/L).",
"      </span>",
"      If the patient is hypocalcemic, we recommend that calcium supplementation",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      vitamin D therapy be given (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Hypocalcemia'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/24/28042/abstract/1\">",
"      National Kidney Foundation. K/DOQI clinical practice guidelines for bone metabolism and disease in children with chronic kidney disease. Am J Kidney Dis 2005; 46(Suppl1):S1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/24/28042/abstract/2\">",
"      Moe S, Dr&uuml;eke T, Cunningham J, et al. Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 2006; 69:1945.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/24/28042/abstract/3\">",
"      National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002; 39:S1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/24/28042/abstract/4\">",
"      Martinez I, Saracho R, Montenegro J, Llach F. The importance of dietary calcium and phosphorous in the secondary hyperparathyroidism of patients with early renal failure. Am J Kidney Dis 1997; 29:496.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/24/28042/abstract/5\">",
"      Zi&oacute;lkowska H, Pa��iczyk-Tomaszewska M, Debi��ski A, et al. Bone biopsy results and serum bone turnover parameters in uremic children. Acta Paediatr 2000; 89:666.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/24/28042/abstract/6\">",
"      Waller S, Shroff R, Freemont AJ, Rees L. Bone histomorphometry in children prior to commencing renal replacement therapy. Pediatr Nephrol 2008; 23:1523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/24/28042/abstract/7\">",
"      Wesseling-Perry K, Pereira RC, Tseng CH, et al. Early skeletal and biochemical alterations in pediatric chronic kidney disease. Clin J Am Soc Nephrol 2012; 7:146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/24/28042/abstract/8\">",
"      Andrade MC, Carvalhaes JT, Carvalho AB, et al. Bone mineral density and bone histomorphometry in children on long-term dialysis. Pediatr Nephrol 2007; 22:1767.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/24/28042/abstract/9\">",
"      Pieper AK, Haffner D, Hoppe B, et al. A randomized crossover trial comparing sevelamer with calcium acetate in children with CKD. Am J Kidney Dis 2006; 47:625.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/24/28042/abstract/10\">",
"      Gonzalez E, Schomberg J, Amin N, et al. Sevelamer carbonate increases serum bicarbonate in pediatric dialysis patients. Pediatr Nephrol 2010; 25:373.",
"     </a>",
"    </li>",
"    <li>",
"     Salusky IB, Ramirez, JA, Oppenheim W, et al. Biochemical markers of renal osteodystrophy in pediatric patients undergoing CAPD/CCPD.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/24/28042/abstract/12\">",
"      Mathias R, Salusky I, Harman W, et al. Renal bone disease in pediatric and young adult patients on hemodialysis in a children's hospital. J Am Soc Nephrol 1993; 3:1938.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/24/28042/abstract/13\">",
"      Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl 2009; :S1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/24/28042/abstract/14\">",
"      Rees L. What parathyroid hormone levels should we aim for in children with stage 5 chronic kidney disease; what is the evidence? Pediatr Nephrol 2008; 23:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/24/28042/abstract/15\">",
"      Klaus G, Watson A, Edefonti A, et al. Prevention and treatment of renal osteodystrophy in children on chronic renal failure: European guidelines. Pediatr Nephrol 2006; 21:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/24/28042/abstract/16\">",
"      Portale AA, Booth BE, Halloran BP, Morris RC Jr. Effect of dietary phosphorus on circulating concentrations of 1,25-dihydroxyvitamin D and immunoreactive parathyroid hormone in children with moderate renal insufficiency. J Clin Invest 1984; 73:1580.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/24/28042/abstract/17\">",
"      Turner C, Compston J, Mak RH, et al. Bone turnover and 1,25-dihydroxycholecalciferol during treatment with phosphate binders. Kidney Int 1988; 33:989.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/24/28042/abstract/18\">",
"      National Kidney Foundation. K/DOQI clinical practice guidelines for nutrition in children with CKD: 2008 Update. Bone mineral and vitamin D requirements and therapy. Am J Kidney Dis 2009; 53:S61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/24/28042/abstract/19\">",
"      Wingen AM, Fabian-Bach C, Schaefer F, Mehls O. Randomised multicentre study of a low-protein diet on the progression of chronic renal failure in children. European Study Group of Nutritional Treatment of Chronic Renal Failure in Childhood. Lancet 1997; 349:1117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/24/28042/abstract/20\">",
"      Kist-van Holthe tot Echten JE, Nauta J, Hop WC, et al. Protein restriction in chronic renal failure. Arch Dis Child 1993; 68:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/24/28042/abstract/21\">",
"      Jureidini KF, Hogg RJ, van Renen MJ, et al. Evaluation of long-term aggressive dietary management of chronic renal failure in children. Pediatr Nephrol 1990; 4:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/24/28042/abstract/22\">",
"      Uauy RD, Hogg RJ, Brewer ED, et al. Dietary protein and growth in infants with chronic renal insufficiency: a report from the Southwest Pediatric Nephrology Study Group and the University of California, San Francisco. Pediatr Nephrol 1994; 8:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/24/28042/abstract/23\">",
"      Tamanaha K, Mak RH, Rigden SP, et al. Long-term suppression of hyperparathyroidism by phosphate binders in uremic children. Pediatr Nephrol 1987; 1:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/24/28042/abstract/24\">",
"      Andreoli SP, Dunson JW, Bergstein JM. Calcium carbonate is an effective phosphorus binder in children with chronic renal failure. Am J Kidney Dis 1987; 9:206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/24/28042/abstract/25\">",
"      Geary DF, Hodson EM, Craig JC. Interventions for bone disease in children with chronic kidney disease. Cochrane Database Syst Rev 2010; :CD008327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/24/28042/abstract/26\">",
"      Andreoli SP, Bergstein JM, Sherrard DJ. Aluminum intoxication from aluminum-containing phosphate binders in children with azotemia not undergoing dialysis. N Engl J Med 1984; 310:1079.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/24/28042/abstract/27\">",
"      Mahdavi H, Kuizon BD, Gales B, et al. Sevelamer hydrochloride: an effective phosphate binder in dialyzed children. Pediatr Nephrol 2003; 18:1260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/24/28042/abstract/28\">",
"      van Husen M, Fischer AK, Lehnhardt A, et al. Fibroblast growth factor 23 and bone metabolism in children with chronic kidney disease. Kidney Int 2010; 78:200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/24/28042/abstract/29\">",
"      Bacchetta J, Dubourg L, Harambat J, et al. The influence of glomerular filtration rate and age on fibroblast growth factor 23 serum levels in pediatric chronic kidney disease. J Clin Endocrinol Metab 2010; 95:1741.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/24/28042/abstract/30\">",
"      Wolf M. FGF23: fashion or physiology? Clin J Am Soc Nephrol 2010; 5:1727.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/24/28042/abstract/31\">",
"      Shimada T, Hasegawa H, Yamazaki Y, et al. FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. J Bone Miner Res 2004; 19:429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/24/28042/abstract/32\">",
"      Seeherunvong W, Abitbol CL, Chandar J, et al. Vitamin D insufficiency and deficiency in children with early chronic kidney disease. J Pediatr 2009; 154:906.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/24/28042/abstract/33\">",
"      Ali FN, Arguelles LM, Langman CB, Price HE. Vitamin D deficiency in children with chronic kidney disease: uncovering an epidemic. Pediatrics 2009; 123:791.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/24/28042/abstract/34\">",
"      Shroff R, Wan M, Gullett A, et al. Ergocalciferol supplementation in children with CKD delays the onset of secondary hyperparathyroidism: a randomized trial. Clin J Am Soc Nephrol 2012; 7:216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/24/28042/abstract/35\">",
"      Menon S, Valentini RP, Hidalgo G, et al. Vitamin D insufficiency and hyperparathyroidism in children with chronic kidney disease. Pediatr Nephrol 2008; 23:1831.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/24/28042/abstract/36\">",
"      Hari P, Gupta N, Hari S, et al. Vitamin D insufficiency and effect of cholecalciferol in children with chronic kidney disease. Pediatr Nephrol 2010; 25:2483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/24/28042/abstract/37\">",
"      Heaney RP, Recker RR, Grote J, et al. Vitamin D(3) is more potent than vitamin D(2) in humans. J Clin Endocrinol Metab 2011; 96:E447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/24/28042/abstract/38\">",
"      Chesney RW, Moorthy AV, Eisman JA, et al. Increased growth after long-term oral 1alpha,25-vitamin D3 in childhood renal osteodystrophy. N Engl J Med 1978; 298:238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/24/28042/abstract/39\">",
"      Waller S, Ledermann S, Trompeter R, et al. Catch-up growth with normal parathyroid hormone levels in chronic renal failure. Pediatr Nephrol 2003; 18:1236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/24/28042/abstract/40\">",
"      Borzych D, Rees L, Ha IS, et al. The bone and mineral disorder of children undergoing chronic peritoneal dialysis. Kidney Int 2010; 78:1295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/24/28042/abstract/41\">",
"      Seeherunvong W, Nwobi O, Abitbol CL, et al. Paricalcitol versus calcitriol treatment for hyperparathyroidism in pediatric hemodialysis patients. Pediatr Nephrol 2006; 21:1434.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/24/28042/abstract/42\">",
"      Greenbaum LA, Benador N, Goldstein SL, et al. Intravenous paricalcitol for treatment of secondary hyperparathyroidism in children on hemodialysis. Am J Kidney Dis 2007; 49:814.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/24/28042/abstract/43\">",
"      Muscheites J, Wigger M, Drueckler E, et al. Cinacalcet for secondary hyperparathyroidism in children with end-stage renal disease. Pediatr Nephrol 2008; 23:1823.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/24/28042/abstract/44\">",
"      Silverstein DM, Kher KK, Moudgil A, et al. Cinacalcet is efficacious in pediatric dialysis patients. Pediatr Nephrol 2008; 23:1817.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/24/28042/abstract/45\">",
"      Avila-D&iacute;az M, Matos M, Garc&iacute;a-L&oacute;pez E, et al. Serum markers of low-turnover bone disease in Mexican children with chronic kidney disease undergoing dialysis. Perit Dial Int 2006; 26:78.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/24/28042/abstract/46\">",
"      Krempien B, Mehls O, Ritz E. Morphological studies on pathogenesis of epiphyeal slipping in uremic children. Virchows Arch A Pathol Anat Histol 1982; 362:120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/24/28042/abstract/47\">",
"      Milliner DS, Zinsmeister AR, Lieberman E, Landing B. Soft tissue calcification in pediatric patients with end-stage renal disease. Kidney Int 1990; 38:931.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/24/28042/abstract/48\">",
"      Goodman WG, Goldin J, Kuizon BD, et al. Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med 2000; 342:1478.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/24/28042/abstract/49\">",
"      Eifinger F, Wahn F, Querfeld U, et al. Coronary artery calcifications in children and young adults treated with renal replacement therapy. Nephrol Dial Transplant 2000; 15:1892.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/24/28042/abstract/50\">",
"      Lumpaopong A, Mathew AV, John E, et al. Early coronary calcification in children and young adults with end-stage renal disease. Transplant Proc 2007; 39:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/24/28042/abstract/51\">",
"      Oh J, Wunsch R, Turzer M, et al. Advanced coronary and carotid arteriopathy in young adults with childhood-onset chronic renal failure. Circulation 2002; 106:100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/24/28042/abstract/52\">",
"      Civilibal M, Caliskan S, Adaletli I, et al. Coronary artery calcifications in children with end-stage renal disease. Pediatr Nephrol 2006; 21:1426.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/24/28042/abstract/53\">",
"      Shroff RC, McNair R, Figg N, et al. Dialysis accelerates medial vascular calcification in part by triggering smooth muscle cell apoptosis. Circulation 2008; 118:1748.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/24/28042/abstract/54\">",
"      Shroff RC, Shah V, Hiorns MP, et al. The circulating calcification inhibitors, fetuin-A and osteoprotegerin, but not matrix Gla protein, are associated with vascular stiffness and calcification in children on dialysis. Nephrol Dial Transplant 2008; 23:3263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/24/28042/abstract/55\">",
"      Shroff RC, Donald AE, Hiorns MP, et al. Mineral metabolism and vascular damage in children on dialysis. J Am Soc Nephrol 2007; 18:2996.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/24/28042/abstract/56\">",
"      Groothoff JW, Grootenhuis MA, Offringa M, et al. Social consequences in adult life of end-stage renal disease in childhood. J Pediatr 2005; 146:512.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/24/28042/abstract/57\">",
"      Srivaths PR, Goldstein SL, Silverstein DM, et al. Elevated FGF 23 and phosphorus are associated with coronary calcification in hemodialysis patients. Pediatr Nephrol 2011; 26:945.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/24/28042/abstract/58\">",
"      Shroff R, Egerton M, Bridel M, et al. A bimodal association of vitamin D levels and vascular disease in children on dialysis. J Am Soc Nephrol 2008; 19:1239.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6092 Version 17.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-115.25.216.6-3FB984B900-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_24_28042=[""].join("\n");
var outline_f27_24_28042=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H27\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      STAGES OF CHRONIC KIDNEY DISEASE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      TYPES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Osteitis fibrosa cystica",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Adynamic bone disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Osteomalacia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Mixed osteodystrophy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Other factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Monitoring",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Phosphate",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Goals",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Interventions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H39327940\">",
"      Diet",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H39327947\">",
"      Phosphate binders",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H39327954\">",
"      - Potential role for FGF23",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Vitamin D",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Evaluation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Management of 25-OH vitamin D deficiency",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4786570\">",
"      - Elevated PTH and normal 25-OH vitamin D",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H4786680\">",
"      CKD stage 2 to 4",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H4786687\">",
"      CKD stage 5",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H496449353\">",
"      - Other vitamin D analogues",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Calcium",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Hypocalcemia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Hypercalcemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Parathyroid hormone",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Aluminum in chronic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Growth failure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Musculoskeletal deformities",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Soft tissue and vascular calcification",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/6092\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6092|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?16/26/16815\" title=\"algorithm 1\">",
"      EPDWG clinical algorithm",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6092|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?28/43/29373\" title=\"figure 1\">",
"      Relationship between GFR and PTH",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6092|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?28/13/28883\" title=\"picture 1\">",
"      Normal bone",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?31/5/31832\" title=\"picture 2\">",
"      Osteitis fibrosa",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?30/56/31623\" title=\"picture 3\">",
"      Adynamic bone disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?0/32/520\" title=\"picture 4\">",
"      Low turnover osteomalacia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?19/57/20376\" title=\"picture 5\">",
"      Mixed osteodystrophy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6092|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?22/4/22603\" title=\"table 1\">",
"      Stages of CKD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?13/11/13501\" title=\"table 2\">",
"      Nutritional assessment for children with CKD",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/14/5352?source=related_link\">",
"      Aluminum toxicity in end-stage renal disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/43/28343?source=related_link\">",
"      Bone biopsy and the diagnosis of renal osteodystrophy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/42/15017?source=related_link\">",
"      Calciphylaxis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/36/2631?source=related_link\">",
"      Chapter 6F: Hormonal regulation of calcium and phosphate balance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/21/9562?source=related_link\">",
"      Drugs that affect bone metabolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/18/26919?source=related_link\">",
"      Epidemiology, etiology, and course of chronic kidney disease in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/16/8456?source=related_link\">",
"      Eye disorders associated with chronic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/14/27881?source=related_link\">",
"      Growth hormone treatment in children with chronic kidney disease and postrenal transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/58/32681?source=related_link\">",
"      Management of secondary hyperparathyroidism and mineral metabolism abnormalities in adult predialysis patients with chronic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/36/38474?source=related_link\">",
"      Management of secondary hyperparathyroidism and mineral metabolism abnormalities in dialysis patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/14/31976?source=related_link\">",
"      Measurement of growth in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/21/26967?source=related_link\">",
"      Overview of rickets in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/56/36744?source=related_link\">",
"      Parathyroid hormone secretion and action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/50/18218?source=related_link\">",
"      Pathogenesis of renal osteodystrophy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?24/17/24850?source=related_link\">",
"      Patient information: Bone problems caused by kidney disease (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/42/23209?source=related_link\">",
"      Slipped capital femoral epiphysis (SCFE)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/57/33690?source=related_link\">",
"      Treatment of hyperphosphatemia in chronic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/37/44632?source=related_link\">",
"      Treatment of hypocalcemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/20/17738?source=related_link\">",
"      Vascular calcification in chronic kidney disease",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f27_24_28043="Axillary nodes Paget dz";
var content_f27_24_28043=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F80724&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F80724&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Axillary node metastasis in patients with Paget disease of the breast with or without a palpable mass",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Number of patients",
"       </td>",
"       <td class=\"subtitle1\">",
"        Percent node-positive with a palpable mass",
"       </td>",
"       <td class=\"subtitle1\">",
"        Percent node-positive in absence of a palpable mass",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Paone, 1981",
"       </td>",
"       <td>",
"        50",
"       </td>",
"       <td>",
"        64",
"       </td>",
"       <td>",
"        0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Chaudary, 1986",
"       </td>",
"       <td>",
"        35",
"       </td>",
"       <td>",
"        45",
"       </td>",
"       <td>",
"        12",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Eusebio, 1992",
"       </td>",
"       <td>",
"        45",
"       </td>",
"       <td>",
"        45",
"       </td>",
"       <td>",
"        0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Kollmorgen, 1998",
"       </td>",
"       <td>",
"        68",
"       </td>",
"       <td>",
"        57",
"       </td>",
"       <td>",
"        21",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sukumvanich P; 2007",
"       </td>",
"       <td>",
"        39",
"       </td>",
"       <td>",
"        45",
"       </td>",
"       <td>",
"        11",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Paon, JF, et al. Cancer 1981; 48:825. Chaudary MA, et al. Breast Cancer Res Treat 1986; 8:139. Eusebio RB, et al. Contemp Surg 1992; 40:13. Kollmorgen DR, et al. J Am Coll Surg 1998; 187:17. Sukumvanich P, et al. Ann Surg Oncol 2007; 14:1020.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_24_28043=[""].join("\n");
var outline_f27_24_28043=null;
var title_f27_24_28044="Complications of transsphenoidal surgery";
var content_f27_24_28044=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F68269&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F68269&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Complications of transsphenoidal surgery in relationship to the experience of the surgeon",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" colspan=\"1\" rowspan=\"3\">",
"        Complication",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"3\" rowspan=\"1\">",
"        Percent",
"of operations resulting in complication",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\" colspan=\"3\" rowspan=\"1\">",
"        # of previous operations:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3\">",
"        &lt;200",
"       </td>",
"       <td class=\"subtitle3\">",
"        20-500",
"       </td>",
"       <td class=\"subtitle3\">",
"        &gt;500",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Carotid artery injury",
"       </td>",
"       <td>",
"        1.4",
"       </td>",
"       <td>",
"        0.6",
"       </td>",
"       <td>",
"        0.4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Central nervous system injury",
"       </td>",
"       <td>",
"        1.6",
"       </td>",
"       <td>",
"        0.9",
"       </td>",
"       <td>",
"        0.6",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hemorrhage into tumor bed",
"       </td>",
"       <td>",
"        2.8",
"       </td>",
"       <td>",
"        4.0",
"       </td>",
"       <td>",
"        0.8",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Loss of vision",
"       </td>",
"       <td>",
"        2.4",
"       </td>",
"       <td>",
"        0.8",
"       </td>",
"       <td>",
"        0.5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ophthalmoplegia",
"       </td>",
"       <td>",
"        1.9",
"       </td>",
"       <td>",
"        0.8",
"       </td>",
"       <td>",
"        0.4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cerebrospinal fluid leak",
"       </td>",
"       <td>",
"        4.2",
"       </td>",
"       <td>",
"        2.8",
"       </td>",
"       <td>",
"        0.5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Meningitis",
"       </td>",
"       <td>",
"        1.9",
"       </td>",
"       <td>",
"        0.8",
"       </td>",
"       <td>",
"        0.5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Nasal septum perforation",
"       </td>",
"       <td>",
"        7.6",
"       </td>",
"       <td>",
"        4.6",
"       </td>",
"       <td>",
"        3.3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Anterior pituitary insufficiency",
"       </td>",
"       <td>",
"        20.6",
"       </td>",
"       <td>",
"        14.9",
"       </td>",
"       <td>",
"        7.2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Diabetes insipidus",
"       </td>",
"       <td>",
"        19.0",
"       </td>",
"       <td>",
"        NA",
"       </td>",
"       <td>",
"        7.6",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Death",
"       </td>",
"       <td>",
"        1.2",
"       </td>",
"       <td>",
"        0.6",
"       </td>",
"       <td>",
"        0.2",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     Data were collected from participating surgeons by questionnaire.",
"    </div>",
"    <div class=\"reference\">",
"     Modified from: Ciric I, Ragin A, Baumgartner C, Pierce D. Complications of transsphenoidal surgery: results of a national survey, review of the literature, and personal experience. Neurosurgery 1997; 40:225.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_24_28044=[""].join("\n");
var outline_f27_24_28044=null;
var title_f27_24_28045="Contents: Oncology calculators";
var content_f27_24_28045=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ���������������������������",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"UTD.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"UTD.htm?3/43/3774\">",
"       Oncology",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Oncology calculators",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"UTD.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Oncology calculators",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <strong>",
"         Medical Equations",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/31/4593\">",
"           Calculator: Body Surface Area (Du Bois Method)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/27/4529\">",
"           Calculator: Body Surface Area (Mosteller, square root method)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/26/29089\">",
"           Calculator: Lean body weight (adult female)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/21/29009\">",
"           Calculator: Lean body weight (adult male)",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0605-95.154.198.148-4E79DB556E-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f27_24_28045=[""].join("\n");
var outline_f27_24_28045=null;
var title_f27_24_28046="Coagulase test";
var content_f27_24_28046=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F77734&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F77734&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Tube test for free coagulase activity",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 357px; height: 240px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    When Staphylococcus aureus, which produces coagulase, is incubated in plasma, a visible fibrin clot is formed (lower tube). Coagulase-negative organisms (top tube) do not form this complex.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Harriet Provine.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_24_28046=[""].join("\n");
var outline_f27_24_28046=null;
var title_f27_24_28047="Dinner fork deformity";
var content_f27_24_28047=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F78559&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F78559&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 562px\">",
"   <div class=\"ttl\">",
"    Colles' fracture",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 542px; height: 366px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Due to the dorsal displacement of the distal fragment, Colles' type fractures are often said to have a \"dinner fork\" appearance.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_24_28047=[""].join("\n");
var outline_f27_24_28047=null;
